#FORMAT=WebAnno TSV 3.3
#T_SP=webanno.custom.ConceptLayer|identifier


#Text=Visuospatial task-related prefrontal activity is correlated with negative symptoms in schizophrenia
#Text=Control of attention is thought to be specifically impaired in schizophrenia due to abnormal function in the prefrontal cortex (PFC).
1-1	0-12	Visuospatial	_	
1-2	13-25	task-related	_	
1-3	26-36	prefrontal	_	
1-4	37-45	activity	_	
1-5	46-48	is	_	
1-6	49-59	correlated	_	
1-7	60-64	with	_	
1-8	65-73	negative	_	
1-9	74-82	symptoms	_	
1-10	83-85	in	_	
1-11	86-99	schizophrenia	http://maven.renci.org/NeuroBridge/neurobridge#Schizophrenia	
1-12	100-107	Control	_	
1-13	108-110	of	_	
1-14	111-120	attention	_	
1-15	121-123	is	_	
1-16	124-131	thought	_	
1-17	132-134	to	_	
1-18	135-137	be	_	
1-19	138-150	specifically	_	
1-20	151-159	impaired	_	
1-21	160-162	in	_	
1-22	163-176	schizophrenia	http://maven.renci.org/NeuroBridge/neurobridge#Schizophrenia	
1-23	177-180	due	_	
1-24	181-183	to	_	
1-25	184-192	abnormal	_	
1-26	193-201	function	_	
1-27	202-204	in	_	
1-28	205-208	the	_	
1-29	209-219	prefrontal	_	
1-30	220-226	cortex	_	
1-31	227-228	(	_	
1-32	228-231	PFC	_	
1-33	231-232	)	_	
1-34	232-233	.	_	

#Text=The PFC plays a critical role in the identification of relevant stimuli and the development of appropriate biases for the identified signals, including selection of an appropriate attentional ‘zoom’.
2-1	234-237	The	_	
2-2	238-241	PFC	_	
2-3	242-247	plays	_	
2-4	248-249	a	_	
2-5	250-258	critical	_	
2-6	259-263	role	_	
2-7	264-266	in	_	
2-8	267-270	the	_	
2-9	271-285	identification	_	
2-10	286-288	of	_	
2-11	289-297	relevant	_	
2-12	298-305	stimuli	_	
2-13	306-309	and	_	
2-14	310-313	the	_	
2-15	314-325	development	_	
2-16	326-328	of	_	
2-17	329-340	appropriate	_	
2-18	341-347	biases	_	
2-19	348-351	for	_	
2-20	352-355	the	_	
2-21	356-366	identified	_	
2-22	367-374	signals	_	
2-23	374-375	,	_	
2-24	376-385	including	_	
2-25	386-395	selection	_	
2-26	396-398	of	_	
2-27	399-401	an	_	
2-28	402-413	appropriate	_	
2-29	414-425	attentional	_	
2-30	426-427	‘	_	
2-31	427-431	zoom	_	
2-32	431-432	’	_	
2-33	432-433	.	_	

#Text=We examined how demands associated with changes in attentional requirements in a Sustained Attention Task (SAT) may contribute to differences in functional involvement of the PFC and relation to clinical status.
3-1	434-436	We	_	
3-2	437-445	examined	_	
3-3	446-449	how	_	
3-4	450-457	demands	_	
3-5	458-468	associated	_	
3-6	469-473	with	_	
3-7	474-481	changes	_	
3-8	482-484	in	_	
3-9	485-496	attentional	_	
3-10	497-509	requirements	_	
3-11	510-512	in	_	
3-12	513-514	a	_	
3-13	515-524	Sustained	_	
3-14	525-534	Attention	_	
3-15	535-539	Task	_	
3-16	540-541	(	_	
3-17	541-544	SAT	_	
3-18	544-545	)	_	
3-19	546-549	may	_	
3-20	550-560	contribute	_	
3-21	561-563	to	_	
3-22	564-575	differences	_	
3-23	576-578	in	_	
3-24	579-589	functional	_	
3-25	590-601	involvement	_	
3-26	602-604	of	_	
3-27	605-608	the	_	
3-28	609-612	PFC	_	
3-29	613-616	and	_	
3-30	617-625	relation	_	
3-31	626-628	to	_	
3-32	629-637	clinical	_	
3-33	638-644	status	_	
3-34	644-645	.	_	

#Text=A group of 24 individuals with schizophrenia and 16 healthy controls (N = 40) performed the SAT and a visuospatial condition (vSAT) while activity in the bilateral anterior PFC was monitored using functional Near Infrared Spectroscopy (fNIRS).
4-1	646-647	A	_	
4-2	648-653	group	_	
4-3	654-656	of	_	
4-4	657-659	24	_	
4-5	660-671	individuals	_	
4-6	672-676	with	_	
4-7	677-690	schizophrenia	http://maven.renci.org/NeuroBridge/neurobridge#Schizophrenia	
4-8	691-694	and	_	
4-9	695-697	16	_	
4-10	698-705	healthy	http://maven.renci.org/NeuroBridge/neurobridge#NoKnownDisorder[1]	
4-11	706-714	controls	http://maven.renci.org/NeuroBridge/neurobridge#NoKnownDisorder[1]	
4-12	715-716	(	_	
4-13	716-717	N	_	
4-14	718-719	=	_	
4-15	720-722	40	_	
4-16	722-723	)	_	
4-17	724-733	performed	_	
4-18	734-737	the	_	
4-19	738-741	SAT	_	
4-20	742-745	and	_	
4-21	746-747	a	_	
4-22	748-760	visuospatial	_	
4-23	761-770	condition	_	
4-24	771-772	(	_	
4-25	772-776	vSAT	_	
4-26	776-777	)	_	
4-27	778-783	while	_	
4-28	784-792	activity	_	
4-29	793-795	in	_	
4-30	796-799	the	_	
4-31	800-809	bilateral	_	
4-32	810-818	anterior	_	
4-33	819-822	PFC	_	
4-34	823-826	was	_	
4-35	827-836	monitored	_	
4-36	837-842	using	_	
4-37	843-853	functional	http://maven.renci.org/NeuroBridge/neurobridge#FunctionalNearInfraredSpectroscopy[2]	
4-38	854-858	Near	http://maven.renci.org/NeuroBridge/neurobridge#FunctionalNearInfraredSpectroscopy[2]	
4-39	859-867	Infrared	http://maven.renci.org/NeuroBridge/neurobridge#FunctionalNearInfraredSpectroscopy[2]	
4-40	868-880	Spectroscopy	http://maven.renci.org/NeuroBridge/neurobridge#FunctionalNearInfraredSpectroscopy[2]	
4-41	881-882	(	http://maven.renci.org/NeuroBridge/neurobridge#FunctionalNearInfraredSpectroscopy[2]	
4-42	882-887	fNIRS	http://maven.renci.org/NeuroBridge/neurobridge#FunctionalNearInfraredSpectroscopy[2]	
4-43	887-888	)	http://maven.renci.org/NeuroBridge/neurobridge#FunctionalNearInfraredSpectroscopy[2]	
4-44	888-889	.	_	

#Text=The results confirm that the right frontopolar region plays a role in control of attention for both patients and healthy controls.
5-1	890-893	The	_	
5-2	894-901	results	_	
5-3	902-909	confirm	_	
5-4	910-914	that	_	
5-5	915-918	the	_	
5-6	919-924	right	_	
5-7	925-936	frontopolar	_	
5-8	937-943	region	_	
5-9	944-949	plays	_	
5-10	950-951	a	_	
5-11	952-956	role	_	
5-12	957-959	in	_	
5-13	960-967	control	_	
5-14	968-970	of	_	
5-15	971-980	attention	_	
5-16	981-984	for	_	
5-17	985-989	both	_	
5-18	990-998	patients	_	
5-19	999-1002	and	_	
5-20	1003-1010	healthy	http://maven.renci.org/NeuroBridge/neurobridge#NoKnownDisorder[3]	
5-21	1011-1019	controls	http://maven.renci.org/NeuroBridge/neurobridge#NoKnownDisorder[3]	
5-22	1019-1020	.	_	

#Text=However, patients with schizophrenia exhibited a general attentional deficit and inefficient right-medial PFC activation.
6-1	1021-1028	However	_	
6-2	1028-1029	,	_	
6-3	1030-1038	patients	_	
6-4	1039-1043	with	_	
6-5	1044-1057	schizophrenia	http://maven.renci.org/NeuroBridge/neurobridge#Schizophrenia	
6-6	1058-1067	exhibited	_	
6-7	1068-1069	a	_	
6-8	1070-1077	general	_	
6-9	1078-1089	attentional	_	
6-10	1090-1097	deficit	_	
6-11	1098-1101	and	_	
6-12	1102-1113	inefficient	_	
6-13	1114-1126	right-medial	_	
6-14	1127-1130	PFC	_	
6-15	1131-1141	activation	_	
6-16	1141-1142	.	_	

#Text=Additionally, we observed a strong regional association between left Middle Frontal Gyrus (MFG) activity during the vSAT task and the PANSS score driven by the negative symptom subscale.
7-1	1143-1155	Additionally	_	
7-2	1155-1156	,	_	
7-3	1157-1159	we	_	
7-4	1160-1168	observed	_	
7-5	1169-1170	a	_	
7-6	1171-1177	strong	_	
7-7	1178-1186	regional	_	
7-8	1187-1198	association	_	
7-9	1199-1206	between	_	
7-10	1207-1211	left	_	
7-11	1212-1218	Middle	_	
7-12	1219-1226	Frontal	_	
7-13	1227-1232	Gyrus	_	
7-14	1233-1234	(	_	
7-15	1234-1237	MFG	_	
7-16	1237-1238	)	_	
7-17	1239-1247	activity	_	
7-18	1248-1254	during	_	
7-19	1255-1258	the	_	
7-20	1259-1263	vSAT	_	
7-21	1264-1268	task	_	
7-22	1269-1272	and	_	
7-23	1273-1276	the	_	
7-24	1277-1282	PANSS	http://maven.renci.org/NeuroBridge/neurobridge#PositiveandNegativeSyndromeScale	
7-25	1283-1288	score	_	
7-26	1289-1295	driven	_	
7-27	1296-1298	by	_	
7-28	1299-1302	the	_	
7-29	1303-1311	negative	_	
7-30	1312-1319	symptom	_	
7-31	1320-1328	subscale	_	
7-32	1328-1329	.	_	

#Text=The presence of aberrant activation differences within the left-MFG region may describe a dysregulation of attentional networks linked to the clinical expression of negative and general symptoms.
8-1	1330-1333	The	_	
8-2	1334-1342	presence	_	
8-3	1343-1345	of	_	
8-4	1346-1354	aberrant	_	
8-5	1355-1365	activation	_	
8-6	1366-1377	differences	_	
8-7	1378-1384	within	_	
8-8	1385-1388	the	_	
8-9	1389-1397	left-MFG	_	
8-10	1398-1404	region	_	
8-11	1405-1408	may	_	
8-12	1409-1417	describe	_	
8-13	1418-1419	a	_	
8-14	1420-1433	dysregulation	_	
8-15	1434-1436	of	_	
8-16	1437-1448	attentional	_	
8-17	1449-1457	networks	_	
8-18	1458-1464	linked	_	
8-19	1465-1467	to	_	
8-20	1468-1471	the	_	
8-21	1472-1480	clinical	_	
8-22	1481-1491	expression	_	
8-23	1492-1494	of	_	
8-24	1495-1503	negative	_	
8-25	1504-1507	and	_	
8-26	1508-1515	general	_	
8-27	1516-1524	symptoms	_	
8-28	1524-1525	.	_	

#Text=Introduction
#Text=Schizophrenia is a debilitating brain disorder characterized by positive, negative, and cognitive symptoms that affects approximately 1% of the global population.
9-1	1526-1538	Introduction	_	
9-2	1539-1552	Schizophrenia	_	
9-3	1553-1555	is	_	
9-4	1556-1557	a	_	
9-5	1558-1570	debilitating	_	
9-6	1571-1576	brain	_	
9-7	1577-1585	disorder	_	
9-8	1586-1599	characterized	_	
9-9	1600-1602	by	_	
9-10	1603-1611	positive	_	
9-11	1611-1612	,	_	
9-12	1613-1621	negative	_	
9-13	1621-1622	,	_	
9-14	1623-1626	and	_	
9-15	1627-1636	cognitive	_	
9-16	1637-1645	symptoms	_	
9-17	1646-1650	that	_	
9-18	1651-1658	affects	_	
9-19	1659-1672	approximately	_	
9-20	1673-1675	1%	_	
9-21	1676-1678	of	_	
9-22	1679-1682	the	_	
9-23	1683-1689	global	_	
9-24	1690-1700	population	_	
9-25	1700-1701	.	_	

#Text=Attention deficits are among the key cognitive impairments associated with the illness and are a driving factor in quality of life and other functional outcomes.
10-1	1702-1711	Attention	_	
10-2	1712-1720	deficits	_	
10-3	1721-1724	are	_	
10-4	1725-1730	among	_	
10-5	1731-1734	the	_	
10-6	1735-1738	key	_	
10-7	1739-1748	cognitive	_	
10-8	1749-1760	impairments	_	
10-9	1761-1771	associated	_	
10-10	1772-1776	with	_	
10-11	1777-1780	the	_	
10-12	1781-1788	illness	_	
10-13	1789-1792	and	_	
10-14	1793-1796	are	_	
10-15	1797-1798	a	_	
10-16	1799-1806	driving	_	
10-17	1807-1813	factor	_	
10-18	1814-1816	in	_	
10-19	1817-1824	quality	_	
10-20	1825-1827	of	_	
10-21	1828-1832	life	_	
10-22	1833-1836	and	_	
10-23	1837-1842	other	_	
10-24	1843-1853	functional	_	
10-25	1854-1862	outcomes	_	
10-26	1862-1863	.	_	

#Text=These symptoms typically predate psychosis and may act as a stable indicator of schizophrenia vulnerability but are largely unresponsive to pharmaceutical intervention with traditional or atypical neuroleptics.
11-1	1864-1869	These	_	
11-2	1870-1878	symptoms	_	
11-3	1879-1888	typically	_	
11-4	1889-1896	predate	_	
11-5	1897-1906	psychosis	_	
11-6	1907-1910	and	_	
11-7	1911-1914	may	_	
11-8	1915-1918	act	_	
11-9	1919-1921	as	_	
11-10	1922-1923	a	_	
11-11	1924-1930	stable	_	
11-12	1931-1940	indicator	_	
11-13	1941-1943	of	_	
11-14	1944-1957	schizophrenia	_	
11-15	1958-1971	vulnerability	_	
11-16	1972-1975	but	_	
11-17	1976-1979	are	_	
11-18	1980-1987	largely	_	
11-19	1988-2000	unresponsive	_	
11-20	2001-2003	to	_	
11-21	2004-2018	pharmaceutical	_	
11-22	2019-2031	intervention	_	
11-23	2032-2036	with	_	
11-24	2037-2048	traditional	_	
11-25	2049-2051	or	_	
11-26	2052-2060	atypical	_	
11-27	2061-2073	neuroleptics	_	
11-28	2073-2074	.	_	

#Text=Without any appropriate avenue for remediation, attention impairment represents a fundamental cognitive symptom that is unaddressed by currently available clinical therapies.
12-1	2075-2082	Without	_	
12-2	2083-2086	any	_	
12-3	2087-2098	appropriate	_	
12-4	2099-2105	avenue	_	
12-5	2106-2109	for	_	
12-6	2110-2121	remediation	_	
12-7	2121-2122	,	_	
12-8	2123-2132	attention	_	
12-9	2133-2143	impairment	_	
12-10	2144-2154	represents	_	
12-11	2155-2156	a	_	
12-12	2157-2168	fundamental	_	
12-13	2169-2178	cognitive	_	
12-14	2179-2186	symptom	_	
12-15	2187-2191	that	_	
12-16	2192-2194	is	_	
12-17	2195-2206	unaddressed	_	
12-18	2207-2209	by	_	
12-19	2210-2219	currently	_	
12-20	2220-2229	available	_	
12-21	2230-2238	clinical	_	
12-22	2239-2248	therapies	_	
12-23	2248-2249	.	_	

#Text=Illuminating the interactions between neural dynamics and attentional deficits may offer insight into neuro-individualized approaches to therapy.
13-1	2250-2262	Illuminating	_	
13-2	2263-2266	the	_	
13-3	2267-2279	interactions	_	
13-4	2280-2287	between	_	
13-5	2288-2294	neural	_	
13-6	2295-2303	dynamics	_	
13-7	2304-2307	and	_	
13-8	2308-2319	attentional	_	
13-9	2320-2328	deficits	_	
13-10	2329-2332	may	_	
13-11	2333-2338	offer	_	
13-12	2339-2346	insight	_	
13-13	2347-2351	into	_	
13-14	2352-2372	neuro-individualized	_	
13-15	2373-2383	approaches	_	
13-16	2384-2386	to	_	
13-17	2387-2394	therapy	_	
13-18	2394-2395	.	_	

#Text=Neuroimaging studies investigating the impairment of attention have found that behavioral deficits in schizophrenia are observed in conjunction with abnormal activation patterns within cortical regions strongly associated with attention such as the dorsolateral prefrontal cortex (dlPFC), anterior prefrontal cortex (aPFC), anterior cingulate cortex (Acc), the insula, and other subcortical regions.
14-1	2396-2408	Neuroimaging	_	
14-2	2409-2416	studies	_	
14-3	2417-2430	investigating	_	
14-4	2431-2434	the	_	
14-5	2435-2445	impairment	_	
14-6	2446-2448	of	_	
14-7	2449-2458	attention	_	
14-8	2459-2463	have	_	
14-9	2464-2469	found	_	
14-10	2470-2474	that	_	
14-11	2475-2485	behavioral	_	
14-12	2486-2494	deficits	_	
14-13	2495-2497	in	_	
14-14	2498-2511	schizophrenia	_	
14-15	2512-2515	are	_	
14-16	2516-2524	observed	_	
14-17	2525-2527	in	_	
14-18	2528-2539	conjunction	_	
14-19	2540-2544	with	_	
14-20	2545-2553	abnormal	_	
14-21	2554-2564	activation	_	
14-22	2565-2573	patterns	_	
14-23	2574-2580	within	_	
14-24	2581-2589	cortical	_	
14-25	2590-2597	regions	_	
14-26	2598-2606	strongly	_	
14-27	2607-2617	associated	_	
14-28	2618-2622	with	_	
14-29	2623-2632	attention	_	
14-30	2633-2637	such	_	
14-31	2638-2640	as	_	
14-32	2641-2644	the	_	
14-33	2645-2657	dorsolateral	_	
14-34	2658-2668	prefrontal	_	
14-35	2669-2675	cortex	_	
14-36	2676-2677	(	_	
14-37	2677-2682	dlPFC	_	
14-38	2682-2683	)	_	
14-39	2683-2684	,	_	
14-40	2685-2693	anterior	_	
14-41	2694-2704	prefrontal	_	
14-42	2705-2711	cortex	_	
14-43	2712-2713	(	_	
14-44	2713-2717	aPFC	_	
14-45	2717-2718	)	_	
14-46	2718-2719	,	_	
14-47	2720-2728	anterior	_	
14-48	2729-2738	cingulate	_	
14-49	2739-2745	cortex	_	
14-50	2746-2747	(	_	
14-51	2747-2750	Acc	_	
14-52	2750-2751	)	_	
14-53	2751-2752	,	_	
14-54	2753-2756	the	_	
14-55	2757-2763	insula	_	
14-56	2763-2764	,	_	
14-57	2765-2768	and	_	
14-58	2769-2774	other	_	
14-59	2775-2786	subcortical	_	
14-60	2787-2794	regions	_	
14-61	2794-2795	.	_	

#Text=In particular, dysfunction in the prefrontal cortex (PFC) is commonly observed as diminished activation, termed “hypofrontality”.
15-1	2796-2798	In	_	
15-2	2799-2809	particular	_	
15-3	2809-2810	,	_	
15-4	2811-2822	dysfunction	_	
15-5	2823-2825	in	_	
15-6	2826-2829	the	_	
15-7	2830-2840	prefrontal	_	
15-8	2841-2847	cortex	_	
15-9	2848-2849	(	_	
15-10	2849-2852	PFC	_	
15-11	2852-2853	)	_	
15-12	2854-2856	is	_	
15-13	2857-2865	commonly	_	
15-14	2866-2874	observed	_	
15-15	2875-2877	as	_	
15-16	2878-2888	diminished	_	
15-17	2889-2899	activation	_	
15-18	2899-2900	,	_	
15-19	2901-2907	termed	_	
15-20	2908-2909	“	_	
15-21	2909-2923	hypofrontality	_	
15-22	2923-2924	”	_	
15-23	2924-2925	.	_	

#Text=However, both insufficient activation (decreased) and excessive activation (increased) in the PFC have been reported in patients, suggesting that rather than an explicit failure of function, irregular involvement of the PFC may reflect dysregulation in the processes of attention itself.
16-1	2926-2933	However	_	
16-2	2933-2934	,	_	
16-3	2935-2939	both	_	
16-4	2940-2952	insufficient	_	
16-5	2953-2963	activation	_	
16-6	2964-2965	(	_	
16-7	2965-2974	decreased	_	
16-8	2974-2975	)	_	
16-9	2976-2979	and	_	
16-10	2980-2989	excessive	_	
16-11	2990-3000	activation	_	
16-12	3001-3002	(	_	
16-13	3002-3011	increased	_	
16-14	3011-3012	)	_	
16-15	3013-3015	in	_	
16-16	3016-3019	the	_	
16-17	3020-3023	PFC	_	
16-18	3024-3028	have	_	
16-19	3029-3033	been	_	
16-20	3034-3042	reported	_	
16-21	3043-3045	in	_	
16-22	3046-3054	patients	_	
16-23	3054-3055	,	_	
16-24	3056-3066	suggesting	_	
16-25	3067-3071	that	_	
16-26	3072-3078	rather	_	
16-27	3079-3083	than	_	
16-28	3084-3086	an	_	
16-29	3087-3095	explicit	_	
16-30	3096-3103	failure	_	
16-31	3104-3106	of	_	
16-32	3107-3115	function	_	
16-33	3115-3116	,	_	
16-34	3117-3126	irregular	_	
16-35	3127-3138	involvement	_	
16-36	3139-3141	of	_	
16-37	3142-3145	the	_	
16-38	3146-3149	PFC	_	
16-39	3150-3153	may	_	
16-40	3154-3161	reflect	_	
16-41	3162-3175	dysregulation	_	
16-42	3176-3178	in	_	
16-43	3179-3182	the	_	
16-44	3183-3192	processes	_	
16-45	3193-3195	of	_	
16-46	3196-3205	attention	_	
16-47	3206-3212	itself	_	
16-48	3212-3213	.	_	

#Text=Evidence from cued target tasks and saccadic responses indicate that the bottom-up maintenance of processes is relatively intact within schizophrenia, while in the presence of unpredictable cues and stimuli, the top-down processes are impaired.
17-1	3214-3222	Evidence	_	
17-2	3223-3227	from	_	
17-3	3228-3232	cued	_	
17-4	3233-3239	target	_	
17-5	3240-3245	tasks	_	
17-6	3246-3249	and	_	
17-7	3250-3258	saccadic	_	
17-8	3259-3268	responses	_	
17-9	3269-3277	indicate	_	
17-10	3278-3282	that	_	
17-11	3283-3286	the	_	
17-12	3287-3296	bottom-up	_	
17-13	3297-3308	maintenance	_	
17-14	3309-3311	of	_	
17-15	3312-3321	processes	_	
17-16	3322-3324	is	_	
17-17	3325-3335	relatively	_	
17-18	3336-3342	intact	_	
17-19	3343-3349	within	_	
17-20	3350-3363	schizophrenia	_	
17-21	3363-3364	,	_	
17-22	3365-3370	while	_	
17-23	3371-3373	in	_	
17-24	3374-3377	the	_	
17-25	3378-3386	presence	_	
17-26	3387-3389	of	_	
17-27	3390-3403	unpredictable	_	
17-28	3404-3408	cues	_	
17-29	3409-3412	and	_	
17-30	3413-3420	stimuli	_	
17-31	3420-3421	,	_	
17-32	3422-3425	the	_	
17-33	3426-3434	top-down	_	
17-34	3435-3444	processes	_	
17-35	3445-3448	are	_	
17-36	3449-3457	impaired	_	
17-37	3457-3458	.	_	

#Text=As a result, it has been proposed that people with schizophrenia may be particularly impaired during the “Control of Attention”, a top-down process through which information is restricted to relevant stimuli and appropriate attentional biases are developed including selection of an appropriate attentional ‘zoom’.
18-1	3459-3461	As	_	
18-2	3462-3463	a	_	
18-3	3464-3470	result	_	
18-4	3470-3471	,	_	
18-5	3472-3474	it	_	
18-6	3475-3478	has	_	
18-7	3479-3483	been	_	
18-8	3484-3492	proposed	_	
18-9	3493-3497	that	_	
18-10	3498-3504	people	_	
18-11	3505-3509	with	_	
18-12	3510-3523	schizophrenia	_	
18-13	3524-3527	may	_	
18-14	3528-3530	be	_	
18-15	3531-3543	particularly	_	
18-16	3544-3552	impaired	_	
18-17	3553-3559	during	_	
18-18	3560-3563	the	_	
18-19	3564-3565	“	_	
18-20	3565-3572	Control	_	
18-21	3573-3575	of	_	
18-22	3576-3585	Attention	_	
18-23	3585-3586	”	_	
18-24	3586-3587	,	_	
18-25	3588-3589	a	_	
18-26	3590-3598	top-down	_	
18-27	3599-3606	process	_	
18-28	3607-3614	through	_	
18-29	3615-3620	which	_	
18-30	3621-3632	information	_	
18-31	3633-3635	is	_	
18-32	3636-3646	restricted	_	
18-33	3647-3649	to	_	
18-34	3650-3658	relevant	_	
18-35	3659-3666	stimuli	_	
18-36	3667-3670	and	_	
18-37	3671-3682	appropriate	_	
18-38	3683-3694	attentional	_	
18-39	3695-3701	biases	_	
18-40	3702-3705	are	_	
18-41	3706-3715	developed	_	
18-42	3716-3725	including	_	
18-43	3726-3735	selection	_	
18-44	3736-3738	of	_	
18-45	3739-3741	an	_	
18-46	3742-3753	appropriate	_	
18-47	3754-3765	attentional	_	
18-48	3766-3767	‘	_	
18-49	3767-3771	zoom	_	
18-50	3771-3772	’	_	
18-51	3772-3773	.	_	

#Text=Attentional biases towards task-relevant information are theorized to occur through the coordination of top-down and bottom-up mechanisms according to the biased competition model of selective attention.
19-1	3774-3785	Attentional	_	
19-2	3786-3792	biases	_	
19-3	3793-3800	towards	_	
19-4	3801-3814	task-relevant	_	
19-5	3815-3826	information	_	
19-6	3827-3830	are	_	
19-7	3831-3840	theorized	_	
19-8	3841-3843	to	_	
19-9	3844-3849	occur	_	
19-10	3850-3857	through	_	
19-11	3858-3861	the	_	
19-12	3862-3874	coordination	_	
19-13	3875-3877	of	_	
19-14	3878-3886	top-down	_	
19-15	3887-3890	and	_	
19-16	3891-3900	bottom-up	_	
19-17	3901-3911	mechanisms	_	
19-18	3912-3921	according	_	
19-19	3922-3924	to	_	
19-20	3925-3928	the	_	
19-21	3929-3935	biased	_	
19-22	3936-3947	competition	_	
19-23	3948-3953	model	_	
19-24	3954-3956	of	_	
19-25	3957-3966	selective	_	
19-26	3967-3976	attention	_	
19-27	3976-3977	.	_	

#Text=Researchers have sought to tease out the differences between these affected processes in order to quantify and evaluate the control of attention as a candidate marker for drug development.
20-1	3978-3989	Researchers	_	
20-2	3990-3994	have	_	
20-3	3995-4001	sought	_	
20-4	4002-4004	to	_	
20-5	4005-4010	tease	_	
20-6	4011-4014	out	_	
20-7	4015-4018	the	_	
20-8	4019-4030	differences	_	
20-9	4031-4038	between	_	
20-10	4039-4044	these	_	
20-11	4045-4053	affected	_	
20-12	4054-4063	processes	_	
20-13	4064-4066	in	_	
20-14	4067-4072	order	_	
20-15	4073-4075	to	_	
20-16	4076-4084	quantify	_	
20-17	4085-4088	and	_	
20-18	4089-4097	evaluate	_	
20-19	4098-4101	the	_	
20-20	4102-4109	control	_	
20-21	4110-4112	of	_	
20-22	4113-4122	attention	_	
20-23	4123-4125	as	_	
20-24	4126-4127	a	_	
20-25	4128-4137	candidate	_	
20-26	4138-4144	marker	_	
20-27	4145-4148	for	_	
20-28	4149-4153	drug	_	
20-29	4154-4165	development	_	
20-30	4165-4166	.	_	

#Text=Attention can be conceived as a limited cognitive resource which must be allocated appropriately in order to operate efficiently.
21-1	4167-4176	Attention	_	
21-2	4177-4180	can	_	
21-3	4181-4183	be	_	
21-4	4184-4193	conceived	_	
21-5	4194-4196	as	_	
21-6	4197-4198	a	_	
21-7	4199-4206	limited	_	
21-8	4207-4216	cognitive	_	
21-9	4217-4225	resource	_	
21-10	4226-4231	which	_	
21-11	4232-4236	must	_	
21-12	4237-4239	be	_	
21-13	4240-4249	allocated	_	
21-14	4250-4263	appropriately	_	
21-15	4264-4266	in	_	
21-16	4267-4272	order	_	
21-17	4273-4275	to	_	
21-18	4276-4283	operate	_	
21-19	4284-4295	efficiently	_	
21-20	4295-4296	.	_	

#Text=‘Control of Attention’ guides this allocation as described in part by the “Spotlight” or “Zoom Lens” theory of attention, which postulates that attention operates on a continuum between two stages.
22-1	4297-4298	‘	_	
22-2	4298-4305	Control	_	
22-3	4306-4308	of	_	
22-4	4309-4318	Attention	_	
22-5	4318-4319	’	_	
22-6	4320-4326	guides	_	
22-7	4327-4331	this	_	
22-8	4332-4342	allocation	_	
22-9	4343-4345	as	_	
22-10	4346-4355	described	_	
22-11	4356-4358	in	_	
22-12	4359-4363	part	_	
22-13	4364-4366	by	_	
22-14	4367-4370	the	_	
22-15	4371-4372	“	_	
22-16	4372-4381	Spotlight	_	
22-17	4381-4382	”	_	
22-18	4383-4385	or	_	
22-19	4386-4387	“	_	
22-20	4387-4391	Zoom	_	
22-21	4392-4396	Lens	_	
22-22	4396-4397	”	_	
22-23	4398-4404	theory	_	
22-24	4405-4407	of	_	
22-25	4408-4417	attention	_	
22-26	4417-4418	,	_	
22-27	4419-4424	which	_	
22-28	4425-4435	postulates	_	
22-29	4436-4440	that	_	
22-30	4441-4450	attention	_	
22-31	4451-4459	operates	_	
22-32	4460-4462	on	_	
22-33	4463-4464	a	_	
22-34	4465-4474	continuum	_	
22-35	4475-4482	between	_	
22-36	4483-4486	two	_	
22-37	4487-4493	stages	_	
22-38	4493-4494	.	_	

#Text=In the first stage, attention is fairly evenly distributed over the central field of a view to allow for parallel processing of an area.
23-1	4495-4497	In	_	
23-2	4498-4501	the	_	
23-3	4502-4507	first	_	
23-4	4508-4513	stage	_	
23-5	4513-4514	,	_	
23-6	4515-4524	attention	_	
23-7	4525-4527	is	_	
23-8	4528-4534	fairly	_	
23-9	4535-4541	evenly	_	
23-10	4542-4553	distributed	_	
23-11	4554-4558	over	_	
23-12	4559-4562	the	_	
23-13	4563-4570	central	_	
23-14	4571-4576	field	_	
23-15	4577-4579	of	_	
23-16	4580-4581	a	_	
23-17	4582-4586	view	_	
23-18	4587-4589	to	_	
23-19	4590-4595	allow	_	
23-20	4596-4599	for	_	
23-21	4600-4608	parallel	_	
23-22	4609-4619	processing	_	
23-23	4620-4622	of	_	
23-24	4623-4625	an	_	
23-25	4626-4630	area	_	
23-26	4630-4631	.	_	

#Text=Whereas in the second stage, attention becomes focused on a specific area, leading to improved focal awareness at the expense of more distributed stimuli.
24-1	4632-4639	Whereas	_	
24-2	4640-4642	in	_	
24-3	4643-4646	the	_	
24-4	4647-4653	second	_	
24-5	4654-4659	stage	_	
24-6	4659-4660	,	_	
24-7	4661-4670	attention	_	
24-8	4671-4678	becomes	_	
24-9	4679-4686	focused	_	
24-10	4687-4689	on	_	
24-11	4690-4691	a	_	
24-12	4692-4700	specific	_	
24-13	4701-4705	area	_	
24-14	4705-4706	,	_	
24-15	4707-4714	leading	_	
24-16	4715-4717	to	_	
24-17	4718-4726	improved	_	
24-18	4727-4732	focal	_	
24-19	4733-4742	awareness	_	
24-20	4743-4745	at	_	
24-21	4746-4749	the	_	
24-22	4750-4757	expense	_	
24-23	4758-4760	of	_	
24-24	4761-4765	more	_	
24-25	4766-4777	distributed	_	
24-26	4778-4785	stimuli	_	
24-27	4785-4786	.	_	

#Text=Thus, there exists a tradeoff between processing efficiency and the size of the area being attended according to the level of ‘zoom’ that is engaged during a task.
25-1	4787-4791	Thus	_	
25-2	4791-4792	,	_	
25-3	4793-4798	there	_	
25-4	4799-4805	exists	_	
25-5	4806-4807	a	_	
25-6	4808-4816	tradeoff	_	
25-7	4817-4824	between	_	
25-8	4825-4835	processing	_	
25-9	4836-4846	efficiency	_	
25-10	4847-4850	and	_	
25-11	4851-4854	the	_	
25-12	4855-4859	size	_	
25-13	4860-4862	of	_	
25-14	4863-4866	the	_	
25-15	4867-4871	area	_	
25-16	4872-4877	being	_	
25-17	4878-4886	attended	_	
25-18	4887-4896	according	_	
25-19	4897-4899	to	_	
25-20	4900-4903	the	_	
25-21	4904-4909	level	_	
25-22	4910-4912	of	_	
25-23	4913-4914	‘	_	
25-24	4914-4918	zoom	_	
25-25	4918-4919	’	_	
25-26	4920-4924	that	_	
25-27	4925-4927	is	_	
25-28	4928-4935	engaged	_	
25-29	4936-4942	during	_	
25-30	4943-4944	a	_	
25-31	4945-4949	task	_	
25-32	4949-4950	.	_	

#Text=In schizophrenia, an inefficient ability to define or maintain appropriate attentional distribution may lead to a state of “hyperfocusing” which may reduce the visual span or saccadic length, and even contribute to failures in spatial working memory.
26-1	4951-4953	In	_	
26-2	4954-4967	schizophrenia	_	
26-3	4967-4968	,	_	
26-4	4969-4971	an	_	
26-5	4971-4972	 	_	
26-6	4972-4983	inefficient	_	
26-7	4984-4991	ability	_	
26-8	4992-4994	to	_	
26-9	4995-5001	define	_	
26-10	5002-5004	or	_	
26-11	5005-5013	maintain	_	
26-12	5014-5025	appropriate	_	
26-13	5026-5037	attentional	_	
26-14	5038-5050	distribution	_	
26-15	5051-5054	may	_	
26-16	5055-5059	lead	_	
26-17	5060-5062	to	_	
26-18	5063-5064	a	_	
26-19	5065-5070	state	_	
26-20	5071-5073	of	_	
26-21	5074-5075	“	_	
26-22	5075-5088	hyperfocusing	_	
26-23	5088-5089	”	_	
26-24	5090-5095	which	_	
26-25	5096-5099	may	_	
26-26	5100-5106	reduce	_	
26-27	5107-5110	the	_	
26-28	5111-5117	visual	_	
26-29	5118-5122	span	_	
26-30	5123-5125	or	_	
26-31	5126-5134	saccadic	_	
26-32	5135-5141	length	_	
26-33	5141-5142	,	_	
26-34	5143-5146	and	_	
26-35	5147-5151	even	_	
26-36	5152-5162	contribute	_	
26-37	5163-5165	to	_	
26-38	5166-5174	failures	_	
26-39	5175-5177	in	_	
26-40	5178-5185	spatial	_	
26-41	5186-5193	working	_	
26-42	5194-5200	memory	_	
26-43	5200-5201	.	_	

#Text=A recent Arterial Spin Labeling (ASL) imaging study using the Sustained Attention Task (SAT) identified a role for the right-PFC (BA 9/10) in healthy subjects when task difficulty was modulated by the presence of a distractor and it was later proposed that dysfunction in this region may be the cause of observed behavioral deficits in patients with schizophrenia.
27-1	5202-5203	A	_	
27-2	5204-5210	recent	_	
27-3	5211-5219	Arterial	_	
27-4	5220-5224	Spin	_	
27-5	5225-5233	Labeling	_	
27-6	5234-5235	(	_	
27-7	5235-5238	ASL	_	
27-8	5238-5239	)	_	
27-9	5240-5247	imaging	_	
27-10	5248-5253	study	_	
27-11	5254-5259	using	_	
27-12	5260-5263	the	_	
27-13	5264-5273	Sustained	_	
27-14	5274-5283	Attention	_	
27-15	5284-5288	Task	_	
27-16	5289-5290	(	_	
27-17	5290-5293	SAT	_	
27-18	5293-5294	)	_	
27-19	5295-5305	identified	_	
27-20	5306-5307	a	_	
27-21	5308-5312	role	_	
27-22	5313-5316	for	_	
27-23	5317-5320	the	_	
27-24	5321-5330	right-PFC	_	
27-25	5331-5332	(	_	
27-26	5332-5334	BA	_	
27-27	5335-5336	9	_	
27-28	5336-5337	/	_	
27-29	5337-5339	10	_	
27-30	5339-5340	)	_	
27-31	5341-5343	in	_	
27-32	5344-5351	healthy	_	
27-33	5352-5360	subjects	_	
27-34	5361-5365	when	_	
27-35	5366-5370	task	_	
27-36	5371-5381	difficulty	_	
27-37	5382-5385	was	_	
27-38	5386-5395	modulated	_	
27-39	5396-5398	by	_	
27-40	5399-5402	the	_	
27-41	5403-5411	presence	_	
27-42	5412-5414	of	_	
27-43	5415-5416	a	_	
27-44	5417-5427	distractor	_	
27-45	5428-5431	and	_	
27-46	5432-5434	it	_	
27-47	5435-5438	was	_	
27-48	5439-5444	later	_	
27-49	5445-5453	proposed	_	
27-50	5454-5458	that	_	
27-51	5459-5470	dysfunction	_	
27-52	5471-5473	in	_	
27-53	5474-5478	this	_	
27-54	5479-5485	region	_	
27-55	5486-5489	may	_	
27-56	5490-5492	be	_	
27-57	5493-5496	the	_	
27-58	5497-5502	cause	_	
27-59	5503-5505	of	_	
27-60	5506-5514	observed	_	
27-61	5515-5525	behavioral	_	
27-62	5526-5534	deficits	_	
27-63	5535-5537	in	_	
27-64	5538-5546	patients	_	
27-65	5547-5551	with	_	
27-66	5552-5565	schizophrenia	_	
27-67	5565-5566	.	_	

#Text=The right-PFC region has previously been ascribed a substantial role in initiation and maintenance of attentional processes as well as attentional dysfunction associated with fatigue and distraction.
28-1	5567-5570	The	_	
28-2	5571-5580	right-PFC	_	
28-3	5581-5587	region	_	
28-4	5588-5591	has	_	
28-5	5592-5602	previously	_	
28-6	5603-5607	been	_	
28-7	5608-5616	ascribed	_	
28-8	5617-5618	a	_	
28-9	5619-5630	substantial	_	
28-10	5631-5635	role	_	
28-11	5636-5638	in	_	
28-12	5639-5649	initiation	_	
28-13	5650-5653	and	_	
28-14	5654-5665	maintenance	_	
28-15	5666-5668	of	_	
28-16	5669-5680	attentional	_	
28-17	5681-5690	processes	_	
28-18	5691-5693	as	_	
28-19	5694-5698	well	_	
28-20	5699-5701	as	_	
28-21	5702-5713	attentional	_	
28-22	5714-5725	dysfunction	_	
28-23	5726-5736	associated	_	
28-24	5737-5741	with	_	
28-25	5742-5749	fatigue	_	
28-26	5750-5753	and	_	
28-27	5754-5765	distraction	_	
28-28	5765-5766	.	_	

#Text=In schizophrenia, studies of attentional processes have noted the specific involvement of the right-PFC as an important regional hub and observed failures in attention have been as ascribed to a “frontal inefficiency” stemming from diminished connectivity between the executive network guided by the dlPFC and a salience network driven by the anterior insula.
29-1	5767-5769	In	_	
29-2	5770-5783	schizophrenia	_	
29-3	5783-5784	,	_	
29-4	5785-5792	studies	_	
29-5	5793-5795	of	_	
29-6	5796-5807	attentional	_	
29-7	5808-5817	processes	_	
29-8	5818-5822	have	_	
29-9	5823-5828	noted	_	
29-10	5829-5832	the	_	
29-11	5833-5841	specific	_	
29-12	5842-5853	involvement	_	
29-13	5854-5856	of	_	
29-14	5857-5860	the	_	
29-15	5861-5870	right-PFC	_	
29-16	5871-5873	as	_	
29-17	5874-5876	an	_	
29-18	5877-5886	important	_	
29-19	5887-5895	regional	_	
29-20	5896-5899	hub	_	
29-21	5900-5903	and	_	
29-22	5904-5912	observed	_	
29-23	5913-5921	failures	_	
29-24	5922-5924	in	_	
29-25	5925-5934	attention	_	
29-26	5935-5939	have	_	
29-27	5940-5944	been	_	
29-28	5945-5947	as	_	
29-29	5948-5956	ascribed	_	
29-30	5957-5959	to	_	
29-31	5960-5961	a	_	
29-32	5962-5963	“	_	
29-33	5963-5970	frontal	_	
29-34	5971-5983	inefficiency	_	
29-35	5983-5984	”	_	
29-36	5985-5993	stemming	_	
29-37	5994-5998	from	_	
29-38	5999-6009	diminished	_	
29-39	6010-6022	connectivity	_	
29-40	6023-6030	between	_	
29-41	6031-6034	the	_	
29-42	6035-6044	executive	_	
29-43	6045-6052	network	_	
29-44	6053-6059	guided	_	
29-45	6060-6062	by	_	
29-46	6063-6066	the	_	
29-47	6067-6072	dlPFC	_	
29-48	6073-6076	and	_	
29-49	6077-6078	a	_	
29-50	6079-6087	salience	_	
29-51	6088-6095	network	_	
29-52	6096-6102	driven	_	
29-53	6103-6105	by	_	
29-54	6106-6109	the	_	
29-55	6110-6118	anterior	_	
29-56	6119-6125	insula	_	
29-57	6125-6126	.	_	

#Text=Functional studies have also identified this region as an area of interest; whether due to dysfunctional changes in lateralization of activity, failure to modulate with attention demands, or even as an area which is increasingly engaged following cognitive remediation.
30-1	6127-6137	Functional	_	
30-2	6138-6145	studies	_	
30-3	6146-6150	have	_	
30-4	6151-6155	also	_	
30-5	6156-6166	identified	_	
30-6	6167-6171	this	_	
30-7	6172-6178	region	_	
30-8	6179-6181	as	_	
30-9	6182-6184	an	_	
30-10	6185-6189	area	_	
30-11	6190-6192	of	_	
30-12	6193-6201	interest	_	
30-13	6201-6202	;	_	
30-14	6203-6210	whether	_	
30-15	6211-6214	due	_	
30-16	6215-6217	to	_	
30-17	6218-6231	dysfunctional	_	
30-18	6232-6239	changes	_	
30-19	6240-6242	in	_	
30-20	6243-6257	lateralization	_	
30-21	6258-6260	of	_	
30-22	6261-6269	activity	_	
30-23	6269-6270	,	_	
30-24	6271-6278	failure	_	
30-25	6279-6281	to	_	
30-26	6282-6290	modulate	_	
30-27	6291-6295	with	_	
30-28	6296-6305	attention	_	
30-29	6306-6313	demands	_	
30-30	6313-6314	,	_	
30-31	6315-6317	or	_	
30-32	6318-6322	even	_	
30-33	6323-6325	as	_	
30-34	6326-6328	an	_	
30-35	6329-6333	area	_	
30-36	6334-6339	which	_	
30-37	6340-6342	is	_	
30-38	6343-6355	increasingly	_	
30-39	6356-6363	engaged	_	
30-40	6364-6373	following	_	
30-41	6374-6383	cognitive	_	
30-42	6384-6395	remediation	_	
30-43	6395-6396	.	_	

#Text=We hypothesized that sensitivity to differences between broader attentional distribution and focused attention, as measured by contrasting a visuospatial SAT with the standard SAT, could create a candidate assessment for attentional control deficits in schizophrenia.
31-1	6397-6399	We	_	
31-2	6400-6412	hypothesized	_	
31-3	6413-6417	that	_	
31-4	6418-6429	sensitivity	_	
31-5	6430-6432	to	_	
31-6	6433-6444	differences	_	
31-7	6445-6452	between	_	
31-8	6453-6460	broader	_	
31-9	6461-6472	attentional	_	
31-10	6473-6485	distribution	_	
31-11	6486-6489	and	_	
31-12	6490-6497	focused	_	
31-13	6498-6507	attention	_	
31-14	6507-6508	,	_	
31-15	6509-6511	as	_	
31-16	6512-6520	measured	_	
31-17	6521-6523	by	_	
31-18	6524-6535	contrasting	_	
31-19	6536-6537	a	_	
31-20	6538-6550	visuospatial	_	
31-21	6551-6554	SAT	_	
31-22	6555-6559	with	_	
31-23	6560-6563	the	_	
31-24	6564-6572	standard	_	
31-25	6573-6576	SAT	_	
31-26	6576-6577	,	_	
31-27	6578-6583	could	_	
31-28	6584-6590	create	_	
31-29	6591-6592	a	_	
31-30	6593-6602	candidate	_	
31-31	6603-6613	assessment	_	
31-32	6614-6617	for	_	
31-33	6618-6629	attentional	_	
31-34	6630-6637	control	_	
31-35	6638-6646	deficits	_	
31-36	6647-6649	in	_	
31-37	6650-6663	schizophrenia	_	
31-38	6663-6664	.	_	

#Text=Furthermore, we hypothesized that activity in the right-PFC would reflect the sensitivity of attentional processes to increased visuospatial demands, and that this sensitivity would be dysregulated in schizophrenia in a way which may provide clinically useful information.
32-1	6665-6676	Furthermore	_	
32-2	6676-6677	,	_	
32-3	6678-6680	we	_	
32-4	6681-6693	hypothesized	_	
32-5	6694-6698	that	_	
32-6	6699-6707	activity	_	
32-7	6708-6710	in	_	
32-8	6711-6714	the	_	
32-9	6715-6724	right-PFC	_	
32-10	6725-6730	would	_	
32-11	6731-6738	reflect	_	
32-12	6739-6742	the	_	
32-13	6743-6754	sensitivity	_	
32-14	6755-6757	of	_	
32-15	6758-6769	attentional	_	
32-16	6770-6779	processes	_	
32-17	6780-6782	to	_	
32-18	6783-6792	increased	_	
32-19	6793-6805	visuospatial	_	
32-20	6806-6813	demands	_	
32-21	6813-6814	,	_	
32-22	6815-6818	and	_	
32-23	6819-6823	that	_	
32-24	6824-6828	this	_	
32-25	6829-6840	sensitivity	_	
32-26	6841-6846	would	_	
32-27	6847-6849	be	_	
32-28	6850-6862	dysregulated	_	
32-29	6863-6865	in	_	
32-30	6866-6879	schizophrenia	_	
32-31	6880-6882	in	_	
32-32	6883-6884	a	_	
32-33	6885-6888	way	_	
32-34	6889-6894	which	_	
32-35	6895-6898	may	_	
32-36	6899-6906	provide	_	
32-37	6907-6917	clinically	_	
32-38	6918-6924	useful	_	
32-39	6925-6936	information	_	
32-40	6936-6937	.	_	

#Text=To test these hypotheses we sought to monitor task-evoked activities with functional Near Infrared Spectroscopy (fNIRS), a non-invasive neuroimaging technique which measures relative changes in cortical hemoglobin concentrations associated with cognitive activity.
33-1	6938-6940	To	_	
33-2	6941-6945	test	_	
33-3	6946-6951	these	_	
33-4	6952-6962	hypotheses	_	
33-5	6963-6965	we	_	
33-6	6966-6972	sought	_	
33-7	6973-6975	to	_	
33-8	6976-6983	monitor	_	
33-9	6984-6995	task-evoked	_	
33-10	6996-7006	activities	_	
33-11	7007-7011	with	_	
33-12	7012-7022	functional	_	
33-13	7023-7027	Near	_	
33-14	7028-7036	Infrared	_	
33-15	7037-7049	Spectroscopy	_	
33-16	7050-7051	(	_	
33-17	7051-7056	fNIRS	_	
33-18	7056-7057	)	_	
33-19	7057-7058	,	_	
33-20	7059-7060	a	_	
33-21	7061-7073	non-invasive	_	
33-22	7074-7086	neuroimaging	_	
33-23	7087-7096	technique	_	
33-24	7097-7102	which	_	
33-25	7103-7111	measures	_	
33-26	7112-7120	relative	_	
33-27	7121-7128	changes	_	
33-28	7129-7131	in	_	
33-29	7132-7140	cortical	_	
33-30	7141-7151	hemoglobin	_	
33-31	7152-7166	concentrations	_	
33-32	7167-7177	associated	_	
33-33	7178-7182	with	_	
33-34	7183-7192	cognitive	_	
33-35	7193-7201	activity	_	
33-36	7201-7202	.	_	

#Text=We used linear mixed effects (LME) models to evaluate the relationship between prefrontal activation, cognitive function, and clinical measures.
34-1	7203-7205	We	_	
34-2	7206-7210	used	_	
34-3	7211-7217	linear	_	
34-4	7218-7223	mixed	_	
34-5	7224-7231	effects	_	
34-6	7232-7233	(	_	
34-7	7233-7236	LME	_	
34-8	7236-7237	)	_	
34-9	7238-7244	models	_	
34-10	7245-7247	to	_	
34-11	7248-7256	evaluate	_	
34-12	7257-7260	the	_	
34-13	7261-7273	relationship	_	
34-14	7274-7281	between	_	
34-15	7282-7292	prefrontal	_	
34-16	7293-7303	activation	_	
34-17	7303-7304	,	_	
34-18	7305-7314	cognitive	_	
34-19	7315-7323	function	_	
34-20	7323-7324	,	_	
34-21	7325-7328	and	_	
34-22	7329-7337	clinical	_	
34-23	7338-7346	measures	_	
34-24	7346-7347	.	_	

#Text=Methods
#Text=Demographic information
#Text=Demographic and clinical severity information for participants in study.
35-1	7348-7355	Methods	http://www.case.edu/ProvCaRe/provcare#StudyMethod	
35-2	7356-7367	Demographic	_	
35-3	7368-7379	information	_	
35-4	7380-7391	Demographic	_	
35-5	7392-7395	and	_	
35-6	7396-7404	clinical	_	
35-7	7405-7413	severity	_	
35-8	7414-7425	information	_	
35-9	7426-7429	for	_	
35-10	7430-7442	participants	_	
35-11	7443-7445	in	_	
35-12	7446-7451	study	_	
35-13	7451-7452	.	_	

#Text=Patients (N = 24)\tControls (N = 16)\tComparison\t \tDemographic Information\tSex\t8 Male\t16 Female\t6 Male\t10 Female\tNS\t \tMean\tStd\tMean\tStd\t \tAge (years)\t35.63\t(13.54)\t36.06\t(12.29)\tNS\t \tEducation (years)\t10.83\t(3.52)\t13.81\t(3.82)\tNS\t \tClinical Information\tDuration Ill (years)\t11.36\t(10.90)\t—\t—\t\t \tPANSS\t71.65\t(17.92)\t—\t—\t\t \tPositive\t17\t(6.32)\t—\t—\t\t \tNegative\t18.46\t(6.72)\t—\t—\t\t \tGeneral\t34.92\t(10.31)\t—\t—\t\t \tHAM-D 24\t8.92\t(9.49)\t0.56\t(0.89)\tp = 0.001\t \tHAM-A\t2.96\t(4.16)\t0.31\t(0.70)\tp < 0.1\t \tSeverity (SI)\t3.58\t(1.10)\t—\t—\t\t \tGlobal (GI)\t2.92\t(1.06)\t—\t—\t\t \tCPZe dosage\t297.2\t(177.87)\t—\t—\t\t \t
#Text=PANSS = Positive and Negative Syndrome Scale.
36-1	7454-7462	Patients	_	
36-2	7463-7464	(	_	
36-3	7464-7465	N	_	
36-4	7466-7467	=	_	
36-5	7468-7470	24	_	
36-6	7470-7471	)	_	
36-7	7472-7480	Controls	_	
36-8	7481-7482	(	_	
36-9	7482-7483	N	_	
36-10	7484-7485	=	_	
36-11	7486-7488	16	_	
36-12	7488-7489	)	_	
36-13	7490-7500	Comparison	_	
36-14	7503-7514	Demographic	_	
36-15	7514-7515	 	_	
36-16	7515-7526	Information	_	
36-17	7527-7530	Sex	_	
36-18	7531-7532	8	_	
36-19	7533-7537	Male	_	
36-20	7538-7540	16	_	
36-21	7541-7547	Female	_	
36-22	7548-7549	6	_	
36-23	7550-7554	Male	_	
36-24	7555-7557	10	_	
36-25	7558-7564	Female	_	
36-26	7565-7567	NS	_	
36-27	7570-7574	Mean	_	
36-28	7575-7578	Std	_	
36-29	7579-7583	Mean	_	
36-30	7584-7587	Std	_	
36-31	7590-7593	Age	_	
36-32	7593-7594	 	_	
36-33	7594-7595	(	_	
36-34	7595-7600	years	_	
36-35	7600-7601	)	_	
36-36	7602-7607	35.63	_	
36-37	7608-7609	(	_	
36-38	7609-7614	13.54	_	
36-39	7614-7615	)	_	
36-40	7616-7621	36.06	_	
36-41	7622-7623	(	_	
36-42	7623-7628	12.29	_	
36-43	7628-7629	)	_	
36-44	7630-7632	NS	_	
36-45	7635-7644	Education	_	
36-46	7644-7645	 	_	
36-47	7645-7646	(	_	
36-48	7646-7651	years	_	
36-49	7651-7652	)	_	
36-50	7653-7658	10.83	_	
36-51	7659-7660	(	_	
36-52	7660-7664	3.52	_	
36-53	7664-7665	)	_	
36-54	7666-7671	13.81	_	
36-55	7672-7673	(	_	
36-56	7673-7677	3.82	_	
36-57	7677-7678	)	_	
36-58	7679-7681	NS	_	
36-59	7684-7692	Clinical	_	
36-60	7693-7704	Information	_	
36-61	7705-7713	Duration	_	
36-62	7714-7717	Ill	_	
36-63	7718-7719	(	_	
36-64	7719-7724	years	_	
36-65	7724-7725	)	_	
36-66	7726-7731	11.36	_	
36-67	7732-7733	(	_	
36-68	7733-7738	10.90	_	
36-69	7738-7739	)	_	
36-70	7740-7741	—	_	
36-71	7742-7743	—	_	
36-72	7747-7752	PANSS	_	
36-73	7753-7758	71.65	_	
36-74	7759-7760	(	_	
36-75	7760-7765	17.92	_	
36-76	7765-7766	)	_	
36-77	7767-7768	—	_	
36-78	7769-7770	—	_	
36-79	7774-7782	Positive	_	
36-80	7783-7785	17	_	
36-81	7786-7787	(	_	
36-82	7787-7791	6.32	_	
36-83	7791-7792	)	_	
36-84	7793-7794	—	_	
36-85	7795-7796	—	_	
36-86	7800-7808	Negative	_	
36-87	7809-7814	18.46	_	
36-88	7815-7816	(	_	
36-89	7816-7820	6.72	_	
36-90	7820-7821	)	_	
36-91	7822-7823	—	_	
36-92	7824-7825	—	_	
36-93	7829-7836	General	_	
36-94	7837-7842	34.92	_	
36-95	7843-7844	(	_	
36-96	7844-7849	10.31	_	
36-97	7849-7850	)	_	
36-98	7851-7852	—	_	
36-99	7853-7854	—	_	
36-100	7858-7863	HAM-D	_	
36-101	7864-7866	24	_	
36-102	7867-7871	8.92	_	
36-103	7872-7873	(	_	
36-104	7873-7877	9.49	_	
36-105	7877-7878	)	_	
36-106	7879-7883	0.56	_	
36-107	7884-7885	(	_	
36-108	7885-7889	0.89	_	
36-109	7889-7890	)	_	
36-110	7891-7892	p	_	
36-111	7893-7894	=	_	
36-112	7895-7900	0.001	_	
36-113	7903-7908	HAM-A	_	
36-114	7909-7913	2.96	_	
36-115	7914-7915	(	_	
36-116	7915-7919	4.16	_	
36-117	7919-7920	)	_	
36-118	7921-7925	0.31	_	
36-119	7926-7927	(	_	
36-120	7927-7931	0.70	_	
36-121	7931-7932	)	_	
36-122	7933-7934	p	_	
36-123	7935-7936	<	_	
36-124	7937-7940	0.1	_	
36-125	7943-7951	Severity	_	
36-126	7952-7953	(	_	
36-127	7953-7955	SI	_	
36-128	7955-7956	)	_	
36-129	7957-7961	3.58	_	
36-130	7962-7963	(	_	
36-131	7963-7967	1.10	_	
36-132	7967-7968	)	_	
36-133	7969-7970	—	_	
36-134	7971-7972	—	_	
36-135	7976-7982	Global	_	
36-136	7983-7984	(	_	
36-137	7984-7986	GI	_	
36-138	7986-7987	)	_	
36-139	7988-7992	2.92	_	
36-140	7993-7994	(	_	
36-141	7994-7998	1.06	_	
36-142	7998-7999	)	_	
36-143	8000-8001	—	_	
36-144	8002-8003	—	_	
36-145	8007-8011	CPZe	_	
36-146	8012-8018	dosage	_	
36-147	8019-8024	297.2	_	
36-148	8025-8026	(	_	
36-149	8026-8032	177.87	_	
36-150	8032-8033	)	_	
36-151	8034-8035	—	_	
36-152	8036-8037	—	_	
36-153	8042-8047	PANSS	_	
36-154	8048-8049	=	_	
36-155	8050-8058	Positive	_	
36-156	8059-8062	and	_	
36-157	8063-8071	Negative	_	
36-158	8072-8080	Syndrome	_	
36-159	8081-8086	Scale	_	
36-160	8086-8087	.	_	

#Text=HAM-D = Hamilton Scale for Depression.
37-1	8088-8093	HAM-D	_	
37-2	8094-8095	=	_	
37-3	8096-8104	Hamilton	_	
37-4	8105-8110	Scale	_	
37-5	8111-8114	for	_	
37-6	8115-8125	Depression	_	
37-7	8125-8126	.	_	

#Text=HAM-A = Hamilton Scale for Anxiety.
38-1	8127-8132	HAM-A	_	
38-2	8133-8134	=	_	
38-3	8135-8143	Hamilton	_	
38-4	8144-8149	Scale	_	
38-5	8150-8153	for	_	
38-6	8154-8161	Anxiety	_	
38-7	8161-8162	.	_	

#Text=CPZe = Chlorpromazine equivalent dosage in mg.
39-1	8163-8167	CPZe	_	
39-2	8168-8169	=	_	
39-3	8170-8184	Chlorpromazine	_	
39-4	8185-8195	equivalent	_	
39-5	8196-8202	dosage	_	
39-6	8203-8205	in	_	
39-7	8206-8208	mg	_	
39-8	8208-8209	.	_	

#Text=Parentheses indicate standard deviation (SD).
40-1	8210-8221	Parentheses	_	
40-2	8222-8230	indicate	_	
40-3	8231-8239	standard	_	
40-4	8240-8249	deviation	_	
40-5	8250-8251	(	_	
40-6	8251-8253	SD	_	
40-7	8253-8254	)	_	
40-8	8254-8255	.	_	

#Text=Participates in this study consisted of 16 healthy controls (10 female) recruited from the local community and 24 patients (16 female) diagnosed with schizophrenia who were recruited from the Shanghai Mental Health Center in Shanghai, China.
41-1	8256-8268	Participates	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[4]	
41-2	8269-8271	in	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[4]	
41-3	8272-8276	this	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[4]	
41-4	8277-8282	study	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[4]	
41-5	8283-8292	consisted	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[4]	
41-6	8293-8295	of	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[4]	
41-7	8296-8298	16	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[4]	
41-8	8299-8306	healthy	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[4]|http://maven.renci.org/NeuroBridge/neurobridge#NoKnownDisorder[5]	
41-9	8307-8315	controls	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[4]|http://maven.renci.org/NeuroBridge/neurobridge#NoKnownDisorder[5]	
41-10	8316-8317	(	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[4]	
41-11	8317-8319	10	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[4]	
41-12	8320-8326	female	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[4]	
41-13	8326-8327	)	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[4]	
41-14	8328-8337	recruited	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[4]	
41-15	8338-8342	from	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[4]	
41-16	8343-8346	the	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[4]	
41-17	8347-8352	local	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[4]	
41-18	8353-8362	community	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[4]	
41-19	8363-8366	and	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[4]	
41-20	8367-8369	24	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[4]	
41-21	8370-8378	patients	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[4]	
41-22	8379-8380	(	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[4]	
41-23	8380-8382	16	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[4]	
41-24	8383-8389	female	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[4]	
41-25	8389-8390	)	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[4]	
41-26	8391-8400	diagnosed	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[4]	
41-27	8401-8405	with	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[4]	
41-28	8406-8419	schizophrenia	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[4]|http://maven.renci.org/NeuroBridge/neurobridge#Schizophrenia[6]	
41-29	8420-8423	who	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[4]	
41-30	8424-8428	were	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[4]	
41-31	8429-8438	recruited	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[4]	
41-32	8439-8443	from	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[4]	
41-33	8444-8447	the	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[4]	
41-34	8448-8456	Shanghai	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[4]	
41-35	8457-8463	Mental	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[4]	
41-36	8464-8470	Health	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[4]	
41-37	8471-8477	Center	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[4]	
41-38	8478-8480	in	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[4]	
41-39	8481-8489	Shanghai	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[4]	
41-40	8489-8490	,	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[4]	
41-41	8491-8496	China	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[4]	
41-42	8496-8497	.	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[4]	

#Text=Participants were all native Chinese over 18 years of age who voluntarily gave informed and written consent to participate in the study.
42-1	8498-8510	Participants	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[7]	
42-2	8511-8515	were	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[7]	
42-3	8516-8519	all	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[7]	
42-4	8520-8526	native	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[7]	
42-5	8527-8534	Chinese	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[7]	
42-6	8535-8539	over	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[7]	
42-7	8540-8542	18	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[7]	
42-8	8543-8548	years	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[7]	
42-9	8549-8551	of	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[7]	
42-10	8552-8555	age	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[7]	
42-11	8556-8559	who	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[7]	
42-12	8560-8571	voluntarily	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[7]	
42-13	8572-8576	gave	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[7]	
42-14	8577-8585	informed	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[7]	
42-15	8586-8589	and	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[7]	
42-16	8590-8597	written	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[7]	
42-17	8598-8605	consent	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[7]	
42-18	8606-8608	to	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[7]	
42-19	8609-8620	participate	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[7]	
42-20	8621-8623	in	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[7]	
42-21	8624-8627	the	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[7]	
42-22	8628-8633	study	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[7]	
42-23	8633-8634	.	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[7]	

#Text=The protocol in this study was reviewed, approved, and carried out according to the guidelines of the IRB of the Shanghai Mental Health.
43-1	8635-8638	The	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[8]	
43-2	8639-8647	protocol	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[8]	
43-3	8648-8650	in	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[8]	
43-4	8651-8655	this	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[8]	
43-5	8656-8661	study	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[8]	
43-6	8662-8665	was	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[8]	
43-7	8666-8674	reviewed	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[8]	
43-8	8674-8675	,	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[8]	
43-9	8676-8684	approved	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[8]	
43-10	8684-8685	,	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[8]	
43-11	8686-8689	and	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[8]	
43-12	8690-8697	carried	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[8]	
43-13	8698-8701	out	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[8]	
43-14	8702-8711	according	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[8]	
43-15	8712-8714	to	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[8]	
43-16	8715-8718	the	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[8]	
43-17	8719-8729	guidelines	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[8]	
43-18	8730-8732	of	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[8]	
43-19	8733-8736	the	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[8]	
43-20	8737-8740	IRB	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[8]	
43-21	8741-8743	of	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[8]	
43-22	8744-8747	the	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[8]	
43-23	8748-8756	Shanghai	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[8]	
43-24	8757-8763	Mental	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[8]	
43-25	8764-8770	Health	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[8]	
43-26	8770-8771	.	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[8]	

#Text=No significant differences were found between group age, education, or gender.
44-1	8772-8774	No	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[9]	
44-2	8775-8786	significant	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[9]	
44-3	8787-8798	differences	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[9]	
44-4	8799-8803	were	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[9]	
44-5	8804-8809	found	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[9]	
44-6	8810-8817	between	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[9]	
44-7	8818-8823	group	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[9]	
44-8	8824-8827	age	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[9]	
44-9	8827-8828	,	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[9]	
44-10	8829-8838	education	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[9]	
44-11	8838-8839	,	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[9]	
44-12	8840-8842	or	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[9]	
44-13	8843-8849	gender	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[9]	
44-14	8849-8850	.	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[9]	

#Text=All subjects participated in the HAM-D 24 Depression Scales and HAM-A Anxiety Scales.
45-1	8851-8854	All	_	
45-2	8855-8863	subjects	_	
45-3	8864-8876	participated	_	
45-4	8877-8879	in	_	
45-5	8880-8883	the	_	
45-6	8884-8889	HAM-D	_	
45-7	8890-8892	24	_	
45-8	8893-8903	Depression	_	
45-9	8904-8910	Scales	_	
45-10	8911-8914	and	_	
45-11	8915-8920	HAM-A	_	
45-12	8921-8928	Anxiety	_	
45-13	8929-8935	Scales	_	
45-14	8935-8936	.	_	

#Text=Patients were assessed according to the PANSS and its subscales.
46-1	8937-8945	Patients	_	
46-2	8946-8950	were	_	
46-3	8951-8959	assessed	_	
46-4	8960-8969	according	_	
46-5	8970-8972	to	_	
46-6	8973-8976	the	_	
46-7	8977-8982	PANSS	http://maven.renci.org/NeuroBridge/neurobridge#PositiveandNegativeSyndromeScale	
46-8	8983-8986	and	_	
46-9	8987-8990	its	_	
46-10	8991-9000	subscales	_	
46-11	9000-9001	.	_	

#Text=Patients scored significantly higher than controls on HAM Depression (p = 0.001) and Anxiety scores (p < 0.01) respectively.
47-1	9002-9010	Patients	_	
47-2	9011-9017	scored	_	
47-3	9018-9031	significantly	_	
47-4	9032-9038	higher	_	
47-5	9039-9043	than	_	
47-6	9044-9052	controls	_	
47-7	9053-9055	on	_	
47-8	9056-9059	HAM	_	
47-9	9060-9070	Depression	_	
47-10	9071-9072	(	_	
47-11	9072-9073	p	_	
47-12	9074-9075	=	_	
47-13	9076-9081	0.001	_	
47-14	9081-9082	)	_	
47-15	9083-9086	and	_	
47-16	9087-9094	Anxiety	_	
47-17	9095-9101	scores	_	
47-18	9102-9103	(	_	
47-19	9103-9104	p	_	
47-20	9105-9106	<	_	
47-21	9107-9111	0.01	_	
47-22	9111-9112	)	_	
47-23	9113-9125	respectively	_	
47-24	9125-9126	.	_	

#Text=Demographic information is presented in Table 1.
48-1	9127-9138	Demographic	_	
48-2	9139-9150	information	_	
48-3	9151-9153	is	_	
48-4	9154-9163	presented	_	
48-5	9164-9166	in	_	
48-6	9167-9172	Table	_	
48-7	9172-9173	 	_	
48-8	9173-9174	1	_	
48-9	9174-9175	.	_	

#Text=Detailed antipsychotic medication at time of testing for participants is listed in Supplementary Table A2.
49-1	9176-9184	Detailed	_	
49-2	9185-9198	antipsychotic	_	
49-3	9199-9209	medication	_	
49-4	9210-9212	at	_	
49-5	9213-9217	time	_	
49-6	9218-9220	of	_	
49-7	9221-9228	testing	_	
49-8	9229-9232	for	_	
49-9	9233-9245	participants	_	
49-10	9246-9248	is	_	
49-11	9249-9255	listed	_	
49-12	9256-9258	in	_	
49-13	9259-9272	Supplementary	_	
49-14	9273-9278	Table	_	
49-15	9278-9279	 	_	
49-16	9279-9281	A2	_	
49-17	9281-9282	.	_	

#Text=Experimental procedure
#Text=Protocol for implementation of the sustained attention task (SAT) trial (A) and the visuospatial SAT (vSAT) trial (B) (Based on modified task from Demeter et al.).
50-1	9283-9295	Experimental	_	
50-2	9296-9305	procedure	_	
50-3	9306-9314	Protocol	_	
50-4	9315-9318	for	_	
50-5	9319-9333	implementation	_	
50-6	9334-9336	of	_	
50-7	9337-9340	the	_	
50-8	9341-9350	sustained	_	
50-9	9351-9360	attention	_	
50-10	9361-9365	task	_	
50-11	9366-9367	(	_	
50-12	9367-9370	SAT	_	
50-13	9370-9371	)	_	
50-14	9372-9377	trial	_	
50-15	9377-9378	 	_	
50-16	9378-9379	(	_	
50-17	9379-9380	A	_	
50-18	9380-9381	)	_	
50-19	9382-9385	and	_	
50-20	9386-9389	the	_	
50-21	9390-9402	visuospatial	_	
50-22	9403-9406	SAT	_	
50-23	9407-9408	(	_	
50-24	9408-9412	vSAT	_	
50-25	9412-9413	)	_	
50-26	9414-9419	trial	_	
50-27	9420-9421	(	_	
50-28	9421-9422	B	_	
50-29	9422-9423	)	_	
50-30	9423-9424	 	_	
50-31	9424-9425	(	_	
50-32	9425-9430	Based	_	
50-33	9431-9433	on	_	
50-34	9434-9442	modified	_	
50-35	9443-9447	task	_	
50-36	9448-9452	from	_	
50-37	9453-9460	Demeter	_	
50-38	9461-9463	et	_	
50-39	9464-9466	al	_	
50-40	9466-9467	.	_	
50-41	9467-9468	)	_	
50-42	9468-9469	.	_	

#Text=The SAT was constructed using a custom OpenGL program based on the methodology detailed in Demeter et al..
51-1	9470-9473	The	_	
51-2	9474-9477	SAT	_	
51-3	9478-9481	was	_	
51-4	9482-9493	constructed	_	
51-5	9494-9499	using	_	
51-6	9500-9501	a	_	
51-7	9502-9508	custom	_	
51-8	9509-9515	OpenGL	_	
51-9	9516-9523	program	_	
51-10	9524-9529	based	_	
51-11	9530-9532	on	_	
51-12	9533-9536	the	_	
51-13	9537-9548	methodology	_	
51-14	9549-9557	detailed	_	
51-15	9558-9560	in	_	
51-16	9561-9568	Demeter	_	
51-17	9569-9571	et	_	
51-18	9572-9574	al	_	
51-19	9574-9575	.	_	
51-20	9575-9576	.	_	

#Text=Participants were asked to monitor a silver screen (Lum 170) for a signal consisting of the appearance of a small gray square (Lum 107) in the center of the screen for varying durations of 20, 30 or 50 ms (corresponding to 1, 2, and 3 frames at a typical refresh rate of 60 Hz).
52-1	9577-9589	Participants	_	
52-2	9590-9594	were	_	
52-3	9595-9600	asked	_	
52-4	9601-9603	to	_	
52-5	9604-9611	monitor	_	
52-6	9612-9613	a	_	
52-7	9614-9620	silver	_	
52-8	9621-9627	screen	_	
52-9	9628-9629	(	_	
52-10	9629-9632	Lum	_	
52-11	9633-9636	170	_	
52-12	9636-9637	)	_	
52-13	9638-9641	for	_	
52-14	9642-9643	a	_	
52-15	9644-9650	signal	_	
52-16	9651-9661	consisting	_	
52-17	9662-9664	of	_	
52-18	9665-9668	the	_	
52-19	9669-9679	appearance	_	
52-20	9680-9682	of	_	
52-21	9683-9684	a	_	
52-22	9685-9690	small	_	
52-23	9691-9695	gray	_	
52-24	9696-9702	square	_	
52-25	9703-9704	(	_	
52-26	9704-9707	Lum	_	
52-27	9708-9711	107	_	
52-28	9711-9712	)	_	
52-29	9713-9715	in	_	
52-30	9716-9719	the	_	
52-31	9720-9726	center	_	
52-32	9727-9729	of	_	
52-33	9730-9733	the	_	
52-34	9734-9740	screen	_	
52-35	9741-9744	for	_	
52-36	9745-9752	varying	_	
52-37	9753-9762	durations	_	
52-38	9763-9765	of	_	
52-39	9766-9768	20	_	
52-40	9768-9769	,	_	
52-41	9770-9772	30	_	
52-42	9773-9775	or	_	
52-43	9776-9778	50	_	
52-44	9779-9781	ms	_	
52-45	9782-9783	(	_	
52-46	9783-9796	corresponding	_	
52-47	9797-9799	to	_	
52-48	9800-9801	1	_	
52-49	9801-9802	,	_	
52-50	9803-9804	2	_	
52-51	9804-9805	,	_	
52-52	9806-9809	and	_	
52-53	9810-9811	3	_	
52-54	9812-9818	frames	_	
52-55	9819-9821	at	_	
52-56	9822-9823	a	_	
52-57	9824-9831	typical	_	
52-58	9832-9839	refresh	_	
52-59	9840-9844	rate	_	
52-60	9845-9847	of	_	
52-61	9848-9850	60	_	
52-62	9851-9853	Hz	_	
52-63	9853-9854	)	_	
52-64	9854-9855	.	_	

#Text=Monitoring times before signal/non-signal presentation were varied pseudo randomly at a 1, 2, or 3 s inter-trial interval, and signal frequency was roughly 50% (Fig. 1). 100 ms following the appearance or non-appearance of the signal, the subject was informed by an audio cue and asked to denote whether the event was a signal or non-signal using the left and right mouse click respectively.
53-1	9856-9866	Monitoring	_	
53-2	9867-9872	times	_	
53-3	9873-9879	before	_	
53-4	9880-9886	signal	_	
53-5	9886-9887	/	_	
53-6	9887-9897	non-signal	_	
53-7	9898-9910	presentation	_	
53-8	9911-9915	were	_	
53-9	9916-9922	varied	_	
53-10	9923-9929	pseudo	_	
53-11	9930-9938	randomly	_	
53-12	9939-9941	at	_	
53-13	9942-9943	a	_	
53-14	9944-9945	1	_	
53-15	9945-9946	,	_	
53-16	9947-9948	2	_	
53-17	9948-9949	,	_	
53-18	9950-9952	or	_	
53-19	9953-9954	3	_	
53-20	9955-9956	s	_	
53-21	9957-9968	inter-trial	_	
53-22	9969-9977	interval	_	
53-23	9977-9978	,	_	
53-24	9979-9982	and	_	
53-25	9983-9989	signal	_	
53-26	9990-9999	frequency	_	
53-27	10000-10003	was	_	
53-28	10004-10011	roughly	_	
53-29	10012-10015	50%	_	
53-30	10016-10017	(	_	
53-31	10017-10020	Fig	_	
53-32	10020-10021	.	_	
53-33	10021-10022	 	_	
53-34	10022-10023	1	_	
53-35	10023-10024	)	_	
53-36	10024-10025	.	_	
53-37	10026-10029	100	_	
53-38	10030-10032	ms	_	
53-39	10033-10042	following	_	
53-40	10043-10046	the	_	
53-41	10047-10057	appearance	_	
53-42	10058-10060	or	_	
53-43	10061-10075	non-appearance	_	
53-44	10076-10078	of	_	
53-45	10079-10082	the	_	
53-46	10083-10089	signal	_	
53-47	10089-10090	,	_	
53-48	10091-10094	the	_	
53-49	10095-10102	subject	_	
53-50	10103-10106	was	_	
53-51	10107-10115	informed	_	
53-52	10116-10118	by	_	
53-53	10119-10121	an	_	
53-54	10122-10127	audio	_	
53-55	10128-10131	cue	_	
53-56	10132-10135	and	_	
53-57	10136-10141	asked	_	
53-58	10142-10144	to	_	
53-59	10145-10151	denote	_	
53-60	10152-10159	whether	_	
53-61	10160-10163	the	_	
53-62	10164-10169	event	_	
53-63	10170-10173	was	_	
53-64	10174-10175	a	_	
53-65	10176-10182	signal	_	
53-66	10183-10185	or	_	
53-67	10186-10196	non-signal	_	
53-68	10197-10202	using	_	
53-69	10203-10206	the	_	
53-70	10207-10211	left	_	
53-71	10212-10215	and	_	
53-72	10216-10221	right	_	
53-73	10222-10227	mouse	_	
53-74	10228-10233	click	_	
53-75	10234-10246	respectively	_	
53-76	10246-10247	.	_	

#Text=The subject then was given 1500 ms to classify the event.
54-1	10248-10251	The	_	
54-2	10252-10259	subject	_	
54-3	10260-10264	then	_	
54-4	10265-10268	was	_	
54-5	10269-10274	given	_	
54-6	10275-10279	1500	_	
54-7	10280-10282	ms	_	
54-8	10283-10285	to	_	
54-9	10286-10294	classify	_	
54-10	10295-10298	the	_	
54-11	10299-10304	event	_	
54-12	10304-10305	.	_	

#Text=Correct classifications were immediately given an audio feedback, while incorrect trials receive no feedback.
55-1	10306-10313	Correct	_	
55-2	10314-10329	classifications	_	
55-3	10330-10334	were	_	
55-4	10335-10346	immediately	_	
55-5	10347-10352	given	_	
55-6	10353-10355	an	_	
55-7	10356-10361	audio	_	
55-8	10362-10370	feedback	_	
55-9	10370-10371	,	_	
55-10	10372-10377	while	_	
55-11	10378-10387	incorrect	_	
55-12	10388-10394	trials	_	
55-13	10395-10402	receive	_	
55-14	10403-10405	no	_	
55-15	10406-10414	feedback	_	
55-16	10414-10415	.	_	

#Text=Each task block was preceded by a 30 second resting period and lasted for approximately 120 seconds with approximately 42 stimulus trials in each task block.
56-1	10416-10420	Each	_	
56-2	10421-10425	task	_	
56-3	10426-10431	block	_	
56-4	10432-10435	was	_	
56-5	10436-10444	preceded	_	
56-6	10445-10447	by	_	
56-7	10448-10449	a	_	
56-8	10450-10452	30	_	
56-9	10453-10459	second	_	
56-10	10460-10467	resting	_	
56-11	10468-10474	period	_	
56-12	10475-10478	and	_	
56-13	10479-10485	lasted	_	
56-14	10486-10489	for	_	
56-15	10490-10503	approximately	_	
56-16	10504-10507	120	_	
56-17	10508-10515	seconds	_	
56-18	10516-10520	with	_	
56-19	10521-10534	approximately	_	
56-20	10535-10537	42	_	
56-21	10538-10546	stimulus	_	
56-22	10547-10553	trials	_	
56-23	10554-10556	in	_	
56-24	10557-10561	each	_	
56-25	10562-10566	task	_	
56-26	10567-10572	block	_	
56-27	10572-10573	.	_	

#Text=Following the end of each block, a cumulative performance metric is displayed to the subject.
57-1	10574-10583	Following	_	
57-2	10584-10587	the	_	
57-3	10588-10591	end	_	
57-4	10592-10594	of	_	
57-5	10595-10599	each	_	
57-6	10600-10605	block	_	
57-7	10605-10606	,	_	
57-8	10607-10608	a	_	
57-9	10609-10619	cumulative	_	
57-10	10620-10631	performance	_	
57-11	10632-10638	metric	_	
57-12	10639-10641	is	_	
57-13	10642-10651	displayed	_	
57-14	10652-10654	to	_	
57-15	10655-10658	the	_	
57-16	10659-10666	subject	_	
57-17	10666-10667	.	_	

#Text=Each subject performed a total of 4 blocks, with two repetitions for each task type (vSAT & SAT).
58-1	10668-10672	Each	_	
58-2	10673-10680	subject	_	
58-3	10681-10690	performed	_	
58-4	10691-10692	a	_	
58-5	10693-10698	total	_	
58-6	10699-10701	of	_	
58-7	10702-10703	4	_	
58-8	10704-10710	blocks	_	
58-9	10710-10711	,	_	
58-10	10712-10716	with	_	
58-11	10717-10720	two	_	
58-12	10721-10732	repetitions	_	
58-13	10733-10736	for	_	
58-14	10737-10741	each	_	
58-15	10742-10746	task	_	
58-16	10747-10751	type	_	
58-17	10752-10753	(	_	
58-18	10753-10757	vSAT	_	
58-19	10758-10759	&	_	
58-20	10760-10763	SAT	_	
58-21	10763-10764	)	_	
58-22	10764-10765	.	_	

#Text=A modification to the SAT, detailed here as vSAT, was used to introduce broadened attentional focus through the introduction of a visuospatial component.
59-1	10766-10767	A	_	
59-2	10768-10780	modification	_	
59-3	10781-10783	to	_	
59-4	10784-10787	the	_	
59-5	10788-10791	SAT	_	
59-6	10791-10792	,	_	
59-7	10793-10801	detailed	_	
59-8	10802-10806	here	_	
59-9	10807-10809	as	_	
59-10	10810-10814	vSAT	_	
59-11	10814-10815	,	_	
59-12	10816-10819	was	_	
59-13	10820-10824	used	_	
59-14	10825-10827	to	_	
59-15	10828-10837	introduce	_	
59-16	10838-10847	broadened	_	
59-17	10848-10859	attentional	_	
59-18	10860-10865	focus	_	
59-19	10866-10873	through	_	
59-20	10874-10877	the	_	
59-21	10878-10890	introduction	_	
59-22	10891-10893	of	_	
59-23	10894-10895	a	_	
59-24	10896-10908	visuospatial	_	
59-25	10909-10918	component	_	
59-26	10918-10919	.	_	

#Text=The task in vSAT is similar to the VSL-SAT task described by Demeter et al. with two modifications intended to increase task difficulty by requiring additional attentional resources.
60-1	10920-10923	The	_	
60-2	10924-10928	task	_	
60-3	10929-10931	in	_	
60-4	10932-10936	vSAT	_	
60-5	10937-10939	is	_	
60-6	10940-10947	similar	_	
60-7	10948-10950	to	_	
60-8	10951-10954	the	_	
60-9	10955-10962	VSL-SAT	_	
60-10	10963-10967	task	_	
60-11	10968-10977	described	_	
60-12	10978-10980	by	_	
60-13	10981-10988	Demeter	_	
60-14	10989-10991	et	_	
60-15	10992-10994	al	_	
60-16	10994-10995	.	_	
60-17	10996-11000	with	_	
60-18	11001-11004	two	_	
60-19	11005-11018	modifications	_	
60-20	11019-11027	intended	_	
60-21	11028-11030	to	_	
60-22	11031-11039	increase	_	
60-23	11040-11044	task	_	
60-24	11045-11055	difficulty	_	
60-25	11056-11058	by	_	
60-26	11059-11068	requiring	_	
60-27	11069-11079	additional	_	
60-28	11080-11091	attentional	_	
60-29	11092-11101	resources	_	
60-30	11101-11102	.	_	

#Text=Contrast between the silver background and the signal was reduced by using a lighter gray block (Lum 155) to reduce the prominence of the signal.
61-1	11103-11111	Contrast	_	
61-2	11112-11119	between	_	
61-3	11120-11123	the	_	
61-4	11124-11130	silver	_	
61-5	11131-11141	background	_	
61-6	11142-11145	and	_	
61-7	11146-11149	the	_	
61-8	11150-11156	signal	_	
61-9	11157-11160	was	_	
61-10	11161-11168	reduced	_	
61-11	11169-11171	by	_	
61-12	11172-11177	using	_	
61-13	11178-11179	a	_	
61-14	11180-11187	lighter	_	
61-15	11188-11192	gray	_	
61-16	11193-11198	block	_	
61-17	11199-11200	(	_	
61-18	11200-11203	Lum	_	
61-19	11204-11207	155	_	
61-20	11207-11208	)	_	
61-21	11209-11211	to	_	
61-22	11212-11218	reduce	_	
61-23	11219-11222	the	_	
61-24	11223-11233	prominence	_	
61-25	11234-11236	of	_	
61-26	11237-11240	the	_	
61-27	11241-11247	signal	_	
61-28	11247-11248	.	_	

#Text=Additionally, signal location was pseudo randomly presented at one of 5 separate locations on the screen (Center, Top-Left, Top-Right, Bottom-Right, and Bottom-Left).
62-1	11249-11261	Additionally	_	
62-2	11261-11262	,	_	
62-3	11263-11269	signal	_	
62-4	11270-11278	location	_	
62-5	11279-11282	was	_	
62-6	11283-11289	pseudo	_	
62-7	11290-11298	randomly	_	
62-8	11299-11308	presented	_	
62-9	11309-11311	at	_	
62-10	11312-11315	one	_	
62-11	11316-11318	of	_	
62-12	11319-11320	5	_	
62-13	11321-11329	separate	_	
62-14	11330-11339	locations	_	
62-15	11340-11342	on	_	
62-16	11343-11346	the	_	
62-17	11347-11353	screen	_	
62-18	11354-11355	(	_	
62-19	11355-11361	Center	_	
62-20	11361-11362	,	_	
62-21	11363-11371	Top-Left	_	
62-22	11371-11372	,	_	
62-23	11373-11382	Top-Right	_	
62-24	11382-11383	,	_	
62-25	11384-11396	Bottom-Right	_	
62-26	11396-11397	,	_	
62-27	11398-11401	and	_	
62-28	11402-11413	Bottom-Left	_	
62-29	11413-11414	)	_	
62-30	11414-11415	.	_	

#Text=An illustration describing the protocol is presented in Fig. 1.
63-1	11416-11418	An	_	
63-2	11419-11431	illustration	_	
63-3	11432-11442	describing	_	
63-4	11443-11446	the	_	
63-5	11447-11455	protocol	_	
63-6	11456-11458	is	_	
63-7	11459-11468	presented	_	
63-8	11469-11471	in	_	
63-9	11472-11475	Fig	_	
63-10	11475-11476	.	_	
63-11	11476-11477	 	_	
63-12	11477-11478	1	_	
63-13	11478-11479	.	_	

#Text=Task performance was assessed using the SAT score, calculated using the methodology defined by Demeter et al..
64-1	11480-11484	Task	_	
64-2	11485-11496	performance	_	
64-3	11497-11500	was	_	
64-4	11501-11509	assessed	_	
64-5	11510-11515	using	_	
64-6	11516-11519	the	_	
64-7	11520-11523	SAT	_	
64-8	11524-11529	score	_	
64-9	11529-11530	,	_	
64-10	11531-11541	calculated	_	
64-11	11542-11547	using	_	
64-12	11548-11551	the	_	
64-13	11552-11563	methodology	_	
64-14	11564-11571	defined	_	
64-15	11572-11574	by	_	
64-16	11575-11582	Demeter	_	
64-17	11583-11585	et	_	
64-18	11586-11588	al	_	
64-19	11588-11589	.	_	
64-20	11589-11590	.	_	

#Text=This metric, which had been previously identified as the “Vigilance Index”, was identified as being comparable to other signal-detection measurements, namely d-prime, and uninfluenced by errors of omission.
65-1	11591-11595	This	_	
65-2	11596-11602	metric	_	
65-3	11602-11603	,	_	
65-4	11604-11609	which	_	
65-5	11610-11613	had	_	
65-6	11614-11618	been	_	
65-7	11619-11629	previously	_	
65-8	11630-11640	identified	_	
65-9	11641-11643	as	_	
65-10	11644-11647	the	_	
65-11	11648-11649	“	_	
65-12	11649-11658	Vigilance	_	
65-13	11659-11664	Index	_	
65-14	11664-11665	”	_	
65-15	11665-11666	,	_	
65-16	11667-11670	was	_	
65-17	11671-11681	identified	_	
65-18	11682-11684	as	_	
65-19	11685-11690	being	_	
65-20	11691-11701	comparable	_	
65-21	11702-11704	to	_	
65-22	11705-11710	other	_	
65-23	11711-11727	signal-detection	_	
65-24	11728-11740	measurements	_	
65-25	11740-11741	,	_	
65-26	11742-11748	namely	_	
65-27	11749-11756	d-prime	_	
65-28	11756-11757	,	_	
65-29	11758-11761	and	_	
65-30	11762-11774	uninfluenced	_	
65-31	11775-11777	by	_	
65-32	11778-11784	errors	_	
65-33	11785-11787	of	_	
65-34	11788-11796	omission	_	
65-35	11796-11797	.	_	

#Text=SAT score is defined aswhere Hits mean probability of correct signal/non-signal classification and False Alarms denote probability of incorrect signal/non-signal classification.
66-1	11798-11801	SAT	_	
66-2	11802-11807	score	_	
66-3	11808-11810	is	_	
66-4	11811-11818	defined	_	
66-5	11819-11826	aswhere	_	
66-6	11827-11831	Hits	_	
66-7	11832-11836	mean	_	
66-8	11837-11848	probability	_	
66-9	11849-11851	of	_	
66-10	11852-11859	correct	_	
66-11	11860-11866	signal	_	
66-12	11866-11867	/	_	
66-13	11867-11877	non-signal	_	
66-14	11878-11892	classification	_	
66-15	11893-11896	and	_	
66-16	11897-11902	False	_	
66-17	11903-11909	Alarms	_	
66-18	11910-11916	denote	_	
66-19	11917-11928	probability	_	
66-20	11929-11931	of	_	
66-21	11932-11941	incorrect	_	
66-22	11942-11948	signal	_	
66-23	11948-11949	/	_	
66-24	11949-11959	non-signal	_	
66-25	11960-11974	classification	_	
66-26	11974-11975	.	_	

#Text=SAT score ranges from −1 to + 1, with +1 indicating correct classification of all signal/non-signal events and −1 indicating that all responses were false alarms.
67-1	11976-11979	SAT	_	
67-2	11980-11985	score	_	
67-3	11986-11992	ranges	_	
67-4	11993-11997	from	_	
67-5	11998-11999	−	_	
67-6	11999-12000	1	_	
67-7	12001-12003	to	_	
67-8	12004-12005	+	_	
67-9	12006-12007	1	_	
67-10	12007-12008	,	_	
67-11	12009-12013	with	_	
67-12	12014-12015	+	_	
67-13	12015-12016	1	_	
67-14	12017-12027	indicating	_	
67-15	12028-12035	correct	_	
67-16	12036-12050	classification	_	
67-17	12051-12053	of	_	
67-18	12054-12057	all	_	
67-19	12058-12064	signal	_	
67-20	12064-12065	/	_	
67-21	12065-12075	non-signal	_	
67-22	12076-12082	events	_	
67-23	12083-12086	and	_	
67-24	12087-12088	−	_	
67-25	12088-12089	1	_	
67-26	12090-12100	indicating	_	
67-27	12101-12105	that	_	
67-28	12106-12109	all	_	
67-29	12110-12119	responses	_	
67-30	12120-12124	were	_	
67-31	12125-12130	false	_	
67-32	12131-12137	alarms	_	
67-33	12137-12138	.	_	

#Text=Additionally, we calculated the Score Difference as a measure of performance changes associated with Task Type manipulation.
68-1	12139-12151	Additionally	_	
68-2	12151-12152	,	_	
68-3	12153-12155	we	_	
68-4	12156-12166	calculated	_	
68-5	12167-12170	the	_	
68-6	12171-12176	Score	_	
68-7	12177-12187	Difference	_	
68-8	12188-12190	as	_	
68-9	12191-12192	a	_	
68-10	12193-12200	measure	_	
68-11	12201-12203	of	_	
68-12	12204-12215	performance	_	
68-13	12216-12223	changes	_	
68-14	12224-12234	associated	_	
68-15	12235-12239	with	_	
68-16	12240-12244	Task	_	
68-17	12245-12249	Type	_	
68-18	12250-12262	manipulation	_	
68-19	12262-12263	.	_	

#Text=Score Difference (ScoreDiffvSAT) was calculated as the difference between Score on the vSAT task and the subject’s mean SAT score.
69-1	12264-12269	Score	_	
69-2	12270-12280	Difference	_	
69-3	12281-12282	(	_	
69-4	12282-12295	ScoreDiffvSAT	_	
69-5	12295-12296	)	_	
69-6	12297-12300	was	_	
69-7	12301-12311	calculated	_	
69-8	12312-12314	as	_	
69-9	12315-12318	the	_	
69-10	12319-12329	difference	_	
69-11	12330-12337	between	_	
69-12	12338-12343	Score	_	
69-13	12344-12346	on	_	
69-14	12347-12350	the	_	
69-15	12351-12355	vSAT	_	
69-16	12356-12360	task	_	
69-17	12361-12364	and	_	
69-18	12365-12368	the	_	
69-19	12369-12376	subject	_	
69-20	12376-12377	’	_	
69-21	12377-12378	s	_	
69-22	12379-12383	mean	_	
69-23	12384-12387	SAT	_	
69-24	12388-12393	score	_	
69-25	12393-12394	.	_	

#Text=Larger values of ScoreDiffvSAT are undesirable and would indicate large performance decreases associated with task type variation and increased sensitivity to attentional demand manipulation.
#Text=fNIRS data acquisition and processing
#Text=Neuroimaging data was collected for 16 channels at 2 Hz from the anterior PFC (BA 10/46) using the fNIR1100 imager (fNIR Devices, Potomac, MD, USA) using COBI Studio as described in detail at Ayaz et al..
70-1	12395-12401	Larger	_	
70-2	12402-12408	values	_	
70-3	12409-12411	of	_	
70-4	12412-12425	ScoreDiffvSAT	_	
70-5	12426-12429	are	_	
70-6	12430-12441	undesirable	_	
70-7	12442-12445	and	_	
70-8	12446-12451	would	_	
70-9	12452-12460	indicate	_	
70-10	12461-12466	large	_	
70-11	12467-12478	performance	_	
70-12	12479-12488	decreases	_	
70-13	12489-12499	associated	_	
70-14	12500-12504	with	_	
70-15	12505-12509	task	_	
70-16	12510-12514	type	_	
70-17	12515-12524	variation	_	
70-18	12525-12528	and	_	
70-19	12529-12538	increased	_	
70-20	12539-12550	sensitivity	_	
70-21	12551-12553	to	_	
70-22	12554-12565	attentional	_	
70-23	12566-12572	demand	_	
70-24	12573-12585	manipulation	_	
70-25	12585-12586	.	_	
70-26	12587-12592	fNIRS	http://maven.renci.org/NeuroBridge/neurobridge#FunctionalNearInfraredSpectroscopy	
70-27	12593-12597	data	_	
70-28	12598-12609	acquisition	_	
70-29	12610-12613	and	_	
70-30	12614-12624	processing	_	
70-31	12625-12637	Neuroimaging	_	
70-32	12638-12642	data	_	
70-33	12643-12646	was	_	
70-34	12647-12656	collected	_	
70-35	12657-12660	for	_	
70-36	12661-12663	16	_	
70-37	12664-12672	channels	_	
70-38	12673-12675	at	_	
70-39	12676-12677	2	_	
70-40	12678-12680	Hz	_	
70-41	12681-12685	from	_	
70-42	12686-12689	the	_	
70-43	12690-12698	anterior	_	
70-44	12699-12702	PFC	_	
70-45	12703-12704	(	_	
70-46	12704-12706	BA	_	
70-47	12707-12709	10	_	
70-48	12709-12710	/	_	
70-49	12710-12712	46	_	
70-50	12712-12713	)	_	
70-51	12714-12719	using	_	
70-52	12720-12723	the	_	
70-53	12724-12732	fNIR1100	_	
70-54	12733-12739	imager	_	
70-55	12740-12741	(	_	
70-56	12741-12745	fNIR	_	
70-57	12746-12753	Devices	_	
70-58	12753-12754	,	_	
70-59	12755-12762	Potomac	_	
70-60	12762-12763	,	_	
70-61	12764-12766	MD	_	
70-62	12766-12767	,	_	
70-63	12768-12771	USA	_	
70-64	12771-12772	)	_	
70-65	12773-12778	using	_	
70-66	12779-12783	COBI	_	
70-67	12784-12790	Studio	_	
70-68	12791-12793	as	_	
70-69	12794-12803	described	_	
70-70	12804-12806	in	_	
70-71	12807-12813	detail	_	
70-72	12814-12816	at	_	
70-73	12817-12821	Ayaz	_	
70-74	12822-12824	et	_	
70-75	12825-12827	al	_	
70-76	12827-12828	.	_	
70-77	12828-12829	.	_	

#Text=The fNIRS sensor was symmetrically centered and in line with Fp1 and Fp2 of the international 10–20 system on the subject’s forehead.
71-1	12830-12833	The	_	
71-2	12834-12839	fNIRS	http://maven.renci.org/NeuroBridge/neurobridge#FunctionalNearInfraredSpectroscopy	
71-3	12840-12846	sensor	_	
71-4	12847-12850	was	_	
71-5	12851-12864	symmetrically	_	
71-6	12865-12873	centered	_	
71-7	12874-12877	and	_	
71-8	12878-12880	in	_	
71-9	12881-12885	line	_	
71-10	12886-12890	with	_	
71-11	12891-12894	Fp1	_	
71-12	12895-12898	and	_	
71-13	12899-12902	Fp2	_	
71-14	12903-12905	of	_	
71-15	12906-12909	the	_	
71-16	12910-12923	international	_	
71-17	12924-12926	10	_	
71-18	12926-12927	–	_	
71-19	12927-12929	20	_	
71-20	12930-12936	system	_	
71-21	12937-12939	on	_	
71-22	12940-12943	the	_	
71-23	12944-12951	subject	_	
71-24	12951-12952	’	_	
71-25	12952-12953	s	_	
71-26	12954-12962	forehead	_	
71-27	12962-12963	.	_	

#Text=The light intensity and detector gain were adjusted during setup to obtain sufficiently high but unsaturated intensity signals according to subject and environmental conditions.
72-1	12964-12967	The	_	
72-2	12968-12973	light	_	
72-3	12974-12983	intensity	_	
72-4	12984-12987	and	_	
72-5	12988-12996	detector	_	
72-6	12997-13001	gain	_	
72-7	13002-13006	were	_	
72-8	13007-13015	adjusted	_	
72-9	13016-13022	during	_	
72-10	13023-13028	setup	_	
72-11	13029-13031	to	_	
72-12	13032-13038	obtain	_	
72-13	13039-13051	sufficiently	_	
72-14	13052-13056	high	_	
72-15	13057-13060	but	_	
72-16	13061-13072	unsaturated	_	
72-17	13073-13082	intensity	_	
72-18	13083-13090	signals	_	
72-19	13091-13100	according	_	
72-20	13101-13103	to	_	
72-21	13104-13111	subject	_	
72-22	13112-13115	and	_	
72-23	13116-13129	environmental	_	
72-24	13130-13140	conditions	_	
72-25	13140-13141	.	_	

#Text=Channels were visually inspected for signal validity and the signal quality of individual task blocks was assessed and automatically rejected using the criteria adapted from Takizawa et al..
73-1	13142-13150	Channels	_	
73-2	13151-13155	were	_	
73-3	13156-13164	visually	_	
73-4	13165-13174	inspected	_	
73-5	13175-13178	for	_	
73-6	13179-13185	signal	_	
73-7	13186-13194	validity	_	
73-8	13195-13198	and	_	
73-9	13199-13202	the	_	
73-10	13203-13209	signal	_	
73-11	13210-13217	quality	_	
73-12	13218-13220	of	_	
73-13	13221-13231	individual	_	
73-14	13232-13236	task	_	
73-15	13237-13243	blocks	_	
73-16	13244-13247	was	_	
73-17	13248-13256	assessed	_	
73-18	13257-13260	and	_	
73-19	13261-13274	automatically	_	
73-20	13275-13283	rejected	_	
73-21	13284-13289	using	_	
73-22	13290-13293	the	_	
73-23	13294-13302	criteria	_	
73-24	13303-13310	adapted	_	
73-25	13311-13315	from	_	
73-26	13316-13324	Takizawa	_	
73-27	13325-13327	et	_	
73-28	13328-13330	al	_	
73-29	13330-13331	.	_	
73-30	13331-13332	.	_	

#Text=Surviving blocks were screened for motion artifacts using the SMAR algorithm, and a bandpass filter (0.008–0.25 Hz) was used to reduce high frequency noise associated with respiratory or cardiac function and remove signal drift.
74-1	13333-13342	Surviving	_	
74-2	13343-13349	blocks	_	
74-3	13350-13354	were	_	
74-4	13355-13363	screened	_	
74-5	13364-13367	for	_	
74-6	13368-13374	motion	_	
74-7	13375-13384	artifacts	_	
74-8	13385-13390	using	_	
74-9	13391-13394	the	_	
74-10	13395-13399	SMAR	_	
74-11	13400-13409	algorithm	_	
74-12	13409-13410	,	_	
74-13	13411-13414	and	_	
74-14	13415-13416	a	_	
74-15	13417-13425	bandpass	_	
74-16	13426-13432	filter	_	
74-17	13433-13434	(	_	
74-18	13434-13439	0.008	_	
74-19	13439-13440	–	_	
74-20	13440-13444	0.25	_	
74-21	13445-13447	Hz	_	
74-22	13447-13448	)	_	
74-23	13449-13452	was	_	
74-24	13453-13457	used	_	
74-25	13458-13460	to	_	
74-26	13461-13467	reduce	_	
74-27	13468-13472	high	_	
74-28	13473-13482	frequency	_	
74-29	13483-13488	noise	_	
74-30	13489-13499	associated	_	
74-31	13500-13504	with	_	
74-32	13505-13516	respiratory	_	
74-33	13517-13519	or	_	
74-34	13520-13527	cardiac	_	
74-35	13528-13536	function	_	
74-36	13537-13540	and	_	
74-37	13541-13547	remove	_	
74-38	13548-13554	signal	_	
74-39	13555-13560	drift	_	
74-40	13560-13561	.	_	

#Text=Physiological parameters are calculated using the modified Beer-Lambert Law using the 5 seconds before task initiation as a baseline period.
75-1	13562-13575	Physiological	_	
75-2	13576-13586	parameters	_	
75-3	13587-13590	are	_	
75-4	13591-13601	calculated	_	
75-5	13602-13607	using	_	
75-6	13608-13611	the	_	
75-7	13612-13620	modified	_	
75-8	13621-13633	Beer-Lambert	_	
75-9	13634-13637	Law	_	
75-10	13638-13643	using	_	
75-11	13644-13647	the	_	
75-12	13648-13649	5	_	
75-13	13650-13657	seconds	_	
75-14	13658-13664	before	_	
75-15	13665-13669	task	_	
75-16	13670-13680	initiation	_	
75-17	13681-13683	as	_	
75-18	13684-13685	a	_	
75-19	13686-13694	baseline	_	
75-20	13695-13701	period	_	
75-21	13701-13702	.	_	

#Text=Extracted measures are reported as the fNIRS biomarkers of [HbO], [HbR], and an estimate of relative change in Oxygen availability [Oxy] (calculated as the difference between [HbO] and [HbR]).
76-1	13703-13712	Extracted	_	
76-2	13713-13721	measures	_	
76-3	13722-13725	are	_	
76-4	13726-13734	reported	_	
76-5	13735-13737	as	_	
76-6	13738-13741	the	_	
76-7	13742-13747	fNIRS	http://maven.renci.org/NeuroBridge/neurobridge#FunctionalNearInfraredSpectroscopy	
76-8	13748-13758	biomarkers	_	
76-9	13759-13761	of	_	
76-10	13762-13763	[	_	
76-11	13763-13766	HbO	_	
76-12	13766-13767	]	_	
76-13	13767-13768	,	_	
76-14	13769-13770	[	_	
76-15	13770-13773	HbR	_	
76-16	13773-13774	]	_	
76-17	13774-13775	,	_	
76-18	13776-13779	and	_	
76-19	13780-13782	an	_	
76-20	13783-13791	estimate	_	
76-21	13792-13794	of	_	
76-22	13795-13803	relative	_	
76-23	13804-13810	change	_	
76-24	13811-13813	in	_	
76-25	13814-13820	Oxygen	_	
76-26	13821-13833	availability	_	
76-27	13834-13835	[	_	
76-28	13835-13838	Oxy	_	
76-29	13838-13839	]	_	
76-30	13840-13841	(	_	
76-31	13841-13851	calculated	_	
76-32	13852-13854	as	_	
76-33	13855-13858	the	_	
76-34	13859-13869	difference	_	
76-35	13870-13877	between	_	
76-36	13878-13879	[	_	
76-37	13879-13882	HbO	_	
76-38	13882-13883	]	_	
76-39	13884-13887	and	_	
76-40	13888-13889	[	_	
76-41	13889-13892	HbR	_	
76-42	13892-13893	]	_	
76-43	13893-13894	)	_	
76-44	13894-13895	.	_	

#Text=The mean change from the pre-task baseline in fNIRS biomarkers ([HbO], [HbR], and [Oxy]) was assessed as the outcome of interest for statistical tests.
77-1	13896-13899	The	_	
77-2	13900-13904	mean	_	
77-3	13905-13911	change	_	
77-4	13912-13916	from	_	
77-5	13917-13920	the	_	
77-6	13921-13929	pre-task	_	
77-7	13930-13938	baseline	_	
77-8	13939-13941	in	_	
77-9	13942-13947	fNIRS	_	
77-10	13948-13958	biomarkers	_	
77-11	13959-13960	(	_	
77-12	13960-13961	[	_	
77-13	13961-13964	HbO	_	
77-14	13964-13965	]	_	
77-15	13965-13966	,	_	
77-16	13967-13968	[	_	
77-17	13968-13971	HbR	_	
77-18	13971-13972	]	_	
77-19	13972-13973	,	_	
77-20	13974-13977	and	_	
77-21	13978-13979	[	_	
77-22	13979-13982	Oxy	_	
77-23	13982-13983	]	_	
77-24	13983-13984	)	_	
77-25	13985-13988	was	_	
77-26	13989-13997	assessed	_	
77-27	13998-14000	as	_	
77-28	14001-14004	the	_	
77-29	14005-14012	outcome	_	
77-30	14013-14015	of	_	
77-31	14016-14024	interest	_	
77-32	14025-14028	for	_	
77-33	14029-14040	statistical	_	
77-34	14041-14046	tests	_	
77-35	14046-14047	.	_	

#Text=Parametric plots for visualization purposes were registered to a virtual brain according to the methodology described in Ayaz et al..
78-1	14048-14058	Parametric	_	
78-2	14059-14064	plots	_	
78-3	14065-14068	for	_	
78-4	14069-14082	visualization	_	
78-5	14083-14091	purposes	_	
78-6	14092-14096	were	_	
78-7	14097-14107	registered	_	
78-8	14108-14110	to	_	
78-9	14111-14112	a	_	
78-10	14113-14120	virtual	_	
78-11	14121-14126	brain	_	
78-12	14127-14136	according	_	
78-13	14137-14139	to	_	
78-14	14140-14143	the	_	
78-15	14144-14155	methodology	_	
78-16	14156-14165	described	_	
78-17	14166-14168	in	_	
78-18	14169-14173	Ayaz	_	
78-19	14174-14176	et	_	
78-20	14177-14179	al	_	
78-21	14179-14180	.	_	
78-22	14180-14181	.	_	

#Text=Estimated underlying gyri and Brodmann’s areas for Optodes 1–16 are described in the Supplementary Materials of Liu et al..
79-1	14182-14191	Estimated	_	
79-2	14192-14202	underlying	_	
79-3	14203-14207	gyri	_	
79-4	14208-14211	and	_	
79-5	14212-14220	Brodmann	_	
79-6	14220-14221	’	_	
79-7	14221-14222	s	_	
79-8	14223-14228	areas	_	
79-9	14229-14232	for	_	
79-10	14233-14240	Optodes	_	
79-11	14241-14242	1	_	
79-12	14242-14243	–	_	
79-13	14243-14245	16	_	
79-14	14246-14249	are	_	
79-15	14250-14259	described	_	
79-16	14260-14262	in	_	
79-17	14263-14266	the	_	
79-18	14267-14280	Supplementary	_	
79-19	14281-14290	Materials	_	
79-20	14291-14293	of	_	
79-21	14294-14297	Liu	_	
79-22	14298-14300	et	_	
79-23	14301-14303	al	_	
79-24	14303-14304	.	_	
79-25	14304-14305	.	_	

#Text=Statistical analysis
#Text=Data analysis was conducted using R (ver. 3.2.2) and SPSS (ver. 23.0.0, SPSS Inc.).
80-1	14306-14317	Statistical	_	
80-2	14318-14326	analysis	_	
80-3	14327-14331	Data	_	
80-4	14332-14340	analysis	_	
80-5	14341-14344	was	_	
80-6	14345-14354	conducted	_	
80-7	14355-14360	using	_	
80-8	14361-14362	R	_	
80-9	14363-14364	(	_	
80-10	14364-14367	ver	_	
80-11	14367-14368	.	_	
80-12	14369-14374	3.2.2	_	
80-13	14374-14375	)	_	
80-14	14376-14379	and	_	
80-15	14380-14384	SPSS	_	
80-16	14385-14386	(	_	
80-17	14386-14389	ver	_	
80-18	14389-14390	.	_	
80-19	14391-14397	23.0.0	_	
80-20	14397-14398	,	_	
80-21	14399-14403	SPSS	_	
80-22	14404-14407	Inc	_	
80-23	14407-14408	.	_	
80-24	14408-14409	)	_	
80-25	14409-14410	.	_	

#Text=Descriptive demographic and clinical statistics are presented as mean ± standard deviation or as a percentage of cases.
81-1	14411-14422	Descriptive	_	
81-2	14423-14434	demographic	_	
81-3	14435-14438	and	_	
81-4	14439-14447	clinical	_	
81-5	14448-14458	statistics	_	
81-6	14459-14462	are	_	
81-7	14463-14472	presented	_	
81-8	14473-14475	as	_	
81-9	14476-14480	mean	_	
81-10	14481-14482	±	_	
81-11	14483-14491	standard	_	
81-12	14492-14501	deviation	_	
81-13	14502-14504	or	_	
81-14	14505-14507	as	_	
81-15	14508-14509	a	_	
81-16	14510-14520	percentage	_	
81-17	14521-14523	of	_	
81-18	14524-14529	cases	_	
81-19	14529-14530	.	_	

#Text=An alpha level of α = 0.05 was used as the significance criteria for each test.
82-1	14531-14533	An	_	
82-2	14534-14539	alpha	_	
82-3	14540-14545	level	_	
82-4	14546-14548	of	_	
82-5	14549-14550	α	_	
82-6	14551-14552	=	_	
82-7	14553-14557	0.05	_	
82-8	14558-14561	was	_	
82-9	14562-14566	used	_	
82-10	14567-14569	as	_	
82-11	14570-14573	the	_	
82-12	14574-14586	significance	_	
82-13	14587-14595	criteria	_	
82-14	14596-14599	for	_	
82-15	14600-14604	each	_	
82-16	14605-14609	test	_	
82-17	14609-14610	.	_	

#Text=Differences between clinical scores and demographic metrics were tested using the Welch’s t-test except for gender distribution which was assessed using the Chi-square test.
83-1	14611-14622	Differences	_	
83-2	14623-14630	between	_	
83-3	14631-14639	clinical	_	
83-4	14640-14646	scores	_	
83-5	14647-14650	and	_	
83-6	14651-14662	demographic	_	
83-7	14663-14670	metrics	_	
83-8	14671-14675	were	_	
83-9	14676-14682	tested	_	
83-10	14683-14688	using	_	
83-11	14689-14692	the	_	
83-12	14693-14698	Welch	_	
83-13	14698-14699	’	_	
83-14	14699-14700	s	_	
83-15	14701-14707	t-test	_	
83-16	14708-14714	except	_	
83-17	14715-14718	for	_	
83-18	14719-14725	gender	_	
83-19	14726-14738	distribution	_	
83-20	14739-14744	which	_	
83-21	14745-14748	was	_	
83-22	14749-14757	assessed	_	
83-23	14758-14763	using	_	
83-24	14764-14767	the	_	
83-25	14768-14778	Chi-square	_	
83-26	14779-14783	test	_	
83-27	14783-14784	.	_	

#Text=Correlations for continuous variables are reported using Spearman’s rank correlation coefficients for identified groups as two-tailed test.
84-1	14785-14797	Correlations	_	
84-2	14798-14801	for	_	
84-3	14802-14812	continuous	_	
84-4	14813-14822	variables	_	
84-5	14823-14826	are	_	
84-6	14827-14835	reported	_	
84-7	14836-14841	using	_	
84-8	14842-14850	Spearman	_	
84-9	14850-14851	’	_	
84-10	14851-14852	s	_	
84-11	14853-14857	rank	_	
84-12	14858-14869	correlation	_	
84-13	14870-14882	coefficients	_	
84-14	14883-14886	for	_	
84-15	14887-14897	identified	_	
84-16	14898-14904	groups	_	
84-17	14905-14907	as	_	
84-18	14908-14918	two-tailed	_	
84-19	14919-14923	test	_	
84-20	14923-14924	.	_	

#Text=Correlational analysis for biomarkers was controlled for Family-wise error rate using a channel-wise false discovery rate (FDR).
85-1	14925-14938	Correlational	_	
85-2	14939-14947	analysis	_	
85-3	14948-14951	for	_	
85-4	14952-14962	biomarkers	_	
85-5	14963-14966	was	_	
85-6	14967-14977	controlled	_	
85-7	14978-14981	for	_	
85-8	14982-14993	Family-wise	_	
85-9	14994-14999	error	_	
85-10	15000-15004	rate	_	
85-11	15005-15010	using	_	
85-12	15011-15012	a	_	
85-13	15013-15025	channel-wise	_	
85-14	15026-15031	false	_	
85-15	15032-15041	discovery	_	
85-16	15042-15046	rate	_	
85-17	15047-15048	(	_	
85-18	15048-15051	FDR	_	
85-19	15051-15052	)	_	
85-20	15052-15053	.	_	

#Text=Comparisons between behavioral results and published results presented in the appendix were made using unpaired t-tests.
86-1	15054-15065	Comparisons	_	
86-2	15066-15073	between	_	
86-3	15074-15084	behavioral	_	
86-4	15085-15092	results	_	
86-5	15093-15096	and	_	
86-6	15097-15106	published	_	
86-7	15107-15114	results	_	
86-8	15115-15124	presented	_	
86-9	15125-15127	in	_	
86-10	15128-15131	the	_	
86-11	15132-15140	appendix	_	
86-12	15141-15145	were	_	
86-13	15146-15150	made	_	
86-14	15151-15156	using	_	
86-15	15157-15165	unpaired	_	
86-16	15166-15173	t-tests	_	
86-17	15173-15174	.	_	

#Text=Linear mixed-effects (LME) models were constructed to estimate the effects of task types across subject group as well as clinical covariates on observed behavioral metrics and fNIRS biomarkers.
87-1	15175-15181	Linear	_	
87-2	15182-15195	mixed-effects	_	
87-3	15196-15197	(	_	
87-4	15197-15200	LME	_	
87-5	15200-15201	)	_	
87-6	15202-15208	models	_	
87-7	15209-15213	were	_	
87-8	15214-15225	constructed	_	
87-9	15226-15228	to	_	
87-10	15229-15237	estimate	_	
87-11	15238-15241	the	_	
87-12	15242-15249	effects	_	
87-13	15250-15252	of	_	
87-14	15253-15257	task	_	
87-15	15258-15263	types	_	
87-16	15264-15270	across	_	
87-17	15271-15278	subject	_	
87-18	15279-15284	group	_	
87-19	15285-15287	as	_	
87-20	15288-15292	well	_	
87-21	15293-15295	as	_	
87-22	15296-15304	clinical	_	
87-23	15305-15315	covariates	_	
87-24	15316-15318	on	_	
87-25	15319-15327	observed	_	
87-26	15328-15338	behavioral	_	
87-27	15339-15346	metrics	_	
87-28	15347-15350	and	_	
87-29	15351-15356	fNIRS	_	
87-30	15357-15367	biomarkers	_	
87-31	15367-15368	.	_	

#Text=LME models offer significant advantages over repeated measures ANOVA in neuroimaging applications as they do not require equal numbers of observations and allow the models to be fit to individual participants.
88-1	15369-15372	LME	_	
88-2	15373-15379	models	_	
88-3	15380-15385	offer	_	
88-4	15386-15397	significant	_	
88-5	15398-15408	advantages	_	
88-6	15409-15413	over	_	
88-7	15414-15422	repeated	_	
88-8	15423-15431	measures	_	
88-9	15432-15437	ANOVA	_	
88-10	15438-15440	in	_	
88-11	15441-15453	neuroimaging	_	
88-12	15454-15466	applications	_	
88-13	15467-15469	as	_	
88-14	15470-15474	they	_	
88-15	15475-15477	do	_	
88-16	15478-15481	not	_	
88-17	15482-15489	require	_	
88-18	15490-15495	equal	_	
88-19	15496-15503	numbers	_	
88-20	15504-15506	of	_	
88-21	15507-15519	observations	_	
88-22	15520-15523	and	_	
88-23	15524-15529	allow	_	
88-24	15530-15533	the	_	
88-25	15534-15540	models	_	
88-26	15541-15543	to	_	
88-27	15544-15546	be	_	
88-28	15547-15550	fit	_	
88-29	15551-15553	to	_	
88-30	15554-15564	individual	_	
88-31	15565-15577	participants	_	
88-32	15577-15578	.	_	

#Text=Models were analyzed using the maximum likelihood (ML) function and degrees if freedom were approximated using Satterthwaite approximation using the R package “lme4”.
89-1	15579-15585	Models	_	
89-2	15586-15590	were	_	
89-3	15591-15599	analyzed	_	
89-4	15600-15605	using	_	
89-5	15606-15609	the	_	
89-6	15610-15617	maximum	_	
89-7	15618-15628	likelihood	_	
89-8	15629-15630	(	_	
89-9	15630-15632	ML	_	
89-10	15632-15633	)	_	
89-11	15634-15642	function	_	
89-12	15643-15646	and	_	
89-13	15647-15654	degrees	_	
89-14	15655-15657	if	_	
89-15	15658-15665	freedom	_	
89-16	15666-15670	were	_	
89-17	15671-15683	approximated	_	
89-18	15684-15689	using	_	
89-19	15690-15703	Satterthwaite	_	
89-20	15704-15717	approximation	_	
89-21	15718-15723	using	_	
89-22	15724-15727	the	_	
89-23	15728-15729	R	_	
89-24	15730-15737	package	_	
89-25	15738-15739	“	_	
89-26	15739-15743	lme4	_	
89-27	15743-15744	”	_	
89-28	15744-15745	.	_	

#Text=Significance values were thresholded for family error rate using an optode-wise false discovery rate.
90-1	15746-15758	Significance	_	
90-2	15759-15765	values	_	
90-3	15766-15770	were	_	
90-4	15771-15782	thresholded	_	
90-5	15783-15786	for	_	
90-6	15787-15793	family	_	
90-7	15794-15799	error	_	
90-8	15800-15804	rate	_	
90-9	15805-15810	using	_	
90-10	15811-15813	an	_	
90-11	15814-15825	optode-wise	_	
90-12	15826-15831	false	_	
90-13	15832-15841	discovery	_	
90-14	15842-15846	rate	_	
90-15	15846-15847	.	_	

#Text=Models here are reported in a similar style to R syntax.
91-1	15848-15854	Models	_	
91-2	15855-15859	here	_	
91-3	15860-15863	are	_	
91-4	15864-15872	reported	_	
91-5	15873-15875	in	_	
91-6	15876-15877	a	_	
91-7	15878-15885	similar	_	
91-8	15886-15891	style	_	
91-9	15892-15894	to	_	
91-10	15895-15896	R	_	
91-11	15897-15903	syntax	_	
91-12	15903-15904	.	_	

#Text=LME models for the dependent behavioral metrics of Response Time and SAT-Score were constructed with Task Type, Clinical Group, and Duration as candidate fixed effects and Subject as a random effect with a slope fit for each Block.
92-1	15905-15908	LME	_	
92-2	15909-15915	models	_	
92-3	15916-15919	for	_	
92-4	15920-15923	the	_	
92-5	15924-15933	dependent	_	
92-6	15934-15944	behavioral	_	
92-7	15945-15952	metrics	_	
92-8	15953-15955	of	_	
92-9	15956-15964	Response	_	
92-10	15965-15969	Time	_	
92-11	15970-15973	and	_	
92-12	15974-15983	SAT-Score	_	
92-13	15984-15988	were	_	
92-14	15989-16000	constructed	_	
92-15	16001-16005	with	_	
92-16	16006-16010	Task	_	
92-17	16011-16015	Type	_	
92-18	16015-16016	,	_	
92-19	16017-16025	Clinical	_	
92-20	16026-16031	Group	_	
92-21	16031-16032	,	_	
92-22	16033-16036	and	_	
92-23	16037-16045	Duration	_	
92-24	16046-16048	as	_	
92-25	16049-16058	candidate	_	
92-26	16059-16064	fixed	_	
92-27	16065-16072	effects	_	
92-28	16073-16076	and	_	
92-29	16077-16084	Subject	_	
92-30	16085-16087	as	_	
92-31	16088-16089	a	_	
92-32	16090-16096	random	_	
92-33	16097-16103	effect	_	
92-34	16104-16108	with	_	
92-35	16109-16110	a	_	
92-36	16111-16116	slope	_	
92-37	16117-16120	fit	_	
92-38	16121-16124	for	_	
92-39	16125-16129	each	_	
92-40	16130-16135	Block	_	
92-41	16135-16136	.	_	

#Text=Behavioral models were constructed from the initial models:
#Text=To simplify the interpretation of the behavioral models, terms removed through the examination of the full model permutations and the optimal model based on the Akaike Information Criterion (AIC) was analyzed.
93-1	16137-16147	Behavioral	_	
93-2	16148-16154	models	_	
93-3	16155-16159	were	_	
93-4	16160-16171	constructed	_	
93-5	16172-16176	from	_	
93-6	16177-16180	the	_	
93-7	16181-16188	initial	_	
93-8	16189-16195	models	_	
93-9	16195-16196	:	_	
93-10	16197-16199	To	_	
93-11	16200-16208	simplify	_	
93-12	16209-16212	the	_	
93-13	16213-16227	interpretation	_	
93-14	16228-16230	of	_	
93-15	16231-16234	the	_	
93-16	16235-16245	behavioral	_	
93-17	16246-16252	models	_	
93-18	16252-16253	,	_	
93-19	16254-16259	terms	_	
93-20	16260-16267	removed	_	
93-21	16268-16275	through	_	
93-22	16276-16279	the	_	
93-23	16280-16291	examination	_	
93-24	16292-16294	of	_	
93-25	16295-16298	the	_	
93-26	16299-16303	full	_	
93-27	16304-16309	model	_	
93-28	16310-16322	permutations	_	
93-29	16323-16326	and	_	
93-30	16327-16330	the	_	
93-31	16331-16338	optimal	_	
93-32	16339-16344	model	_	
93-33	16345-16350	based	_	
93-34	16351-16353	on	_	
93-35	16354-16357	the	_	
93-36	16358-16364	Akaike	_	
93-37	16365-16376	Information	_	
93-38	16377-16386	Criterion	_	
93-39	16387-16388	(	_	
93-40	16388-16391	AIC	_	
93-41	16391-16392	)	_	
93-42	16393-16396	was	_	
93-43	16397-16405	analyzed	_	
93-44	16405-16406	.	_	

#Text=Models were with an AIC score of difference greater than 2 were considered to be statistically different.
94-1	16407-16413	Models	_	
94-2	16414-16418	were	_	
94-3	16419-16423	with	_	
94-4	16424-16426	an	_	
94-5	16427-16430	AIC	_	
94-6	16431-16436	score	_	
94-7	16437-16439	of	_	
94-8	16440-16450	difference	_	
94-9	16451-16458	greater	_	
94-10	16459-16463	than	_	
94-11	16464-16465	2	_	
94-12	16466-16470	were	_	
94-13	16471-16481	considered	_	
94-14	16482-16484	to	_	
94-15	16485-16487	be	_	
94-16	16488-16501	statistically	_	
94-17	16502-16511	different	_	
94-18	16511-16512	.	_	

#Text=In order to test the effect of task parameters and clinical status on cerebral hemodynamic biomarkers, [HbO], [Hb], and [Oxy] were assessed as dependent measures in separate LME models.
95-1	16513-16515	In	_	
95-2	16516-16521	order	_	
95-3	16522-16524	to	_	
95-4	16525-16529	test	_	
95-5	16530-16533	the	_	
95-6	16534-16540	effect	_	
95-7	16541-16543	of	_	
95-8	16544-16548	task	_	
95-9	16549-16559	parameters	_	
95-10	16560-16563	and	_	
95-11	16564-16572	clinical	_	
95-12	16573-16579	status	_	
95-13	16580-16582	on	_	
95-14	16583-16591	cerebral	_	
95-15	16592-16603	hemodynamic	_	
95-16	16604-16614	biomarkers	_	
95-17	16614-16615	,	_	
95-18	16616-16617	[	_	
95-19	16617-16620	HbO	_	
95-20	16620-16621	]	_	
95-21	16621-16622	,	_	
95-22	16623-16624	[	_	
95-23	16624-16626	Hb	_	
95-24	16626-16627	]	_	
95-25	16627-16628	,	_	
95-26	16629-16632	and	_	
95-27	16633-16634	[	_	
95-28	16634-16637	Oxy	_	
95-29	16637-16638	]	_	
95-30	16639-16643	were	_	
95-31	16644-16652	assessed	_	
95-32	16653-16655	as	_	
95-33	16656-16665	dependent	_	
95-34	16666-16674	measures	_	
95-35	16675-16677	in	_	
95-36	16678-16686	separate	_	
95-37	16687-16690	LME	_	
95-38	16691-16697	models	_	
95-39	16697-16698	.	_	

#Text=Three models were constructed in order to examine the general response to task performance (1), performance sensitivity within the vSAT (2), and the contribution of clinical status to observed activity (3).
96-1	16699-16704	Three	_	
96-2	16705-16711	models	_	
96-3	16712-16716	were	_	
96-4	16717-16728	constructed	_	
96-5	16729-16731	in	_	
96-6	16732-16737	order	_	
96-7	16738-16740	to	_	
96-8	16741-16748	examine	_	
96-9	16749-16752	the	_	
96-10	16753-16760	general	_	
96-11	16761-16769	response	_	
96-12	16770-16772	to	_	
96-13	16773-16777	task	_	
96-14	16778-16789	performance	_	
96-15	16790-16791	(	_	
96-16	16791-16792	1	_	
96-17	16792-16793	)	_	
96-18	16793-16794	,	_	
96-19	16795-16806	performance	_	
96-20	16807-16818	sensitivity	_	
96-21	16819-16825	within	_	
96-22	16826-16829	the	_	
96-23	16830-16834	vSAT	_	
96-24	16835-16836	(	_	
96-25	16836-16837	2	_	
96-26	16837-16838	)	_	
96-27	16838-16839	,	_	
96-28	16840-16843	and	_	
96-29	16844-16847	the	_	
96-30	16848-16860	contribution	_	
96-31	16861-16863	of	_	
96-32	16864-16872	clinical	_	
96-33	16873-16879	status	_	
96-34	16880-16882	to	_	
96-35	16883-16891	observed	_	
96-36	16892-16900	activity	_	
96-37	16901-16902	(	_	
96-38	16902-16903	3	_	
96-39	16903-16904	)	_	
96-40	16904-16905	.	_	

#Text=In the first model, the presence of group differences during task performance was estimated using Task Type, Score, and Clinical Group as fixed effects:
#Text=In the second model, the relationship between cerebral hemodynamics during the vSAT and individualized susceptibility to attentional modulation was assessed using Score Difference and Group as fixed effects:
#Text=In the third model, we examined the influence of clinical status using Task-Type and total PANSS score as fixed effects:
#Text=Selected fNIRS spatial parametric maps are presented using the calculated F-statistics and thresholded using statistical significance for visualization purposes for individual model parameters.
97-1	16906-16908	In	_	
97-2	16909-16912	the	_	
97-3	16913-16918	first	_	
97-4	16919-16924	model	_	
97-5	16924-16925	,	_	
97-6	16926-16929	the	_	
97-7	16930-16938	presence	_	
97-8	16939-16941	of	_	
97-9	16942-16947	group	_	
97-10	16948-16959	differences	_	
97-11	16960-16966	during	_	
97-12	16967-16971	task	_	
97-13	16972-16983	performance	_	
97-14	16984-16987	was	_	
97-15	16988-16997	estimated	_	
97-16	16998-17003	using	_	
97-17	17004-17008	Task	_	
97-18	17009-17013	Type	_	
97-19	17013-17014	,	_	
97-20	17015-17020	Score	_	
97-21	17020-17021	,	_	
97-22	17022-17025	and	_	
97-23	17026-17034	Clinical	_	
97-24	17035-17040	Group	_	
97-25	17041-17043	as	_	
97-26	17044-17049	fixed	_	
97-27	17050-17057	effects	_	
97-28	17057-17058	:	_	
97-29	17059-17061	In	_	
97-30	17062-17065	the	_	
97-31	17066-17072	second	_	
97-32	17073-17078	model	_	
97-33	17078-17079	,	_	
97-34	17080-17083	the	_	
97-35	17084-17096	relationship	_	
97-36	17097-17104	between	_	
97-37	17105-17113	cerebral	_	
97-38	17114-17126	hemodynamics	_	
97-39	17127-17133	during	_	
97-40	17134-17137	the	_	
97-41	17138-17142	vSAT	_	
97-42	17143-17146	and	_	
97-43	17147-17161	individualized	_	
97-44	17162-17176	susceptibility	_	
97-45	17177-17179	to	_	
97-46	17180-17191	attentional	_	
97-47	17192-17202	modulation	_	
97-48	17203-17206	was	_	
97-49	17207-17215	assessed	_	
97-50	17216-17221	using	_	
97-51	17222-17227	Score	_	
97-52	17228-17238	Difference	_	
97-53	17239-17242	and	_	
97-54	17243-17248	Group	_	
97-55	17249-17251	as	_	
97-56	17252-17257	fixed	_	
97-57	17258-17265	effects	_	
97-58	17265-17266	:	_	
97-59	17267-17269	In	_	
97-60	17270-17273	the	_	
97-61	17274-17279	third	_	
97-62	17280-17285	model	_	
97-63	17285-17286	,	_	
97-64	17287-17289	we	_	
97-65	17290-17298	examined	_	
97-66	17299-17302	the	_	
97-67	17303-17312	influence	_	
97-68	17313-17315	of	_	
97-69	17316-17324	clinical	_	
97-70	17325-17331	status	_	
97-71	17332-17337	using	_	
97-72	17338-17347	Task-Type	_	
97-73	17348-17351	and	_	
97-74	17352-17357	total	_	
97-75	17358-17363	PANSS	_	
97-76	17364-17369	score	_	
97-77	17370-17372	as	_	
97-78	17373-17378	fixed	_	
97-79	17379-17386	effects	_	
97-80	17386-17387	:	_	
97-81	17388-17396	Selected	_	
97-82	17397-17402	fNIRS	_	
97-83	17403-17410	spatial	_	
97-84	17411-17421	parametric	_	
97-85	17422-17426	maps	_	
97-86	17427-17430	are	_	
97-87	17431-17440	presented	_	
97-88	17441-17446	using	_	
97-89	17447-17450	the	_	
97-90	17451-17461	calculated	_	
97-91	17462-17474	F-statistics	_	
97-92	17475-17478	and	_	
97-93	17479-17490	thresholded	_	
97-94	17491-17496	using	_	
97-95	17497-17508	statistical	_	
97-96	17509-17521	significance	_	
97-97	17522-17525	for	_	
97-98	17526-17539	visualization	_	
97-99	17540-17548	purposes	_	
97-100	17549-17552	for	_	
97-101	17553-17563	individual	_	
97-102	17564-17569	model	_	
97-103	17570-17580	parameters	_	
97-104	17580-17581	.	_	

#Text=Statistical significance of model fixed effects was assessed using the Satterthwaite approximation for degrees of freedom.
98-1	17582-17593	Statistical	_	
98-2	17594-17606	significance	_	
98-3	17607-17609	of	_	
98-4	17610-17615	model	_	
98-5	17616-17621	fixed	_	
98-6	17622-17629	effects	_	
98-7	17630-17633	was	_	
98-8	17634-17642	assessed	_	
98-9	17643-17648	using	_	
98-10	17649-17652	the	_	
98-11	17653-17666	Satterthwaite	_	
98-12	17667-17680	approximation	_	
98-13	17681-17684	for	_	
98-14	17685-17692	degrees	_	
98-15	17693-17695	of	_	
98-16	17696-17703	freedom	_	
98-17	17703-17704	.	_	

#Text=Results
#Text=Behavioral results
#Text=Task type, stimulus duration, and subject group modulate task performance
#Text=Effects of Task Type and Stimulus Duration on the SAT Score by healthy adult controls and patients with schizophrenia.
99-1	17705-17712	Results	_	
99-2	17713-17723	Behavioral	_	
99-3	17724-17731	results	_	
99-4	17732-17736	Task	_	
99-5	17737-17741	type	_	
99-6	17741-17742	,	_	
99-7	17743-17751	stimulus	_	
99-8	17752-17760	duration	_	
99-9	17760-17761	,	_	
99-10	17762-17765	and	_	
99-11	17766-17773	subject	_	
99-12	17774-17779	group	_	
99-13	17780-17788	modulate	_	
99-14	17789-17793	task	_	
99-15	17794-17805	performance	_	
99-16	17806-17813	Effects	_	
99-17	17814-17816	of	_	
99-18	17817-17821	Task	_	
99-19	17822-17826	Type	_	
99-20	17827-17830	and	_	
99-21	17831-17839	Stimulus	_	
99-22	17840-17848	Duration	_	
99-23	17849-17851	on	_	
99-24	17852-17855	the	_	
99-25	17856-17859	SAT	_	
99-26	17860-17865	Score	_	
99-27	17866-17868	by	_	
99-28	17869-17876	healthy	_	
99-29	17877-17882	adult	_	
99-30	17883-17891	controls	_	
99-31	17892-17895	and	_	
99-32	17896-17904	patients	_	
99-33	17905-17909	with	_	
99-34	17910-17923	schizophrenia	_	
99-35	17923-17924	.	_	

#Text=We constructed an LME model to assess the influence of subject Group, Task Type, and stimulus Duration on behavioral measures using block number as a random slope and Subject as a random effect.
100-1	17925-17927	We	_	
100-2	17928-17939	constructed	_	
100-3	17940-17942	an	_	
100-4	17943-17946	LME	_	
100-5	17947-17952	model	_	
100-6	17953-17955	to	_	
100-7	17956-17962	assess	_	
100-8	17963-17966	the	_	
100-9	17967-17976	influence	_	
100-10	17977-17979	of	_	
100-11	17980-17987	subject	_	
100-12	17988-17993	Group	_	
100-13	17993-17994	,	_	
100-14	17995-17999	Task	_	
100-15	18000-18004	Type	_	
100-16	18004-18005	,	_	
100-17	18006-18009	and	_	
100-18	18010-18018	stimulus	_	
100-19	18019-18027	Duration	_	
100-20	18028-18030	on	_	
100-21	18031-18041	behavioral	_	
100-22	18042-18050	measures	_	
100-23	18051-18056	using	_	
100-24	18057-18062	block	_	
100-25	18063-18069	number	_	
100-26	18070-18072	as	_	
100-27	18073-18074	a	_	
100-28	18075-18081	random	_	
100-29	18082-18087	slope	_	
100-30	18088-18091	and	_	
100-31	18092-18099	Subject	_	
100-32	18100-18102	as	_	
100-33	18103-18104	a	_	
100-34	18105-18111	random	_	
100-35	18112-18118	effect	_	
100-36	18118-18119	.	_	

#Text=Group was treated as a between-subject factor, while Task-Type and Duration were included as within-subject factors.
101-1	18120-18125	Group	_	
101-2	18126-18129	was	_	
101-3	18130-18137	treated	_	
101-4	18138-18140	as	_	
101-5	18141-18142	a	_	
101-6	18143-18158	between-subject	_	
101-7	18159-18165	factor	_	
101-8	18165-18166	,	_	
101-9	18167-18172	while	_	
101-10	18173-18182	Task-Type	_	
101-11	18183-18186	and	_	
101-12	18187-18195	Duration	_	
101-13	18196-18200	were	_	
101-14	18201-18209	included	_	
101-15	18210-18212	as	_	
101-16	18213-18227	within-subject	_	
101-17	18228-18235	factors	_	
101-18	18235-18236	.	_	

#Text=In the reduced model there was a fixed effect for Group on SAT-score (F(1,37.56) = 9.496, p = 0.0038) with Patients performing at an estimated 16 percent lower than Controls.
102-1	18237-18239	In	_	
102-2	18240-18243	the	_	
102-3	18244-18251	reduced	_	
102-4	18252-18257	model	_	
102-5	18258-18263	there	_	
102-6	18264-18267	was	_	
102-7	18268-18269	a	_	
102-8	18270-18275	fixed	_	
102-9	18276-18282	effect	_	
102-10	18283-18286	for	_	
102-11	18287-18292	Group	_	
102-12	18293-18295	on	_	
102-13	18296-18305	SAT-score	_	
102-14	18306-18307	(	_	
102-15	18307-18308	F	_	
102-16	18308-18309	(	_	
102-17	18309-18316	1,37.56	_	
102-18	18316-18317	)	_	
102-19	18318-18319	=	_	
102-20	18320-18325	9.496	_	
102-21	18325-18326	,	_	
102-22	18327-18328	p	_	
102-23	18329-18330	=	_	
102-24	18331-18337	0.0038	_	
102-25	18337-18338	)	_	
102-26	18339-18343	with	_	
102-27	18344-18352	Patients	_	
102-28	18353-18363	performing	_	
102-29	18364-18366	at	_	
102-30	18367-18369	an	_	
102-31	18370-18379	estimated	_	
102-32	18380-18382	16	_	
102-33	18383-18390	percent	_	
102-34	18391-18396	lower	_	
102-35	18397-18401	than	_	
102-36	18402-18410	Controls	_	
102-37	18410-18411	.	_	

#Text=There was a significant fixed effect for SAT type on SAT-score (F(1,258.08) = 40.093, p < 0.0001) with the more difficult vSAT resulting in an estimated 5 percent reduction in Score.
103-1	18412-18417	There	_	
103-2	18418-18421	was	_	
103-3	18422-18423	a	_	
103-4	18424-18435	significant	_	
103-5	18436-18441	fixed	_	
103-6	18442-18448	effect	_	
103-7	18449-18452	for	_	
103-8	18453-18456	SAT	_	
103-9	18457-18461	type	_	
103-10	18462-18464	on	_	
103-11	18465-18474	SAT-score	_	
103-12	18475-18476	(	_	
103-13	18476-18477	F	_	
103-14	18477-18478	(	_	
103-15	18478-18486	1,258.08	_	
103-16	18486-18487	)	_	
103-17	18488-18489	=	_	
103-18	18490-18496	40.093	_	
103-19	18496-18497	,	_	
103-20	18498-18499	p	_	
103-21	18500-18501	<	_	
103-22	18502-18508	0.0001	_	
103-23	18508-18509	)	_	
103-24	18510-18514	with	_	
103-25	18515-18518	the	_	
103-26	18519-18523	more	_	
103-27	18524-18533	difficult	_	
103-28	18534-18538	vSAT	_	
103-29	18539-18548	resulting	_	
103-30	18549-18551	in	_	
103-31	18552-18554	an	_	
103-32	18555-18564	estimated	_	
103-33	18565-18566	5	_	
103-34	18567-18574	percent	_	
103-35	18575-18584	reduction	_	
103-36	18585-18587	in	_	
103-37	18588-18593	Score	_	
103-38	18593-18594	.	_	

#Text=A significant fixed effect was also observed for stimulus duration (F(2,386.97) = 12.142, p < 0.0001) where performance decreased as duration decreased from 50 ms to 20 ms.
104-1	18595-18596	A	_	
104-2	18597-18608	significant	_	
104-3	18609-18614	fixed	_	
104-4	18615-18621	effect	_	
104-5	18622-18625	was	_	
104-6	18626-18630	also	_	
104-7	18631-18639	observed	_	
104-8	18640-18643	for	_	
104-9	18644-18652	stimulus	_	
104-10	18653-18661	duration	_	
104-11	18662-18663	(	_	
104-12	18663-18664	F	_	
104-13	18664-18665	(	_	
104-14	18665-18673	2,386.97	_	
104-15	18673-18674	)	_	
104-16	18675-18676	=	_	
104-17	18677-18683	12.142	_	
104-18	18683-18684	,	_	
104-19	18685-18686	p	_	
104-20	18687-18688	<	_	
104-21	18689-18695	0.0001	_	
104-22	18695-18696	)	_	
104-23	18697-18702	where	_	
104-24	18703-18714	performance	_	
104-25	18715-18724	decreased	_	
104-26	18725-18727	as	_	
104-27	18728-18736	duration	_	
104-28	18737-18746	decreased	_	
104-29	18747-18751	from	_	
104-30	18752-18754	50	_	
104-31	18755-18757	ms	_	
104-32	18758-18760	to	_	
104-33	18761-18763	20	_	
104-34	18764-18766	ms	_	
104-35	18766-18767	.	_	

#Text=No interactions between Task-Type, Group, or Duration were significant for Score and these terms were not present in the selected optimal model.
105-1	18768-18770	No	_	
105-2	18771-18783	interactions	_	
105-3	18784-18791	between	_	
105-4	18792-18801	Task-Type	_	
105-5	18801-18802	,	_	
105-6	18803-18808	Group	_	
105-7	18808-18809	,	_	
105-8	18810-18812	or	_	
105-9	18813-18821	Duration	_	
105-10	18822-18826	were	_	
105-11	18827-18838	significant	_	
105-12	18839-18842	for	_	
105-13	18843-18848	Score	_	
105-14	18849-18852	and	_	
105-15	18853-18858	these	_	
105-16	18859-18864	terms	_	
105-17	18865-18869	were	_	
105-18	18870-18873	not	_	
105-19	18874-18881	present	_	
105-20	18882-18884	in	_	
105-21	18885-18888	the	_	
105-22	18889-18897	selected	_	
105-23	18898-18905	optimal	_	
105-24	18906-18911	model	_	
105-25	18911-18912	.	_	

#Text=The behavioral measures of SAT Score across duration and task type are presented in Fig. 2.
106-1	18913-18916	The	_	
106-2	18917-18927	behavioral	_	
106-3	18928-18936	measures	_	
106-4	18937-18939	of	_	
106-5	18940-18943	SAT	_	
106-6	18944-18949	Score	_	
106-7	18950-18956	across	_	
106-8	18957-18965	duration	_	
106-9	18966-18969	and	_	
106-10	18970-18974	task	_	
106-11	18975-18979	type	_	
106-12	18980-18983	are	_	
106-13	18984-18993	presented	_	
106-14	18994-18996	in	_	
106-15	18997-19000	Fig	_	
106-16	19000-19001	.	_	
106-17	19001-19002	 	_	
106-18	19002-19003	2	_	
106-19	19003-19004	.	_	

#Text=Inclusion of block number in the LME model did not provide either a significant fixed effect for block number (F(1,37.09) = 0.079, p > 0.7) or an improved model (ChiSq = 0.837, p > 0.7) suggesting that SAT-Score was not influenced by block number.
107-1	19005-19014	Inclusion	_	
107-2	19015-19017	of	_	
107-3	19018-19023	block	_	
107-4	19024-19030	number	_	
107-5	19031-19033	in	_	
107-6	19034-19037	the	_	
107-7	19038-19041	LME	_	
107-8	19042-19047	model	_	
107-9	19048-19051	did	_	
107-10	19052-19055	not	_	
107-11	19056-19063	provide	_	
107-12	19064-19070	either	_	
107-13	19071-19072	a	_	
107-14	19073-19084	significant	_	
107-15	19085-19090	fixed	_	
107-16	19091-19097	effect	_	
107-17	19098-19101	for	_	
107-18	19102-19107	block	_	
107-19	19108-19114	number	_	
107-20	19115-19116	(	_	
107-21	19116-19117	F	_	
107-22	19117-19118	(	_	
107-23	19118-19125	1,37.09	_	
107-24	19125-19126	)	_	
107-25	19127-19128	=	_	
107-26	19129-19134	0.079	_	
107-27	19134-19135	,	_	
107-28	19136-19137	p	_	
107-29	19138-19139	>	_	
107-30	19140-19143	0.7	_	
107-31	19143-19144	)	_	
107-32	19145-19147	or	_	
107-33	19148-19150	an	_	
107-34	19151-19159	improved	_	
107-35	19160-19165	model	_	
107-36	19166-19167	(	_	
107-37	19167-19172	ChiSq	_	
107-38	19173-19174	=	_	
107-39	19175-19180	0.837	_	
107-40	19180-19181	,	_	
107-41	19182-19183	p	_	
107-42	19184-19185	>	_	
107-43	19186-19189	0.7	_	
107-44	19189-19190	)	_	
107-45	19191-19201	suggesting	_	
107-46	19202-19206	that	_	
107-47	19207-19216	SAT-Score	_	
107-48	19217-19220	was	_	
107-49	19221-19224	not	_	
107-50	19225-19235	influenced	_	
107-51	19236-19238	by	_	
107-52	19239-19244	block	_	
107-53	19245-19251	number	_	
107-54	19251-19252	.	_	

#Text=Response time strongly differs between clinical groups and is modulated by task conditions
#Text=Effects of Stimulus Duration and Task Type on Mean Response Time for healthy controls and patients with schizophrenia.
108-1	19253-19261	Response	_	
108-2	19262-19266	time	_	
108-3	19267-19275	strongly	_	
108-4	19276-19283	differs	_	
108-5	19284-19291	between	_	
108-6	19292-19300	clinical	_	
108-7	19301-19307	groups	_	
108-8	19308-19311	and	_	
108-9	19312-19314	is	_	
108-10	19315-19324	modulated	_	
108-11	19325-19327	by	_	
108-12	19328-19332	task	_	
108-13	19333-19343	conditions	_	
108-14	19344-19351	Effects	_	
108-15	19352-19354	of	_	
108-16	19355-19363	Stimulus	_	
108-17	19364-19372	Duration	_	
108-18	19373-19376	and	_	
108-19	19377-19381	Task	_	
108-20	19382-19386	Type	_	
108-21	19387-19389	on	_	
108-22	19390-19394	Mean	_	
108-23	19395-19403	Response	_	
108-24	19404-19408	Time	_	
108-25	19409-19412	for	_	
108-26	19413-19420	healthy	_	
108-27	19421-19429	controls	_	
108-28	19430-19433	and	_	
108-29	19434-19442	patients	_	
108-30	19443-19447	with	_	
108-31	19448-19461	schizophrenia	_	
108-32	19461-19462	.	_	

#Text=LME parameter estimates for SAT-Score and Mean Response Time.
109-1	19463-19466	LME	_	
109-2	19467-19476	parameter	_	
109-3	19477-19486	estimates	_	
109-4	19487-19490	for	_	
109-5	19491-19500	SAT-Score	_	
109-6	19501-19504	and	_	
109-7	19505-19509	Mean	_	
109-8	19510-19518	Response	_	
109-9	19519-19523	Time	_	
109-10	19523-19524	.	_	

#Text=Outcome\tMain Effects\t\tParameter Estimates\t \tdf_num\tdf_den\tF\tp\tLinear\tQuadratic\t \tSAT-Score\t \tIntercept\t\t\t\t0.0000\t***\t0.8865\t(0.0482)\t\t\t \tClass\t1\t37.56\t9.496\t0.0038\t**\t−0.1919\t(0.0623)\t\t\t \tTask-Type\t1\t258.08\t40.093\t0.0000\t***\t−0.0811\t(0.0128)\t\t\t \tDuration\t2\t386.97\t12.142\t0.0000\t***\t−0.0645\t(0.0137)\t−0.0197\t(0.0137)\t \tMean Response Time\t \tIntercept\t\t\t\t0.0000\t***\t763.07\t(463.07)\t\t\t \tClass\t1\t37.14\t8.644\t0.0056\t***\t173.77\t(59.03)\t\t\t \tTask × Duration\t5\t395.9\t10.0459\t0.0000\t***\t\t\t\t\t \t20 ms × SAT\t\t\t\t0.0612\t†\t−32.59\t(17.36)\t\t\t \t30 ms × SAT\t\t\t\t0.0380\t\t15.27\t(17.36)\t\t\t \t50 ms × SAT\t\t\t\t0.0002\t***\t64.35\t(17.36)\t\t\t \t30 ms × vSAT\t\t\t\t0.0004\t***\t56.87\t(15.95)\t\t\t \t50 ms × vSAT\t\t\t\t0.0151\t*\t22.87\t(15.95)\t\t\t \t
#Text=Denominator Degrees of freedom calculated with Satterthwaite approximation.
110-1	19525-19532	Outcome	_	
110-2	19533-19537	Main	_	
110-3	19538-19545	Effects	_	
110-4	19547-19556	Parameter	_	
110-5	19557-19566	Estimates	_	
110-6	19569-19575	df_num	_	
110-7	19576-19582	df_den	_	
110-8	19583-19584	F	_	
110-9	19585-19586	p	_	
110-10	19587-19593	Linear	_	
110-11	19594-19603	Quadratic	_	
110-12	19606-19615	SAT-Score	_	
110-13	19618-19627	Intercept	_	
110-14	19631-19637	0.0000	_	
110-15	19638-19639	*	_	
110-16	19639-19640	*	_	
110-17	19640-19641	*	_	
110-18	19642-19648	0.8865	_	
110-19	19649-19650	(	_	
110-20	19650-19656	0.0482	_	
110-21	19656-19657	)	_	
110-22	19662-19667	Class	_	
110-23	19668-19669	1	_	
110-24	19670-19675	37.56	_	
110-25	19676-19681	9.496	_	
110-26	19682-19688	0.0038	_	
110-27	19689-19690	*	_	
110-28	19690-19691	*	_	
110-29	19692-19693	−	_	
110-30	19693-19699	0.1919	_	
110-31	19700-19701	(	_	
110-32	19701-19707	0.0623	_	
110-33	19707-19708	)	_	
110-34	19713-19722	Task-Type	_	
110-35	19723-19724	1	_	
110-36	19725-19731	258.08	_	
110-37	19732-19738	40.093	_	
110-38	19739-19745	0.0000	_	
110-39	19746-19747	*	_	
110-40	19747-19748	*	_	
110-41	19748-19749	*	_	
110-42	19750-19751	−	_	
110-43	19751-19757	0.0811	_	
110-44	19758-19759	(	_	
110-45	19759-19765	0.0128	_	
110-46	19765-19766	)	_	
110-47	19771-19779	Duration	_	
110-48	19780-19781	2	_	
110-49	19782-19788	386.97	_	
110-50	19789-19795	12.142	_	
110-51	19796-19802	0.0000	_	
110-52	19803-19804	*	_	
110-53	19804-19805	*	_	
110-54	19805-19806	*	_	
110-55	19807-19808	−	_	
110-56	19808-19814	0.0645	_	
110-57	19815-19816	(	_	
110-58	19816-19822	0.0137	_	
110-59	19822-19823	)	_	
110-60	19824-19825	−	_	
110-61	19825-19831	0.0197	_	
110-62	19832-19833	(	_	
110-63	19833-19839	0.0137	_	
110-64	19839-19840	)	_	
110-65	19843-19847	Mean	_	
110-66	19848-19856	Response	_	
110-67	19857-19861	Time	_	
110-68	19864-19873	Intercept	_	
110-69	19877-19883	0.0000	_	
110-70	19884-19885	*	_	
110-71	19885-19886	*	_	
110-72	19886-19887	*	_	
110-73	19888-19894	763.07	_	
110-74	19895-19896	(	_	
110-75	19896-19902	463.07	_	
110-76	19902-19903	)	_	
110-77	19908-19913	Class	_	
110-78	19914-19915	1	_	
110-79	19916-19921	37.14	_	
110-80	19922-19927	8.644	_	
110-81	19928-19934	0.0056	_	
110-82	19935-19936	*	_	
110-83	19936-19937	*	_	
110-84	19937-19938	*	_	
110-85	19939-19945	173.77	_	
110-86	19946-19947	(	_	
110-87	19947-19952	59.03	_	
110-88	19952-19953	)	_	
110-89	19958-19962	Task	_	
110-90	19963-19964	×	_	
110-91	19965-19973	Duration	_	
110-92	19974-19975	5	_	
110-93	19976-19981	395.9	_	
110-94	19982-19989	10.0459	_	
110-95	19990-19996	0.0000	_	
110-96	19997-19998	*	_	
110-97	19998-19999	*	_	
110-98	19999-20000	*	_	
110-99	20007-20009	20	_	
110-100	20010-20012	ms	_	
110-101	20013-20014	×	_	
110-102	20015-20018	SAT	_	
110-103	20022-20028	0.0612	_	
110-104	20029-20030	†	_	
110-105	20031-20032	−	_	
110-106	20032-20037	32.59	_	
110-107	20038-20039	(	_	
110-108	20039-20044	17.36	_	
110-109	20044-20045	)	_	
110-110	20050-20052	30	_	
110-111	20053-20055	ms	_	
110-112	20056-20057	×	_	
110-113	20058-20061	SAT	_	
110-114	20065-20071	0.0380	_	
110-115	20073-20078	15.27	_	
110-116	20079-20080	(	_	
110-117	20080-20085	17.36	_	
110-118	20085-20086	)	_	
110-119	20091-20093	50	_	
110-120	20094-20096	ms	_	
110-121	20097-20098	×	_	
110-122	20099-20102	SAT	_	
110-123	20106-20112	0.0002	_	
110-124	20113-20114	*	_	
110-125	20114-20115	*	_	
110-126	20115-20116	*	_	
110-127	20117-20122	64.35	_	
110-128	20123-20124	(	_	
110-129	20124-20129	17.36	_	
110-130	20129-20130	)	_	
110-131	20135-20137	30	_	
110-132	20138-20140	ms	_	
110-133	20141-20142	×	_	
110-134	20143-20147	vSAT	_	
110-135	20151-20157	0.0004	_	
110-136	20158-20159	*	_	
110-137	20159-20160	*	_	
110-138	20160-20161	*	_	
110-139	20162-20167	56.87	_	
110-140	20168-20169	(	_	
110-141	20169-20174	15.95	_	
110-142	20174-20175	)	_	
110-143	20180-20182	50	_	
110-144	20183-20185	ms	_	
110-145	20186-20187	×	_	
110-146	20188-20192	vSAT	_	
110-147	20196-20202	0.0151	_	
110-148	20203-20204	*	_	
110-149	20205-20210	22.87	_	
110-150	20211-20212	(	_	
110-151	20212-20217	15.95	_	
110-152	20217-20218	)	_	
110-153	20224-20235	Denominator	_	
110-154	20236-20243	Degrees	_	
110-155	20244-20246	of	_	
110-156	20247-20254	freedom	_	
110-157	20255-20265	calculated	_	
110-158	20266-20270	with	_	
110-159	20271-20284	Satterthwaite	_	
110-160	20285-20298	approximation	_	
110-161	20298-20299	.	_	

#Text=Random effects specified as random intercept and slope for each participant.
111-1	20300-20306	Random	_	
111-2	20307-20314	effects	_	
111-3	20315-20324	specified	_	
111-4	20325-20327	as	_	
111-5	20328-20334	random	_	
111-6	20335-20344	intercept	_	
111-7	20345-20348	and	_	
111-8	20349-20354	slope	_	
111-9	20355-20358	for	_	
111-10	20359-20363	each	_	
111-11	20364-20375	participant	_	
111-12	20375-20376	.	_	

#Text=†p < 0.1 **p < 0.01.
112-1	20377-20378	†	_	
112-2	20378-20379	p	_	
112-3	20380-20381	<	_	
112-4	20382-20385	0.1	_	
112-5	20386-20387	*	_	
112-6	20387-20388	*	_	
112-7	20388-20389	p	_	
112-8	20390-20391	<	_	
112-9	20392-20396	0.01	_	
112-10	20396-20397	.	_	

#Text=*p < 0.05 ***p < 0.001.
113-1	20398-20399	*	_	
113-2	20399-20400	p	_	
113-3	20401-20402	<	_	
113-4	20403-20407	0.05	_	
113-5	20408-20409	*	_	
113-6	20409-20410	*	_	
113-7	20410-20411	*	_	
113-8	20411-20412	p	_	
113-9	20413-20414	<	_	
113-10	20415-20420	0.001	_	
113-11	20420-20421	.	_	

#Text=A significant fixed effect on mean response time was observed for Group (F(1,37.14) = 8.644, p = 0.0056) and a significant interaction for Task Type and stimulus Duration (F(5,395.50) = 10.046, p < 0.0001) with patients having an estimated delay in average response time of 173 ms.
114-1	20422-20423	A	_	
114-2	20424-20435	significant	_	
114-3	20436-20441	fixed	_	
114-4	20442-20448	effect	_	
114-5	20449-20451	on	_	
114-6	20452-20456	mean	_	
114-7	20457-20465	response	_	
114-8	20466-20470	time	_	
114-9	20471-20474	was	_	
114-10	20475-20483	observed	_	
114-11	20484-20487	for	_	
114-12	20488-20493	Group	_	
114-13	20494-20495	(	_	
114-14	20495-20496	F	_	
114-15	20496-20497	(	_	
114-16	20497-20504	1,37.14	_	
114-17	20504-20505	)	_	
114-18	20506-20507	=	_	
114-19	20508-20513	8.644	_	
114-20	20513-20514	,	_	
114-21	20515-20516	p	_	
114-22	20517-20518	=	_	
114-23	20519-20525	0.0056	_	
114-24	20525-20526	)	_	
114-25	20527-20530	and	_	
114-26	20531-20532	a	_	
114-27	20533-20544	significant	_	
114-28	20545-20556	interaction	_	
114-29	20557-20560	for	_	
114-30	20561-20565	Task	_	
114-31	20566-20570	Type	_	
114-32	20571-20574	and	_	
114-33	20575-20583	stimulus	_	
114-34	20584-20592	Duration	_	
114-35	20593-20594	(	_	
114-36	20594-20595	F	_	
114-37	20595-20596	(	_	
114-38	20596-20604	5,395.50	_	
114-39	20604-20605	)	_	
114-40	20606-20607	=	_	
114-41	20608-20614	10.046	_	
114-42	20614-20615	,	_	
114-43	20616-20617	p	_	
114-44	20618-20619	<	_	
114-45	20620-20626	0.0001	_	
114-46	20626-20627	)	_	
114-47	20628-20632	with	_	
114-48	20633-20641	patients	_	
114-49	20642-20648	having	_	
114-50	20649-20651	an	_	
114-51	20652-20661	estimated	_	
114-52	20662-20667	delay	_	
114-53	20668-20670	in	_	
114-54	20671-20678	average	_	
114-55	20679-20687	response	_	
114-56	20688-20692	time	_	
114-57	20693-20695	of	_	
114-58	20696-20699	173	_	
114-59	20700-20702	ms	_	
114-60	20702-20703	.	_	

#Text=Despite very strong significance for the interaction term for Task Type and Duration, the interpretation of the model terms is not straightforward.
115-1	20704-20711	Despite	_	
115-2	20712-20716	very	_	
115-3	20717-20723	strong	_	
115-4	20724-20736	significance	_	
115-5	20737-20740	for	_	
115-6	20741-20744	the	_	
115-7	20745-20756	interaction	_	
115-8	20757-20761	term	_	
115-9	20762-20765	for	_	
115-10	20766-20770	Task	_	
115-11	20771-20775	Type	_	
115-12	20776-20779	and	_	
115-13	20780-20788	Duration	_	
115-14	20788-20789	,	_	
115-15	20790-20793	the	_	
115-16	20794-20808	interpretation	_	
115-17	20809-20811	of	_	
115-18	20812-20815	the	_	
115-19	20816-20821	model	_	
115-20	20822-20827	terms	_	
115-21	20828-20830	is	_	
115-22	20831-20834	not	_	
115-23	20835-20850	straightforward	_	
115-24	20850-20851	.	_	

#Text=In general, it is observed that shorter stimuli duration increased response time most clearly in the vSAT task.
116-1	20852-20854	In	_	
116-2	20855-20862	general	_	
116-3	20862-20863	,	_	
116-4	20864-20866	it	_	
116-5	20867-20869	is	_	
116-6	20870-20878	observed	_	
116-7	20879-20883	that	_	
116-8	20884-20891	shorter	_	
116-9	20892-20899	stimuli	_	
116-10	20900-20908	duration	_	
116-11	20909-20918	increased	_	
116-12	20919-20927	response	_	
116-13	20928-20932	time	_	
116-14	20933-20937	most	_	
116-15	20938-20945	clearly	_	
116-16	20946-20948	in	_	
116-17	20949-20952	the	_	
116-18	20953-20957	vSAT	_	
116-19	20958-20962	task	_	
116-20	20962-20963	.	_	

#Text=Effect of stimulus Duration and Task-type for each subject Group on the mean response time are presented in Fig. 3.
117-1	20964-20970	Effect	_	
117-2	20971-20973	of	_	
117-3	20974-20982	stimulus	_	
117-4	20983-20991	Duration	_	
117-5	20992-20995	and	_	
117-6	20996-21005	Task-type	_	
117-7	21006-21009	for	_	
117-8	21010-21014	each	_	
117-9	21015-21022	subject	_	
117-10	21023-21028	Group	_	
117-11	21029-21031	on	_	
117-12	21032-21035	the	_	
117-13	21036-21040	mean	_	
117-14	21041-21049	response	_	
117-15	21050-21054	time	_	
117-16	21055-21058	are	_	
117-17	21059-21068	presented	_	
117-18	21069-21071	in	_	
117-19	21072-21075	Fig	_	
117-20	21075-21076	.	_	
117-21	21076-21077	 	_	
117-22	21077-21078	3	_	
117-23	21078-21079	.	_	

#Text=Model results for Behavioral results including parameter estimates are presented in Table 2.
#Text=fNIRS results
#Text=Right-medial prefrontal role for task performance and interaction with group
#Text=Parametric representation of significant model term overlaid onto anatomical reference images.
118-1	21080-21085	Model	_	
118-2	21086-21093	results	_	
118-3	21094-21097	for	_	
118-4	21098-21108	Behavioral	_	
118-5	21109-21116	results	_	
118-6	21117-21126	including	_	
118-7	21127-21136	parameter	_	
118-8	21137-21146	estimates	_	
118-9	21147-21150	are	_	
118-10	21151-21160	presented	_	
118-11	21161-21163	in	_	
118-12	21164-21169	Table	_	
118-13	21169-21170	 	_	
118-14	21170-21171	2	_	
118-15	21171-21172	.	_	
118-16	21173-21178	fNIRS	_	
118-17	21179-21186	results	_	
118-18	21187-21199	Right-medial	_	
118-19	21200-21210	prefrontal	_	
118-20	21211-21215	role	_	
118-21	21216-21219	for	_	
118-22	21220-21224	task	_	
118-23	21225-21236	performance	_	
118-24	21237-21240	and	_	
118-25	21241-21252	interaction	_	
118-26	21253-21257	with	_	
118-27	21258-21263	group	_	
118-28	21264-21274	Parametric	_	
118-29	21275-21289	representation	_	
118-30	21290-21292	of	_	
118-31	21293-21304	significant	_	
118-32	21305-21310	model	_	
118-33	21311-21315	term	_	
118-34	21316-21324	overlaid	_	
118-35	21325-21329	onto	_	
118-36	21330-21340	anatomical	_	
118-37	21341-21350	reference	_	
118-38	21351-21357	images	_	
118-39	21357-21358	.	_	

#Text=Values represent mixed model F-Values thresholded.
119-1	21359-21365	Values	_	
119-2	21366-21375	represent	_	
119-3	21376-21381	mixed	_	
119-4	21382-21387	model	_	
119-5	21388-21396	F-Values	_	
119-6	21397-21408	thresholded	_	
119-7	21408-21409	.	_	

#Text=(A) Behavioral SAT Score, (B) Subject Group, (C) Interaction between Score and Group.
120-1	21410-21411	(	_	
120-2	21411-21412	A	_	
120-3	21412-21413	)	_	
120-4	21414-21424	Behavioral	_	
120-5	21425-21428	SAT	_	
120-6	21429-21434	Score	_	
120-7	21434-21435	,	_	
120-8	21436-21437	(	_	
120-9	21437-21438	B	_	
120-10	21438-21439	)	_	
120-11	21440-21447	Subject	_	
120-12	21448-21453	Group	_	
120-13	21453-21454	,	_	
120-14	21455-21456	(	_	
120-15	21456-21457	C	_	
120-16	21457-21458	)	_	
120-17	21459-21470	Interaction	_	
120-18	21471-21478	between	_	
120-19	21479-21484	Score	_	
120-20	21485-21488	and	_	
120-21	21489-21494	Group	_	
120-22	21494-21495	.	_	

#Text=LME parameter estimates for [Oxy] Optode 9.
121-1	21496-21499	LME	_	
121-2	21500-21509	parameter	_	
121-3	21510-21519	estimates	_	
121-4	21520-21523	for	_	
121-5	21524-21525	[	_	
121-6	21525-21528	Oxy	_	
121-7	21528-21529	]	_	
121-8	21530-21536	Optode	_	
121-9	21537-21538	9	_	
121-10	21538-21539	.	_	

#Text=Outcome\tMain Effects\t\tParameter Estimates\t \tdf_num\tdf_den\tF\tp\tLinear\t \t[Oxy] Optode 9\t \tIntercept\t\t\t\t0.0047\t**\t1.4006\t(0.4860)\t \tGroup\t1\t110.92\t6.9817\t0.0094\t**\t−1.3404\t(0.5073)\t \tTask-Type\t1\t109.79\t1.9087\t0.1699\t\t−1.1614\t(0.6826)\t \tScore\t1\t110.26\t10.4671\t0.0016\t**\t−1.5634\t(0.5268)\t \tGroup × Task\t1\t109.79\t3.6239\t0.0597\t†\t1.35\t(0.71)\t \tGroup × Score\t1\t110.26\t5.5686\t0.0200\t*\t1.32\t(0.56)\t \tTask × Score\t1\t109.39\t1.4607\t0.2294\t\t1.16\t(0.74)\t \tGroup × Task × Score\t1\t109.39\t3.1433\t0.0790\t†\t−1.38\t(0.78)\t \t
#Text=Denominator Degrees of freedom calculated with Satterthwaite approximation.
122-1	21540-21547	Outcome	_	
122-2	21548-21552	Main	_	
122-3	21553-21560	Effects	_	
122-4	21562-21571	Parameter	_	
122-5	21572-21581	Estimates	_	
122-6	21584-21590	df_num	_	
122-7	21591-21597	df_den	_	
122-8	21598-21599	F	_	
122-9	21600-21601	p	_	
122-10	21602-21608	Linear	_	
122-11	21611-21612	[	_	
122-12	21612-21615	Oxy	_	
122-13	21615-21616	]	_	
122-14	21617-21623	Optode	_	
122-15	21624-21625	9	_	
122-16	21628-21637	Intercept	_	
122-17	21641-21647	0.0047	_	
122-18	21648-21649	*	_	
122-19	21649-21650	*	_	
122-20	21651-21657	1.4006	_	
122-21	21658-21659	(	_	
122-22	21659-21665	0.4860	_	
122-23	21665-21666	)	_	
122-24	21669-21674	Group	_	
122-25	21675-21676	1	_	
122-26	21677-21683	110.92	_	
122-27	21684-21690	6.9817	_	
122-28	21691-21697	0.0094	_	
122-29	21698-21699	*	_	
122-30	21699-21700	*	_	
122-31	21701-21702	−	_	
122-32	21702-21708	1.3404	_	
122-33	21709-21710	(	_	
122-34	21710-21716	0.5073	_	
122-35	21716-21717	)	_	
122-36	21720-21729	Task-Type	_	
122-37	21730-21731	1	_	
122-38	21732-21738	109.79	_	
122-39	21739-21745	1.9087	_	
122-40	21746-21752	0.1699	_	
122-41	21754-21755	−	_	
122-42	21755-21761	1.1614	_	
122-43	21762-21763	(	_	
122-44	21763-21769	0.6826	_	
122-45	21769-21770	)	_	
122-46	21773-21778	Score	_	
122-47	21779-21780	1	_	
122-48	21781-21787	110.26	_	
122-49	21788-21795	10.4671	_	
122-50	21796-21802	0.0016	_	
122-51	21803-21804	*	_	
122-52	21804-21805	*	_	
122-53	21806-21807	−	_	
122-54	21807-21813	1.5634	_	
122-55	21814-21815	(	_	
122-56	21815-21821	0.5268	_	
122-57	21821-21822	)	_	
122-58	21825-21830	Group	_	
122-59	21831-21832	×	_	
122-60	21833-21837	Task	_	
122-61	21838-21839	1	_	
122-62	21840-21846	109.79	_	
122-63	21847-21853	3.6239	_	
122-64	21854-21860	0.0597	_	
122-65	21861-21862	†	_	
122-66	21863-21867	1.35	_	
122-67	21868-21869	(	_	
122-68	21869-21873	0.71	_	
122-69	21873-21874	)	_	
122-70	21877-21882	Group	_	
122-71	21883-21884	×	_	
122-72	21885-21890	Score	_	
122-73	21891-21892	1	_	
122-74	21893-21899	110.26	_	
122-75	21900-21906	5.5686	_	
122-76	21907-21913	0.0200	_	
122-77	21914-21915	*	_	
122-78	21916-21920	1.32	_	
122-79	21921-21922	(	_	
122-80	21922-21926	0.56	_	
122-81	21926-21927	)	_	
122-82	21930-21934	Task	_	
122-83	21935-21936	×	_	
122-84	21937-21942	Score	_	
122-85	21943-21944	1	_	
122-86	21945-21951	109.39	_	
122-87	21952-21958	1.4607	_	
122-88	21959-21965	0.2294	_	
122-89	21967-21971	1.16	_	
122-90	21972-21973	(	_	
122-91	21973-21977	0.74	_	
122-92	21977-21978	)	_	
122-93	21981-21986	Group	_	
122-94	21987-21988	×	_	
122-95	21989-21993	Task	_	
122-96	21994-21995	×	_	
122-97	21996-22001	Score	_	
122-98	22002-22003	1	_	
122-99	22004-22010	109.39	_	
122-100	22011-22017	3.1433	_	
122-101	22018-22024	0.0790	_	
122-102	22025-22026	†	_	
122-103	22027-22028	−	_	
122-104	22028-22032	1.38	_	
122-105	22033-22034	(	_	
122-106	22034-22038	0.78	_	
122-107	22038-22039	)	_	
122-108	22043-22054	Denominator	_	
122-109	22055-22062	Degrees	_	
122-110	22063-22065	of	_	
122-111	22066-22073	freedom	_	
122-112	22074-22084	calculated	_	
122-113	22085-22089	with	_	
122-114	22090-22103	Satterthwaite	_	
122-115	22104-22117	approximation	_	
122-116	22117-22118	.	_	

#Text=Random effects specified as random intercept for each participant.
123-1	22119-22125	Random	_	
123-2	22126-22133	effects	_	
123-3	22134-22143	specified	_	
123-4	22144-22146	as	_	
123-5	22147-22153	random	_	
123-6	22154-22163	intercept	_	
123-7	22164-22167	for	_	
123-8	22168-22172	each	_	
123-9	22173-22184	participant	_	
123-10	22184-22185	.	_	

#Text=†p < 0.1 **p < 0.01.
124-1	22186-22187	†	_	
124-2	22187-22188	p	_	
124-3	22189-22190	<	_	
124-4	22191-22194	0.1	_	
124-5	22195-22196	*	_	
124-6	22196-22197	*	_	
124-7	22197-22198	p	_	
124-8	22199-22200	<	_	
124-9	22201-22205	0.01	_	
124-10	22205-22206	.	_	

#Text=*p < 0.05 ***p < 0.001.
125-1	22207-22208	*	_	
125-2	22208-22209	p	_	
125-3	22210-22211	<	_	
125-4	22212-22216	0.05	_	
125-5	22217-22218	*	_	
125-6	22218-22219	*	_	
125-7	22219-22220	*	_	
125-8	22220-22221	p	_	
125-9	22222-22223	<	_	
125-10	22224-22229	0.001	_	
125-11	22229-22230	.	_	

#Text=In order to ascertain the role of the prefrontal cortex associated with variations in task type, we constructed LME models to test the hypothesis that subject Group, Score, and Task Type were related to mean biomarker changes during task performance.
126-1	22231-22233	In	_	
126-2	22234-22239	order	_	
126-3	22240-22242	to	_	
126-4	22243-22252	ascertain	_	
126-5	22253-22256	the	_	
126-6	22257-22261	role	_	
126-7	22262-22264	of	_	
126-8	22265-22268	the	_	
126-9	22269-22279	prefrontal	_	
126-10	22280-22286	cortex	_	
126-11	22287-22297	associated	_	
126-12	22298-22302	with	_	
126-13	22303-22313	variations	_	
126-14	22314-22316	in	_	
126-15	22317-22321	task	_	
126-16	22322-22326	type	_	
126-17	22326-22327	,	_	
126-18	22328-22330	we	_	
126-19	22331-22342	constructed	_	
126-20	22343-22346	LME	_	
126-21	22347-22353	models	_	
126-22	22354-22356	to	_	
126-23	22357-22361	test	_	
126-24	22362-22365	the	_	
126-25	22366-22376	hypothesis	_	
126-26	22377-22381	that	_	
126-27	22382-22389	subject	_	
126-28	22390-22395	Group	_	
126-29	22395-22396	,	_	
126-30	22397-22402	Score	_	
126-31	22402-22403	,	_	
126-32	22404-22407	and	_	
126-33	22408-22412	Task	_	
126-34	22413-22417	Type	_	
126-35	22418-22422	were	_	
126-36	22423-22430	related	_	
126-37	22431-22433	to	_	
126-38	22434-22438	mean	_	
126-39	22439-22448	biomarker	_	
126-40	22449-22456	changes	_	
126-41	22457-22463	during	_	
126-42	22464-22468	task	_	
126-43	22469-22480	performance	_	
126-44	22480-22481	.	_	

#Text=We observed a strong relationship between [Oxy] and the fixed effect of SAT-Score in Optodes 9, and 10 in the right-medial and right-medial-orbital Superior Frontal Gyrus (SFG) respectively.
127-1	22482-22484	We	_	
127-2	22485-22493	observed	_	
127-3	22494-22495	a	_	
127-4	22496-22502	strong	_	
127-5	22503-22515	relationship	_	
127-6	22516-22523	between	_	
127-7	22524-22525	[	_	
127-8	22525-22528	Oxy	_	
127-9	22528-22529	]	_	
127-10	22530-22533	and	_	
127-11	22534-22537	the	_	
127-12	22538-22543	fixed	_	
127-13	22544-22550	effect	_	
127-14	22551-22553	of	_	
127-15	22554-22563	SAT-Score	_	
127-16	22564-22566	in	_	
127-17	22567-22574	Optodes	_	
127-18	22575-22576	9	_	
127-19	22576-22577	,	_	
127-20	22578-22581	and	_	
127-21	22582-22584	10	_	
127-22	22585-22587	in	_	
127-23	22588-22591	the	_	
127-24	22592-22604	right-medial	_	
127-25	22605-22608	and	_	
127-26	22609-22629	right-medial-orbital	_	
127-27	22630-22638	Superior	_	
127-28	22639-22646	Frontal	_	
127-29	22647-22652	Gyrus	_	
127-30	22653-22654	(	_	
127-31	22654-22657	SFG	_	
127-32	22657-22658	)	_	
127-33	22659-22671	respectively	_	
127-34	22671-22672	.	_	

#Text=Both optodes showed significant fixed effects for Score following FDR correction (F(1,110.26) = 10.47, q = 0.012, F(1,87.16) = 10.21, q = 0.016).
128-1	22673-22677	Both	_	
128-2	22678-22685	optodes	_	
128-3	22686-22692	showed	_	
128-4	22693-22704	significant	_	
128-5	22705-22710	fixed	_	
128-6	22711-22718	effects	_	
128-7	22719-22722	for	_	
128-8	22723-22728	Score	_	
128-9	22729-22738	following	_	
128-10	22739-22742	FDR	_	
128-11	22743-22753	correction	_	
128-12	22754-22755	(	_	
128-13	22755-22756	F	_	
128-14	22756-22757	(	_	
128-15	22757-22765	1,110.26	_	
128-16	22765-22766	)	_	
128-17	22767-22768	=	_	
128-18	22769-22774	10.47	_	
128-19	22774-22775	,	_	
128-20	22776-22777	q	_	
128-21	22778-22779	=	_	
128-22	22780-22785	0.012	_	
128-23	22785-22786	,	_	
128-24	22787-22788	F	_	
128-25	22788-22789	(	_	
128-26	22789-22796	1,87.16	_	
128-27	22796-22797	)	_	
128-28	22798-22799	=	_	
128-29	22800-22805	10.21	_	
128-30	22805-22806	,	_	
128-31	22807-22808	q	_	
128-32	22809-22810	=	_	
128-33	22811-22816	0.016	_	
128-34	22816-22817	)	_	
128-35	22817-22818	.	_	

#Text=Additionally, Optodes 9 and 10 showed uncorrected significant effects for Group (F = 6.29~6.98, p < 0.009~0.014) and the Score and Group interaction (F = 5.17~5.57, p < 0.02~0.025).
129-1	22819-22831	Additionally	_	
129-2	22831-22832	,	_	
129-3	22833-22840	Optodes	_	
129-4	22841-22842	9	_	
129-5	22843-22846	and	_	
129-6	22847-22849	10	_	
129-7	22850-22856	showed	_	
129-8	22857-22868	uncorrected	_	
129-9	22869-22880	significant	_	
129-10	22881-22888	effects	_	
129-11	22889-22892	for	_	
129-12	22893-22898	Group	_	
129-13	22899-22900	(	_	
129-14	22900-22901	F	_	
129-15	22902-22903	=	_	
129-16	22904-22908	6.29	_	
129-17	22908-22909	~	_	
129-18	22909-22913	6.98	_	
129-19	22913-22914	,	_	
129-20	22915-22916	p	_	
129-21	22917-22918	<	_	
129-22	22919-22924	0.009	_	
129-23	22924-22925	~	_	
129-24	22925-22930	0.014	_	
129-25	22930-22931	)	_	
129-26	22932-22935	and	_	
129-27	22936-22939	the	_	
129-28	22940-22945	Score	_	
129-29	22946-22949	and	_	
129-30	22950-22955	Group	_	
129-31	22956-22967	interaction	_	
129-32	22968-22969	(	_	
129-33	22969-22970	F	_	
129-34	22971-22972	=	_	
129-35	22973-22977	5.17	_	
129-36	22977-22978	~	_	
129-37	22978-22982	5.57	_	
129-38	22982-22983	,	_	
129-39	22984-22985	p	_	
129-40	22986-22987	<	_	
129-41	22988-22992	0.02	_	
129-42	22992-22993	~	_	
129-43	22993-22998	0.025	_	
129-44	22998-22999	)	_	
129-45	22999-23000	.	_	

#Text=The model term for the interaction of Group and Task Type approached significance for Optode 9 (F = 3.62, p = 0.059).
130-1	23001-23004	The	_	
130-2	23005-23010	model	_	
130-3	23011-23015	term	_	
130-4	23016-23019	for	_	
130-5	23020-23023	the	_	
130-6	23024-23035	interaction	_	
130-7	23036-23038	of	_	
130-8	23039-23044	Group	_	
130-9	23045-23048	and	_	
130-10	23049-23053	Task	_	
130-11	23054-23058	Type	_	
130-12	23059-23069	approached	_	
130-13	23070-23082	significance	_	
130-14	23083-23086	for	_	
130-15	23087-23093	Optode	_	
130-16	23094-23095	9	_	
130-17	23096-23097	(	_	
130-18	23097-23098	F	_	
130-19	23099-23100	=	_	
130-20	23101-23105	3.62	_	
130-21	23105-23106	,	_	
130-22	23107-23108	p	_	
130-23	23109-23110	=	_	
130-24	23111-23116	0.059	_	
130-25	23116-23117	)	_	
130-26	23117-23118	.	_	

#Text=The Biomarkers for [HbO] and [HbR] individually did not identify any Optodes that survived FDR thresholding.
131-1	23119-23122	The	_	
131-2	23123-23133	Biomarkers	_	
131-3	23134-23137	for	_	
131-4	23138-23139	[	_	
131-5	23139-23142	HbO	_	
131-6	23142-23143	]	_	
131-7	23144-23147	and	_	
131-8	23148-23149	[	_	
131-9	23149-23152	HbR	_	
131-10	23152-23153	]	_	
131-11	23154-23166	individually	_	
131-12	23167-23170	did	_	
131-13	23171-23174	not	_	
131-14	23175-23183	identify	_	
131-15	23184-23187	any	_	
131-16	23188-23195	Optodes	_	
131-17	23196-23200	that	_	
131-18	23201-23209	survived	_	
131-19	23210-23213	FDR	_	
131-20	23214-23226	thresholding	_	
131-21	23226-23227	.	_	

#Text=Parametric Maps are presented for significant model terms in Fig. 4.
132-1	23228-23238	Parametric	_	
132-2	23239-23243	Maps	_	
132-3	23244-23247	are	_	
132-4	23248-23257	presented	_	
132-5	23258-23261	for	_	
132-6	23262-23273	significant	_	
132-7	23274-23279	model	_	
132-8	23280-23285	terms	_	
132-9	23286-23288	in	_	
132-10	23289-23292	Fig	_	
132-11	23292-23293	.	_	
132-12	23293-23294	 	_	
132-13	23294-23295	4	_	
132-14	23295-23296	.	_	

#Text=Model results for Optode 9 are presented in Table 3.
133-1	23297-23302	Model	_	
133-2	23303-23310	results	_	
133-3	23311-23314	for	_	
133-4	23315-23321	Optode	_	
133-5	23322-23323	9	_	
133-6	23324-23327	are	_	
133-7	23328-23337	presented	_	
133-8	23338-23340	in	_	
133-9	23341-23346	Table	_	
133-10	23346-23347	 	_	
133-11	23347-23348	3	_	
133-12	23348-23349	.	_	

#Text=Sensitivity to attentional workload localized to right-medial-SFG
#Text=While no significant model terms were observed for Task Type in biomarkers typically associated with activation ([HbO], [Oxy]), we sought to determine whether performance sensitivity to task changes was related to prefrontal cortical activity.
134-1	23350-23361	Sensitivity	_	
134-2	23362-23364	to	_	
134-3	23365-23376	attentional	_	
134-4	23377-23385	workload	_	
134-5	23386-23395	localized	_	
134-6	23396-23398	to	_	
134-7	23399-23415	right-medial-SFG	_	
134-8	23416-23421	While	_	
134-9	23422-23424	no	_	
134-10	23425-23436	significant	_	
134-11	23437-23442	model	_	
134-12	23443-23448	terms	_	
134-13	23449-23453	were	_	
134-14	23454-23462	observed	_	
134-15	23463-23466	for	_	
134-16	23467-23471	Task	_	
134-17	23472-23476	Type	_	
134-18	23477-23479	in	_	
134-19	23480-23490	biomarkers	_	
134-20	23491-23500	typically	_	
134-21	23501-23511	associated	_	
134-22	23512-23516	with	_	
134-23	23517-23527	activation	_	
134-24	23528-23529	(	_	
134-25	23529-23530	[	_	
134-26	23530-23533	HbO	_	
134-27	23533-23534	]	_	
134-28	23534-23535	,	_	
134-29	23536-23537	[	_	
134-30	23537-23540	Oxy	_	
134-31	23540-23541	]	_	
134-32	23541-23542	)	_	
134-33	23542-23543	,	_	
134-34	23544-23546	we	_	
134-35	23547-23553	sought	_	
134-36	23554-23556	to	_	
134-37	23557-23566	determine	_	
134-38	23567-23574	whether	_	
134-39	23575-23586	performance	_	
134-40	23587-23598	sensitivity	_	
134-41	23599-23601	to	_	
134-42	23602-23606	task	_	
134-43	23607-23614	changes	_	
134-44	23615-23618	was	_	
134-45	23619-23626	related	_	
134-46	23627-23629	to	_	
134-47	23630-23640	prefrontal	_	
134-48	23641-23649	cortical	_	
134-49	23650-23658	activity	_	
134-50	23658-23659	.	_	

#Text=To examine this, we defined Score Difference as the difference between the mean score obtained during the SAT task minus the subject’s score obtained during the vSAT task.
135-1	23660-23662	To	_	
135-2	23663-23670	examine	_	
135-3	23671-23675	this	_	
135-4	23675-23676	,	_	
135-5	23677-23679	we	_	
135-6	23680-23687	defined	_	
135-7	23688-23693	Score	_	
135-8	23694-23704	Difference	_	
135-9	23705-23707	as	_	
135-10	23708-23711	the	_	
135-11	23712-23722	difference	_	
135-12	23723-23730	between	_	
135-13	23731-23734	the	_	
135-14	23735-23739	mean	_	
135-15	23740-23745	score	_	
135-16	23746-23754	obtained	_	
135-17	23755-23761	during	_	
135-18	23762-23765	the	_	
135-19	23766-23769	SAT	_	
135-20	23770-23774	task	_	
135-21	23775-23780	minus	_	
135-22	23781-23784	the	_	
135-23	23785-23792	subject	_	
135-24	23792-23793	’	_	
135-25	23793-23794	s	_	
135-26	23795-23800	score	_	
135-27	23801-23809	obtained	_	
135-28	23810-23816	during	_	
135-29	23817-23820	the	_	
135-30	23821-23825	vSAT	_	
135-31	23826-23830	task	_	
135-32	23830-23831	.	_	

#Text=This Score Difference was taken as a measure of a subject’s sensitivity to increased task monitoring difficulty adjusted for baseline attentional performance.
136-1	23832-23836	This	_	
136-2	23837-23842	Score	_	
136-3	23843-23853	Difference	_	
136-4	23854-23857	was	_	
136-5	23858-23863	taken	_	
136-6	23864-23866	as	_	
136-7	23867-23868	a	_	
136-8	23869-23876	measure	_	
136-9	23877-23879	of	_	
136-10	23880-23881	a	_	
136-11	23882-23889	subject	_	
136-12	23889-23890	’	_	
136-13	23890-23891	s	_	
136-14	23892-23903	sensitivity	_	
136-15	23904-23906	to	_	
136-16	23907-23916	increased	_	
136-17	23917-23921	task	_	
136-18	23922-23932	monitoring	_	
136-19	23933-23943	difficulty	_	
136-20	23944-23952	adjusted	_	
136-21	23953-23956	for	_	
136-22	23957-23965	baseline	_	
136-23	23966-23977	attentional	_	
136-24	23978-23989	performance	_	
136-25	23989-23990	.	_	

#Text=A larger Score Difference would imply that the subject experienced more difficulty under the vSAT condition while a smaller score difference would imply that the subject either successfully adapted to task difficulty changes or did not find the task to be more challenging.
137-1	23991-23992	A	_	
137-2	23993-23999	larger	_	
137-3	24000-24005	Score	_	
137-4	24006-24016	Difference	_	
137-5	24017-24022	would	_	
137-6	24023-24028	imply	_	
137-7	24029-24033	that	_	
137-8	24034-24037	the	_	
137-9	24038-24045	subject	_	
137-10	24046-24057	experienced	_	
137-11	24058-24062	more	_	
137-12	24063-24073	difficulty	_	
137-13	24074-24079	under	_	
137-14	24080-24083	the	_	
137-15	24084-24088	vSAT	_	
137-16	24089-24098	condition	_	
137-17	24099-24104	while	_	
137-18	24105-24106	a	_	
137-19	24107-24114	smaller	_	
137-20	24115-24120	score	_	
137-21	24121-24131	difference	_	
137-22	24132-24137	would	_	
137-23	24138-24143	imply	_	
137-24	24144-24148	that	_	
137-25	24149-24152	the	_	
137-26	24153-24160	subject	_	
137-27	24161-24167	either	_	
137-28	24168-24180	successfully	_	
137-29	24181-24188	adapted	_	
137-30	24189-24191	to	_	
137-31	24192-24196	task	_	
137-32	24197-24207	difficulty	_	
137-33	24208-24215	changes	_	
137-34	24216-24218	or	_	
137-35	24219-24222	did	_	
137-36	24223-24226	not	_	
137-37	24227-24231	find	_	
137-38	24232-24235	the	_	
137-39	24236-24240	task	_	
137-40	24241-24243	to	_	
137-41	24244-24246	be	_	
137-42	24247-24251	more	_	
137-43	24252-24263	challenging	_	
137-44	24263-24264	.	_	

#Text=As a measure of performance on the vSAT task, we analyzed neuroimaging data in the context of the vSAT task periods only.
138-1	24265-24267	As	_	
138-2	24268-24269	a	_	
138-3	24270-24277	measure	_	
138-4	24278-24280	of	_	
138-5	24281-24292	performance	_	
138-6	24293-24295	on	_	
138-7	24296-24299	the	_	
138-8	24300-24304	vSAT	_	
138-9	24305-24309	task	_	
138-10	24309-24310	,	_	
138-11	24311-24313	we	_	
138-12	24314-24322	analyzed	_	
138-13	24323-24335	neuroimaging	_	
138-14	24336-24340	data	_	
138-15	24341-24343	in	_	
138-16	24344-24347	the	_	
138-17	24348-24355	context	_	
138-18	24356-24358	of	_	
138-19	24359-24362	the	_	
138-20	24363-24367	vSAT	_	
138-21	24368-24372	task	_	
138-22	24373-24380	periods	_	
138-23	24381-24385	only	_	
138-24	24385-24386	.	_	

#Text=Score Difference shows role for performance sensitivity across clinical groups in Optodes 9 and 11.
139-1	24387-24392	Score	_	
139-2	24393-24403	Difference	_	
139-3	24404-24409	shows	_	
139-4	24410-24414	role	_	
139-5	24415-24418	for	_	
139-6	24419-24430	performance	_	
139-7	24431-24442	sensitivity	_	
139-8	24443-24449	across	_	
139-9	24450-24458	clinical	_	
139-10	24459-24465	groups	_	
139-11	24466-24468	in	_	
139-12	24469-24476	Optodes	_	
139-13	24477-24478	9	_	
139-14	24479-24482	and	_	
139-15	24483-24485	11	_	
139-16	24485-24486	.	_	

#Text=(A) Full model parametric maps overlaid onto anatomical reference image.
140-1	24487-24488	(	_	
140-2	24488-24489	A	_	
140-3	24489-24490	)	_	
140-4	24491-24495	Full	_	
140-5	24496-24501	model	_	
140-6	24502-24512	parametric	_	
140-7	24513-24517	maps	_	
140-8	24518-24526	overlaid	_	
140-9	24527-24531	onto	_	
140-10	24532-24542	anatomical	_	
140-11	24543-24552	reference	_	
140-12	24553-24558	image	_	
140-13	24558-24559	.	_	

#Text=Values represent mixed model F-Values thresholded using FDR.
141-1	24560-24566	Values	_	
141-2	24567-24576	represent	_	
141-3	24577-24582	mixed	_	
141-4	24583-24588	model	_	
141-5	24589-24597	F-Values	_	
141-6	24598-24609	thresholded	_	
141-7	24610-24615	using	_	
141-8	24616-24619	FDR	_	
141-9	24619-24620	.	_	

#Text=Correlations are presented for both groups in Optode 9 (B) and Optode 11 (C) (rho = 0.41, p = 0.016~0.024).
142-1	24621-24633	Correlations	_	
142-2	24634-24637	are	_	
142-3	24638-24647	presented	_	
142-4	24648-24651	for	_	
142-5	24652-24656	both	_	
142-6	24657-24663	groups	_	
142-7	24664-24666	in	_	
142-8	24667-24673	Optode	_	
142-9	24674-24675	9	_	
142-10	24676-24677	(	_	
142-11	24677-24678	B	_	
142-12	24678-24679	)	_	
142-13	24680-24683	and	_	
142-14	24684-24690	Optode	_	
142-15	24691-24693	11	_	
142-16	24694-24695	(	_	
142-17	24695-24696	C	_	
142-18	24696-24697	)	_	
142-19	24698-24699	(	_	
142-20	24699-24702	rho	_	
142-21	24703-24704	=	_	
142-22	24705-24709	0.41	_	
142-23	24709-24710	,	_	
142-24	24711-24712	p	_	
142-25	24713-24714	=	_	
142-26	24715-24720	0.016	_	
142-27	24720-24721	~	_	
142-28	24721-24726	0.024	_	
142-29	24726-24727	)	_	
142-30	24727-24728	.	_	

#Text=In examining the effect of sensitivity to attentional demand on task performance changes, we observed a broad uncorrected significance for Score Difference in many of the medial optodes (3,7,9,10,11,12) for the biomarker [HbO], but only Optodes 9 and 11 survived FDR thresholding (F(1,56) = 10.00, q = 0.02; F(1,46) = 8.46, q = 0.044).
143-1	24729-24731	In	_	
143-2	24732-24741	examining	_	
143-3	24742-24745	the	_	
143-4	24746-24752	effect	_	
143-5	24753-24755	of	_	
143-6	24756-24767	sensitivity	_	
143-7	24768-24770	to	_	
143-8	24771-24782	attentional	_	
143-9	24783-24789	demand	_	
143-10	24790-24792	on	_	
143-11	24793-24797	task	_	
143-12	24798-24809	performance	_	
143-13	24810-24817	changes	_	
143-14	24817-24818	,	_	
143-15	24819-24821	we	_	
143-16	24822-24830	observed	_	
143-17	24831-24832	a	_	
143-18	24833-24838	broad	_	
143-19	24839-24850	uncorrected	_	
143-20	24851-24863	significance	_	
143-21	24864-24867	for	_	
143-22	24868-24873	Score	_	
143-23	24874-24884	Difference	_	
143-24	24885-24887	in	_	
143-25	24888-24892	many	_	
143-26	24893-24895	of	_	
143-27	24896-24899	the	_	
143-28	24900-24906	medial	_	
143-29	24907-24914	optodes	_	
143-30	24915-24916	(	_	
143-31	24916-24930	3,7,9,10,11,12	_	
143-32	24930-24931	)	_	
143-33	24932-24935	for	_	
143-34	24936-24939	the	_	
143-35	24940-24949	biomarker	_	
143-36	24950-24951	[	_	
143-37	24951-24954	HbO	_	
143-38	24954-24955	]	_	
143-39	24955-24956	,	_	
143-40	24957-24960	but	_	
143-41	24961-24965	only	_	
143-42	24966-24973	Optodes	_	
143-43	24974-24975	9	_	
143-44	24976-24979	and	_	
143-45	24980-24982	11	_	
143-46	24983-24991	survived	_	
143-47	24992-24995	FDR	_	
143-48	24996-25008	thresholding	_	
143-49	25009-25010	(	_	
143-50	25010-25011	F	_	
143-51	25011-25012	(	_	
143-52	25012-25016	1,56	_	
143-53	25016-25017	)	_	
143-54	25018-25019	=	_	
143-55	25020-25025	10.00	_	
143-56	25025-25026	,	_	
143-57	25027-25028	q	_	
143-58	25029-25030	=	_	
143-59	25031-25035	0.02	_	
143-60	25035-25036	;	_	
143-61	25037-25038	F	_	
143-62	25038-25039	(	_	
143-63	25039-25043	1,46	_	
143-64	25043-25044	)	_	
143-65	25045-25046	=	_	
143-66	25047-25051	8.46	_	
143-67	25051-25052	,	_	
143-68	25053-25054	q	_	
143-69	25055-25056	=	_	
143-70	25057-25062	0.044	_	
143-71	25062-25063	)	_	
143-72	25063-25064	.	_	

#Text=Score Difference also survived FDR thresholding in Optode 9 for the [Oxy] biomarker (F(1,53.57) = 9.68, q = 0.048).
144-1	25065-25070	Score	_	
144-2	25071-25081	Difference	_	
144-3	25082-25086	also	_	
144-4	25087-25095	survived	_	
144-5	25096-25099	FDR	_	
144-6	25100-25112	thresholding	_	
144-7	25113-25115	in	_	
144-8	25116-25122	Optode	_	
144-9	25123-25124	9	_	
144-10	25125-25128	for	_	
144-11	25129-25132	the	_	
144-12	25133-25134	[	_	
144-13	25134-25137	Oxy	_	
144-14	25137-25138	]	_	
144-15	25139-25148	biomarker	_	
144-16	25149-25150	(	_	
144-17	25150-25151	F	_	
144-18	25151-25152	(	_	
144-19	25152-25159	1,53.57	_	
144-20	25159-25160	)	_	
144-21	25161-25162	=	_	
144-22	25163-25167	9.68	_	
144-23	25167-25168	,	_	
144-24	25169-25170	q	_	
144-25	25171-25172	=	_	
144-26	25173-25178	0.048	_	
144-27	25178-25179	)	_	
144-28	25179-25180	.	_	

#Text=These differences did not appear to differ across subject Group as inferred both by similar regression lines in both groups, and lack of significance in the Group or interaction terms in the linear models.
145-1	25181-25186	These	_	
145-2	25187-25198	differences	_	
145-3	25199-25202	did	_	
145-4	25203-25206	not	_	
145-5	25207-25213	appear	_	
145-6	25214-25216	to	_	
145-7	25217-25223	differ	_	
145-8	25224-25230	across	_	
145-9	25231-25238	subject	_	
145-10	25239-25244	Group	_	
145-11	25245-25247	as	_	
145-12	25248-25256	inferred	_	
145-13	25257-25261	both	_	
145-14	25262-25264	by	_	
145-15	25265-25272	similar	_	
145-16	25273-25283	regression	_	
145-17	25284-25289	lines	_	
145-18	25290-25292	in	_	
145-19	25293-25297	both	_	
145-20	25298-25304	groups	_	
145-21	25304-25305	,	_	
145-22	25306-25309	and	_	
145-23	25310-25314	lack	_	
145-24	25315-25317	of	_	
145-25	25318-25330	significance	_	
145-26	25331-25333	in	_	
145-27	25334-25337	the	_	
145-28	25338-25343	Group	_	
145-29	25344-25346	or	_	
145-30	25347-25358	interaction	_	
145-31	25359-25364	terms	_	
145-32	25365-25367	in	_	
145-33	25368-25371	the	_	
145-34	25372-25378	linear	_	
145-35	25379-25385	models	_	
145-36	25385-25386	.	_	

#Text=No optodes were identified as significant for changes in the [HbR] biomarker.
146-1	25387-25389	No	_	
146-2	25390-25397	optodes	_	
146-3	25398-25402	were	_	
146-4	25403-25413	identified	_	
146-5	25414-25416	as	_	
146-6	25417-25428	significant	_	
146-7	25429-25432	for	_	
146-8	25433-25440	changes	_	
146-9	25441-25443	in	_	
146-10	25444-25447	the	_	
146-11	25448-25449	[	_	
146-12	25449-25452	HbR	_	
146-13	25452-25453	]	_	
146-14	25454-25463	biomarker	_	
146-15	25463-25464	.	_	

#Text=Visualization of FDR-thresholded significant model terms and pertinent correlations are presented in Fig. 5.
#Text=vSAT-evoked activity shows relationship to clinical status in Left-MFG
#Text=Differing relationship between clinical status and left-Prefrontal activity between tasks types (SAT vs. vSAT).
147-1	25465-25478	Visualization	_	
147-2	25479-25481	of	_	
147-3	25482-25497	FDR-thresholded	_	
147-4	25498-25509	significant	_	
147-5	25510-25515	model	_	
147-6	25516-25521	terms	_	
147-7	25522-25525	and	_	
147-8	25526-25535	pertinent	_	
147-9	25536-25548	correlations	_	
147-10	25549-25552	are	_	
147-11	25553-25562	presented	_	
147-12	25563-25565	in	_	
147-13	25566-25569	Fig	_	
147-14	25569-25570	.	_	
147-15	25570-25571	 	_	
147-16	25571-25572	5	_	
147-17	25572-25573	.	_	
147-18	25574-25585	vSAT-evoked	_	
147-19	25586-25594	activity	_	
147-20	25595-25600	shows	_	
147-21	25601-25613	relationship	_	
147-22	25614-25616	to	_	
147-23	25617-25625	clinical	_	
147-24	25626-25632	status	_	
147-25	25633-25635	in	_	
147-26	25636-25644	Left-MFG	_	
147-27	25645-25654	Differing	_	
147-28	25655-25667	relationship	_	
147-29	25668-25675	between	_	
147-30	25676-25684	clinical	_	
147-31	25685-25691	status	_	
147-32	25692-25695	and	_	
147-33	25696-25711	left-Prefrontal	_	
147-34	25712-25720	activity	_	
147-35	25721-25728	between	_	
147-36	25729-25734	tasks	_	
147-37	25735-25740	types	_	
147-38	25741-25742	(	_	
147-39	25742-25745	SAT	_	
147-40	25746-25748	vs	_	
147-41	25748-25749	.	_	
147-42	25750-25754	vSAT	_	
147-43	25754-25755	)	_	
147-44	25755-25756	.	_	

#Text=Parametric representation of significant model term overlaid onto anatomical reference images.
148-1	25757-25767	Parametric	_	
148-2	25768-25782	representation	_	
148-3	25783-25785	of	_	
148-4	25786-25797	significant	_	
148-5	25798-25803	model	_	
148-6	25804-25808	term	_	
148-7	25809-25817	overlaid	_	
148-8	25818-25822	onto	_	
148-9	25823-25833	anatomical	_	
148-10	25834-25843	reference	_	
148-11	25844-25850	images	_	
148-12	25850-25851	.	_	

#Text=Values represent mixed model F-Values thresholded with FDR.
149-1	25852-25858	Values	_	
149-2	25859-25868	represent	_	
149-3	25869-25874	mixed	_	
149-4	25875-25880	model	_	
149-5	25881-25889	F-Values	_	
149-6	25890-25901	thresholded	_	
149-7	25902-25906	with	_	
149-8	25907-25910	FDR	_	
149-9	25910-25911	.	_	

#Text=(A) Task Type, (B) Task and PANSS interaction, (C) Correlations between Optode5 and PANSS total for both tasks.
150-1	25912-25913	(	_	
150-2	25913-25914	A	_	
150-3	25914-25915	)	_	
150-4	25916-25920	Task	_	
150-5	25921-25925	Type	_	
150-6	25925-25926	,	_	
150-7	25927-25928	(	_	
150-8	25928-25929	B	_	
150-9	25929-25930	)	_	
150-10	25931-25935	Task	_	
150-11	25936-25939	and	_	
150-12	25940-25945	PANSS	_	
150-13	25946-25957	interaction	_	
150-14	25957-25958	,	_	
150-15	25959-25960	(	_	
150-16	25960-25961	C	_	
150-17	25961-25962	)	_	
150-18	25963-25975	Correlations	_	
150-19	25976-25983	between	_	
150-20	25984-25991	Optode5	_	
150-21	25992-25995	and	_	
150-22	25996-26001	PANSS	_	
150-23	26002-26007	total	_	
150-24	26008-26011	for	_	
150-25	26012-26016	both	_	
150-26	26017-26022	tasks	_	
150-27	26022-26023	.	_	

#Text=Biomarker models were constructed to evaluate total PANSS score and the relationship between cortical response to Task Type and clinical status.
151-1	26024-26033	Biomarker	_	
151-2	26034-26040	models	_	
151-3	26041-26045	were	_	
151-4	26046-26057	constructed	_	
151-5	26058-26060	to	_	
151-6	26061-26069	evaluate	_	
151-7	26070-26075	total	_	
151-8	26076-26081	PANSS	_	
151-9	26082-26087	score	_	
151-10	26088-26091	and	_	
151-11	26092-26095	the	_	
151-12	26096-26108	relationship	_	
151-13	26109-26116	between	_	
151-14	26117-26125	cortical	_	
151-15	26126-26134	response	_	
151-16	26135-26137	to	_	
151-17	26138-26142	Task	_	
151-18	26143-26147	Type	_	
151-19	26148-26151	and	_	
151-20	26152-26160	clinical	_	
151-21	26161-26167	status	_	
151-22	26167-26168	.	_	

#Text=Following FDR correction, we observed significant fixed effects for Task Type for [HbO] in Optode 3 and 5, near the left Middle Frontal Gyrus (MFG), as well as the interaction between Task Type and PANSS in Optodes 3 and 5 for [HbO] (F(1,54.85) = 8.65, q = 0.038; F(1,52.3) = 10.42, q = 0.017) and Optode 3 for [Oxy] (F(1,71) = 9.44, q = 0.048).
152-1	26169-26178	Following	_	
152-2	26179-26182	FDR	_	
152-3	26183-26193	correction	_	
152-4	26193-26194	,	_	
152-5	26195-26197	we	_	
152-6	26198-26206	observed	_	
152-7	26207-26218	significant	_	
152-8	26219-26224	fixed	_	
152-9	26225-26232	effects	_	
152-10	26233-26236	for	_	
152-11	26237-26241	Task	_	
152-12	26242-26246	Type	_	
152-13	26247-26250	for	_	
152-14	26251-26252	[	_	
152-15	26252-26255	HbO	_	
152-16	26255-26256	]	_	
152-17	26257-26259	in	_	
152-18	26260-26266	Optode	_	
152-19	26267-26268	3	_	
152-20	26269-26272	and	_	
152-21	26273-26274	5	_	
152-22	26274-26275	,	_	
152-23	26276-26280	near	_	
152-24	26281-26284	the	_	
152-25	26285-26289	left	_	
152-26	26290-26296	Middle	_	
152-27	26297-26304	Frontal	_	
152-28	26305-26310	Gyrus	_	
152-29	26311-26312	(	_	
152-30	26312-26315	MFG	_	
152-31	26315-26316	)	_	
152-32	26316-26317	,	_	
152-33	26318-26320	as	_	
152-34	26321-26325	well	_	
152-35	26326-26328	as	_	
152-36	26329-26332	the	_	
152-37	26333-26344	interaction	_	
152-38	26345-26352	between	_	
152-39	26353-26357	Task	_	
152-40	26358-26362	Type	_	
152-41	26363-26366	and	_	
152-42	26367-26372	PANSS	_	
152-43	26373-26375	in	_	
152-44	26376-26383	Optodes	_	
152-45	26384-26385	3	_	
152-46	26386-26389	and	_	
152-47	26390-26391	5	_	
152-48	26392-26395	for	_	
152-49	26396-26397	[	_	
152-50	26397-26400	HbO	_	
152-51	26400-26401	]	_	
152-52	26402-26403	(	_	
152-53	26403-26404	F	_	
152-54	26404-26405	(	_	
152-55	26405-26412	1,54.85	_	
152-56	26412-26413	)	_	
152-57	26414-26415	=	_	
152-58	26416-26420	8.65	_	
152-59	26420-26421	,	_	
152-60	26422-26423	q	_	
152-61	26424-26425	=	_	
152-62	26426-26431	0.038	_	
152-63	26431-26432	;	_	
152-64	26433-26434	F	_	
152-65	26434-26435	(	_	
152-66	26435-26441	1,52.3	_	
152-67	26441-26442	)	_	
152-68	26443-26444	=	_	
152-69	26445-26450	10.42	_	
152-70	26450-26451	,	_	
152-71	26452-26453	q	_	
152-72	26454-26455	=	_	
152-73	26456-26461	0.017	_	
152-74	26461-26462	)	_	
152-75	26463-26466	and	_	
152-76	26467-26473	Optode	_	
152-77	26474-26475	3	_	
152-78	26476-26479	for	_	
152-79	26480-26481	[	_	
152-80	26481-26484	Oxy	_	
152-81	26484-26485	]	_	
152-82	26486-26487	(	_	
152-83	26487-26488	F	_	
152-84	26488-26489	(	_	
152-85	26489-26493	1,71	_	
152-86	26493-26494	)	_	
152-87	26495-26496	=	_	
152-88	26497-26501	9.44	_	
152-89	26501-26502	,	_	
152-90	26503-26504	q	_	
152-91	26505-26506	=	_	
152-92	26507-26512	0.048	_	
152-93	26512-26513	)	_	
152-94	26513-26514	.	_	

#Text=No optodes were identified as significant when [HbR] was investigated as a biomarker.
153-1	26515-26517	No	_	
153-2	26518-26525	optodes	_	
153-3	26526-26530	were	_	
153-4	26531-26541	identified	_	
153-5	26542-26544	as	_	
153-6	26545-26556	significant	_	
153-7	26557-26561	when	_	
153-8	26562-26563	[	_	
153-9	26563-26566	HbR	_	
153-10	26566-26567	]	_	
153-11	26568-26571	was	_	
153-12	26572-26584	investigated	_	
153-13	26585-26587	as	_	
153-14	26588-26589	a	_	
153-15	26590-26599	biomarker	_	
153-16	26599-26600	.	_	

#Text=Significant model terms and selected correlations are presented in Fig. 6.
154-1	26601-26612	Significant	_	
154-2	26613-26618	model	_	
154-3	26619-26624	terms	_	
154-4	26625-26628	and	_	
154-5	26629-26637	selected	_	
154-6	26638-26650	correlations	_	
154-7	26651-26654	are	_	
154-8	26655-26664	presented	_	
154-9	26665-26667	in	_	
154-10	26668-26671	Fig	_	
154-11	26671-26672	.	_	
154-12	26672-26673	 	_	
154-13	26673-26674	6	_	
154-14	26674-26675	.	_	

#Text=PANSS Subscales exhibited strong correlations with left-Prefrontal activity during vSAT Task Condition.
155-1	26676-26681	PANSS	_	
155-2	26682-26691	Subscales	_	
155-3	26692-26701	exhibited	_	
155-4	26702-26708	strong	_	
155-5	26709-26721	correlations	_	
155-6	26722-26726	with	_	
155-7	26727-26742	left-Prefrontal	_	
155-8	26743-26751	activity	_	
155-9	26752-26758	during	_	
155-10	26759-26763	vSAT	_	
155-11	26764-26768	Task	_	
155-12	26769-26778	Condition	_	
155-13	26778-26779	.	_	

#Text=Correlational parametric maps overlaid onto anatomical reference images in panels (A,B).
156-1	26780-26793	Correlational	_	
156-2	26794-26804	parametric	_	
156-3	26805-26809	maps	_	
156-4	26810-26818	overlaid	_	
156-5	26819-26823	onto	_	
156-6	26824-26834	anatomical	_	
156-7	26835-26844	reference	_	
156-8	26845-26851	images	_	
156-9	26852-26854	in	_	
156-10	26855-26861	panels	_	
156-11	26862-26863	(	_	
156-12	26863-26864	A	_	
156-13	26864-26865	,	_	
156-14	26865-26866	B	_	
156-15	26866-26867	)	_	
156-16	26867-26868	.	_	

#Text=Values represent significant correlations strength as measured by Spearman’s Rank Correlation between [HbO] and the (A) PANSS Negative subscale, and (B) PANSS-General Subscale.
157-1	26869-26875	Values	_	
157-2	26876-26885	represent	_	
157-3	26886-26897	significant	_	
157-4	26898-26910	correlations	_	
157-5	26911-26919	strength	_	
157-6	26920-26922	as	_	
157-7	26923-26931	measured	_	
157-8	26932-26934	by	_	
157-9	26935-26943	Spearman	_	
157-10	26943-26944	’	_	
157-11	26944-26945	s	_	
157-12	26946-26950	Rank	_	
157-13	26951-26962	Correlation	_	
157-14	26963-26970	between	_	
157-15	26971-26972	[	_	
157-16	26972-26975	HbO	_	
157-17	26975-26976	]	_	
157-18	26977-26980	and	_	
157-19	26981-26984	the	_	
157-20	26985-26986	(	_	
157-21	26986-26987	A	_	
157-22	26987-26988	)	_	
157-23	26989-26994	PANSS	_	
157-24	26995-27003	Negative	_	
157-25	27004-27012	subscale	_	
157-26	27012-27013	,	_	
157-27	27014-27017	and	_	
157-28	27018-27019	(	_	
157-29	27019-27020	B	_	
157-30	27020-27021	)	_	
157-31	27022-27035	PANSS-General	_	
157-32	27036-27044	Subscale	_	
157-33	27044-27045	.	_	

#Text=(C) Correlations for Optode 5 with PANSS Negative for vSAT task (rho = −0.776, p = 0.0002).
158-1	27046-27047	(	_	
158-2	27047-27048	C	_	
158-3	27048-27049	)	_	
158-4	27050-27062	Correlations	_	
158-5	27063-27066	for	_	
158-6	27067-27073	Optode	_	
158-7	27074-27075	5	_	
158-8	27076-27080	with	_	
158-9	27081-27086	PANSS	_	
158-10	27087-27095	Negative	_	
158-11	27096-27099	for	_	
158-12	27100-27104	vSAT	_	
158-13	27105-27109	task	_	
158-14	27110-27111	(	_	
158-15	27111-27114	rho	_	
158-16	27115-27116	=	_	
158-17	27117-27118	−	_	
158-18	27118-27123	0.776	_	
158-19	27123-27124	,	_	
158-20	27125-27126	p	_	
158-21	27127-27128	=	_	
158-22	27129-27135	0.0002	_	
158-23	27135-27136	)	_	
158-24	27136-27137	.	_	

#Text=To investigate the basis of these relationships, we explored the correlations of both optodes with PANSS total and the Negative, Positive, and General subscales, and the mean biomarkers for each subject.
159-1	27138-27140	To	_	
159-2	27141-27152	investigate	_	
159-3	27153-27156	the	_	
159-4	27157-27162	basis	_	
159-5	27163-27165	of	_	
159-6	27166-27171	these	_	
159-7	27172-27185	relationships	_	
159-8	27185-27186	,	_	
159-9	27187-27189	we	_	
159-10	27190-27198	explored	_	
159-11	27199-27202	the	_	
159-12	27203-27215	correlations	_	
159-13	27216-27218	of	_	
159-14	27219-27223	both	_	
159-15	27224-27231	optodes	_	
159-16	27232-27236	with	_	
159-17	27237-27242	PANSS	_	
159-18	27243-27248	total	_	
159-19	27249-27252	and	_	
159-20	27253-27256	the	_	
159-21	27257-27265	Negative	_	
159-22	27265-27266	,	_	
159-23	27267-27275	Positive	_	
159-24	27275-27276	,	_	
159-25	27277-27280	and	_	
159-26	27281-27288	General	_	
159-27	27289-27298	subscales	_	
159-28	27298-27299	,	_	
159-29	27300-27303	and	_	
159-30	27304-27307	the	_	
159-31	27308-27312	mean	_	
159-32	27313-27323	biomarkers	_	
159-33	27324-27327	for	_	
159-34	27328-27332	each	_	
159-35	27333-27340	subject	_	
159-36	27340-27341	.	_	

#Text=We observed significant correlations at Optode 5 for [HbO] (rho = −0.58, p = 0.014) during the vSAT task which appeared to be related to a strong negative correlation with the PANSS Negative subscale (rho = −0.77, p = 0.0002) and a weaker correlation with the General subscale (rho = −0.46, p = 0.06).
160-1	27342-27344	We	_	
160-2	27345-27353	observed	_	
160-3	27354-27365	significant	_	
160-4	27366-27378	correlations	_	
160-5	27379-27381	at	_	
160-6	27382-27388	Optode	_	
160-7	27389-27390	5	_	
160-8	27391-27394	for	_	
160-9	27395-27396	[	_	
160-10	27396-27399	HbO	_	
160-11	27399-27400	]	_	
160-12	27401-27402	(	_	
160-13	27402-27405	rho	_	
160-14	27406-27407	=	_	
160-15	27408-27409	−	_	
160-16	27409-27413	0.58	_	
160-17	27413-27414	,	_	
160-18	27415-27416	p	_	
160-19	27417-27418	=	_	
160-20	27419-27424	0.014	_	
160-21	27424-27425	)	_	
160-22	27426-27432	during	_	
160-23	27433-27436	the	_	
160-24	27437-27441	vSAT	_	
160-25	27442-27446	task	_	
160-26	27447-27452	which	_	
160-27	27453-27461	appeared	_	
160-28	27462-27464	to	_	
160-29	27465-27467	be	_	
160-30	27468-27475	related	_	
160-31	27476-27478	to	_	
160-32	27479-27480	a	_	
160-33	27481-27487	strong	_	
160-34	27488-27496	negative	_	
160-35	27497-27508	correlation	_	
160-36	27509-27513	with	_	
160-37	27514-27517	the	_	
160-38	27518-27523	PANSS	_	
160-39	27524-27532	Negative	_	
160-40	27533-27541	subscale	_	
160-41	27542-27543	(	_	
160-42	27543-27546	rho	_	
160-43	27547-27548	=	_	
160-44	27549-27550	−	_	
160-45	27550-27554	0.77	_	
160-46	27554-27555	,	_	
160-47	27556-27557	p	_	
160-48	27558-27559	=	_	
160-49	27560-27566	0.0002	_	
160-50	27566-27567	)	_	
160-51	27568-27571	and	_	
160-52	27572-27573	a	_	
160-53	27574-27580	weaker	_	
160-54	27581-27592	correlation	_	
160-55	27593-27597	with	_	
160-56	27598-27601	the	_	
160-57	27602-27609	General	_	
160-58	27610-27618	subscale	_	
160-59	27619-27620	(	_	
160-60	27620-27623	rho	_	
160-61	27624-27625	=	_	
160-62	27626-27627	−	_	
160-63	27627-27631	0.46	_	
160-64	27631-27632	,	_	
160-65	27633-27634	p	_	
160-66	27635-27636	=	_	
160-67	27637-27641	0.06	_	
160-68	27641-27642	)	_	
160-69	27642-27643	.	_	

#Text=Marginally significant correlations during the SAT condition were observed at Optodes 3 and 5 for [HbO] with the PANSS positive subscale (rho = 0.45~0.484, p = 0.035~0.04) but not for other subscales.
161-1	27644-27654	Marginally	_	
161-2	27655-27666	significant	_	
161-3	27667-27679	correlations	_	
161-4	27680-27686	during	_	
161-5	27687-27690	the	_	
161-6	27691-27694	SAT	_	
161-7	27695-27704	condition	_	
161-8	27705-27709	were	_	
161-9	27710-27718	observed	_	
161-10	27719-27721	at	_	
161-11	27722-27729	Optodes	_	
161-12	27730-27731	3	_	
161-13	27732-27735	and	_	
161-14	27736-27737	5	_	
161-15	27738-27741	for	_	
161-16	27742-27743	[	_	
161-17	27743-27746	HbO	_	
161-18	27746-27747	]	_	
161-19	27748-27752	with	_	
161-20	27753-27756	the	_	
161-21	27757-27762	PANSS	_	
161-22	27763-27771	positive	_	
161-23	27772-27780	subscale	_	
161-24	27781-27782	(	_	
161-25	27782-27785	rho	_	
161-26	27786-27787	=	_	
161-27	27788-27792	0.45	_	
161-28	27792-27793	~	_	
161-29	27793-27798	0.484	_	
161-30	27798-27799	,	_	
161-31	27800-27801	p	_	
161-32	27802-27803	=	_	
161-33	27804-27809	0.035	_	
161-34	27809-27810	~	_	
161-35	27810-27814	0.04	_	
161-36	27814-27815	)	_	
161-37	27816-27819	but	_	
161-38	27820-27823	not	_	
161-39	27824-27827	for	_	
161-40	27828-27833	other	_	
161-41	27834-27843	subscales	_	
161-42	27843-27844	.	_	

#Text=Parametric distribution of subscale correlation values and supporting correlations are presented in Fig. 7.
162-1	27845-27855	Parametric	_	
162-2	27856-27868	distribution	_	
162-3	27869-27871	of	_	
162-4	27872-27880	subscale	_	
162-5	27881-27892	correlation	_	
162-6	27893-27899	values	_	
162-7	27900-27903	and	_	
162-8	27904-27914	supporting	_	
162-9	27915-27927	correlations	_	
162-10	27928-27931	are	_	
162-11	27932-27941	presented	_	
162-12	27942-27944	in	_	
162-13	27945-27948	Fig	_	
162-14	27948-27949	.	_	
162-15	27949-27950	 	_	
162-16	27950-27951	7	_	
162-17	27951-27952	.	_	

#Text=Additional correlations for other optodes with behavioral performance, duration of illness, equivalent antipsychotic dosage and other clinical outcome measures are reported in the Supporting Materials (A2).
163-1	27953-27963	Additional	_	
163-2	27964-27976	correlations	_	
163-3	27977-27980	for	_	
163-4	27981-27986	other	_	
163-5	27987-27994	optodes	_	
163-6	27995-27999	with	_	
163-7	28000-28010	behavioral	_	
163-8	28011-28022	performance	_	
163-9	28022-28023	,	_	
163-10	28024-28032	duration	_	
163-11	28033-28035	of	_	
163-12	28036-28043	illness	_	
163-13	28043-28044	,	_	
163-14	28045-28055	equivalent	_	
163-15	28056-28069	antipsychotic	_	
163-16	28070-28076	dosage	_	
163-17	28077-28080	and	_	
163-18	28081-28086	other	_	
163-19	28087-28095	clinical	_	
163-20	28096-28103	outcome	_	
163-21	28104-28112	measures	_	
163-22	28113-28116	are	_	
163-23	28117-28125	reported	_	
163-24	28126-28128	in	_	
163-25	28129-28132	the	_	
163-26	28133-28143	Supporting	_	
163-27	28144-28153	Materials	_	
163-28	28154-28155	(	_	
163-29	28155-28157	A2	_	
163-30	28157-28158	)	_	
163-31	28158-28159	.	_	

#Text=Discussion
#Text=The sustained attention task (SAT) is a key task in the CNTRICS project which had identified the ‘Control of Attention’ as a principle impairment in schizophrenia and proposed the measurement of this impairment as a key biomarker in drug development.
164-1	28160-28170	Discussion	_	
164-2	28171-28174	The	_	
164-3	28175-28184	sustained	_	
164-4	28185-28194	attention	_	
164-5	28195-28199	task	_	
164-6	28200-28201	(	_	
164-7	28201-28204	SAT	_	
164-8	28204-28205	)	_	
164-9	28206-28208	is	_	
164-10	28209-28210	a	_	
164-11	28211-28214	key	_	
164-12	28215-28219	task	_	
164-13	28220-28222	in	_	
164-14	28223-28226	the	_	
164-15	28227-28234	CNTRICS	_	
164-16	28235-28242	project	_	
164-17	28243-28248	which	_	
164-18	28249-28252	had	_	
164-19	28253-28263	identified	_	
164-20	28264-28267	the	_	
164-21	28268-28269	‘	_	
164-22	28269-28276	Control	_	
164-23	28277-28279	of	_	
164-24	28280-28289	Attention	_	
164-25	28289-28290	’	_	
164-26	28291-28293	as	_	
164-27	28294-28295	a	_	
164-28	28296-28305	principle	_	
164-29	28306-28316	impairment	_	
164-30	28317-28319	in	_	
164-31	28320-28333	schizophrenia	_	
164-32	28334-28337	and	_	
164-33	28338-28346	proposed	_	
164-34	28347-28350	the	_	
164-35	28351-28362	measurement	_	
164-36	28363-28365	of	_	
164-37	28366-28370	this	_	
164-38	28371-28381	impairment	_	
164-39	28382-28384	as	_	
164-40	28385-28386	a	_	
164-41	28387-28390	key	_	
164-42	28391-28400	biomarker	_	
164-43	28401-28403	in	_	
164-44	28404-28408	drug	_	
164-45	28409-28420	development	_	
164-46	28420-28421	.	_	

#Text=The test consists primarily of a signal/non-signal classification paradigm, following a brief tone and has been validated to modulate with distraction and stimuli length, and has demonstrated performance sensitivity to a variety of drugs including benzodiazepine, acetylcholine receptor ligands, and 192 IgG-saporin.
165-1	28422-28425	The	_	
165-2	28426-28430	test	_	
165-3	28431-28439	consists	_	
165-4	28440-28449	primarily	_	
165-5	28450-28452	of	_	
165-6	28453-28454	a	_	
165-7	28455-28461	signal	_	
165-8	28461-28462	/	_	
165-9	28462-28472	non-signal	_	
165-10	28473-28487	classification	_	
165-11	28488-28496	paradigm	_	
165-12	28496-28497	,	_	
165-13	28498-28507	following	_	
165-14	28508-28509	a	_	
165-15	28510-28515	brief	_	
165-16	28516-28520	tone	_	
165-17	28521-28524	and	_	
165-18	28525-28528	has	_	
165-19	28529-28533	been	_	
165-20	28534-28543	validated	_	
165-21	28544-28546	to	_	
165-22	28547-28555	modulate	_	
165-23	28556-28560	with	_	
165-24	28561-28572	distraction	_	
165-25	28573-28576	and	_	
165-26	28577-28584	stimuli	_	
165-27	28585-28591	length	_	
165-28	28591-28592	,	_	
165-29	28593-28596	and	_	
165-30	28597-28600	has	_	
165-31	28601-28613	demonstrated	_	
165-32	28614-28625	performance	_	
165-33	28626-28637	sensitivity	_	
165-34	28638-28640	to	_	
165-35	28641-28642	a	_	
165-36	28643-28650	variety	_	
165-37	28651-28653	of	_	
165-38	28654-28659	drugs	_	
165-39	28660-28669	including	_	
165-40	28670-28684	benzodiazepine	_	
165-41	28684-28685	,	_	
165-42	28686-28699	acetylcholine	_	
165-43	28700-28708	receptor	_	
165-44	28709-28716	ligands	_	
165-45	28716-28717	,	_	
165-46	28718-28721	and	_	
165-47	28722-28725	192	_	
165-48	28726-28737	IgG-saporin	_	
165-49	28737-28738	.	_	

#Text=The task has been translated for use in human experimentation with the goal of producing a task which can be relevant at both the animal and human level of neural systems.
166-1	28739-28742	The	_	
166-2	28743-28747	task	_	
166-3	28748-28751	has	_	
166-4	28752-28756	been	_	
166-5	28757-28767	translated	_	
166-6	28768-28771	for	_	
166-7	28772-28775	use	_	
166-8	28776-28778	in	_	
166-9	28779-28784	human	_	
166-10	28785-28800	experimentation	_	
166-11	28801-28805	with	_	
166-12	28806-28809	the	_	
166-13	28810-28814	goal	_	
166-14	28815-28817	of	_	
166-15	28818-28827	producing	_	
166-16	28828-28829	a	_	
166-17	28830-28834	task	_	
166-18	28835-28840	which	_	
166-19	28841-28844	can	_	
166-20	28845-28847	be	_	
166-21	28848-28856	relevant	_	
166-22	28857-28859	at	_	
166-23	28860-28864	both	_	
166-24	28865-28868	the	_	
166-25	28869-28875	animal	_	
166-26	28876-28879	and	_	
166-27	28880-28885	human	_	
166-28	28886-28891	level	_	
166-29	28892-28894	of	_	
166-30	28895-28901	neural	_	
166-31	28902-28909	systems	_	
166-32	28909-28910	.	_	

#Text=This cross-species evaluation potentially provides a closer understanding of the relation between neurotransmitter systems and human functional neuroimaging, as well a tool for evaluating the efficacy of procognitive pharmaceuticals under development.
167-1	28911-28915	This	_	
167-2	28916-28929	cross-species	_	
167-3	28930-28940	evaluation	_	
167-4	28941-28952	potentially	_	
167-5	28953-28961	provides	_	
167-6	28962-28963	a	_	
167-7	28964-28970	closer	_	
167-8	28971-28984	understanding	_	
167-9	28985-28987	of	_	
167-10	28988-28991	the	_	
167-11	28992-29000	relation	_	
167-12	29001-29008	between	_	
167-13	29009-29025	neurotransmitter	_	
167-14	29026-29033	systems	_	
167-15	29034-29037	and	_	
167-16	29038-29043	human	_	
167-17	29044-29054	functional	_	
167-18	29055-29067	neuroimaging	_	
167-19	29067-29068	,	_	
167-20	29069-29071	as	_	
167-21	29072-29076	well	_	
167-22	29077-29078	a	_	
167-23	29079-29083	tool	_	
167-24	29084-29087	for	_	
167-25	29088-29098	evaluating	_	
167-26	29099-29102	the	_	
167-27	29103-29111	efficacy	_	
167-28	29112-29114	of	_	
167-29	29115-29127	procognitive	_	
167-30	29128-29143	pharmaceuticals	_	
167-31	29144-29149	under	_	
167-32	29150-29161	development	_	
167-33	29161-29162	.	_	

#Text=In this study, we noninvasively monitored activity in the bilateral anterior PFC using fNIRS during an implementation of the SAT and a revised version (vSAT) to explore differences in broad vs narrow attention performance in schizophrenia.
168-1	29163-29165	In	_	
168-2	29166-29170	this	_	
168-3	29171-29176	study	_	
168-4	29176-29177	,	_	
168-5	29178-29180	we	_	
168-6	29181-29194	noninvasively	_	
168-7	29195-29204	monitored	_	
168-8	29205-29213	activity	_	
168-9	29214-29216	in	_	
168-10	29217-29220	the	_	
168-11	29221-29230	bilateral	_	
168-12	29231-29239	anterior	_	
168-13	29240-29243	PFC	_	
168-14	29244-29249	using	_	
168-15	29250-29255	fNIRS	_	
168-16	29256-29262	during	_	
168-17	29263-29265	an	_	
168-18	29266-29280	implementation	_	
168-19	29281-29283	of	_	
168-20	29284-29287	the	_	
168-21	29288-29291	SAT	_	
168-22	29292-29295	and	_	
168-23	29296-29297	a	_	
168-24	29298-29305	revised	_	
168-25	29306-29313	version	_	
168-26	29314-29315	(	_	
168-27	29315-29319	vSAT	_	
168-28	29319-29320	)	_	
168-29	29321-29323	to	_	
168-30	29324-29331	explore	_	
168-31	29332-29343	differences	_	
168-32	29344-29346	in	_	
168-33	29347-29352	broad	_	
168-34	29353-29355	vs	_	
168-35	29356-29362	narrow	_	
168-36	29363-29372	attention	_	
168-37	29373-29384	performance	_	
168-38	29385-29387	in	_	
168-39	29388-29401	schizophrenia	_	
168-40	29401-29402	.	_	

#Text=Results confirm a general attentional deficit in patients with schizophrenia as demonstrated by decreased task performance and increased response times relative to healthy controls.
169-1	29403-29410	Results	_	
169-2	29411-29418	confirm	_	
169-3	29419-29420	a	_	
169-4	29421-29428	general	_	
169-5	29429-29440	attentional	_	
169-6	29441-29448	deficit	_	
169-7	29449-29451	in	_	
169-8	29452-29460	patients	_	
169-9	29461-29465	with	_	
169-10	29466-29479	schizophrenia	_	
169-11	29480-29482	as	_	
169-12	29483-29495	demonstrated	_	
169-13	29496-29498	by	_	
169-14	29499-29508	decreased	_	
169-15	29509-29513	task	_	
169-16	29514-29525	performance	_	
169-17	29526-29529	and	_	
169-18	29530-29539	increased	_	
169-19	29540-29548	response	_	
169-20	29549-29554	times	_	
169-21	29555-29563	relative	_	
169-22	29564-29566	to	_	
169-23	29567-29574	healthy	_	
169-24	29575-29583	controls	_	
169-25	29583-29584	.	_	

#Text=Compared with the healthy controls, patients exhibited reduced performance on both task variants and increased response times on average.
170-1	29585-29593	Compared	_	
170-2	29594-29598	with	_	
170-3	29599-29602	the	_	
170-4	29603-29610	healthy	_	
170-5	29611-29619	controls	_	
170-6	29619-29620	,	_	
170-7	29621-29629	patients	_	
170-8	29630-29639	exhibited	_	
170-9	29640-29647	reduced	_	
170-10	29648-29659	performance	_	
170-11	29660-29662	on	_	
170-12	29663-29667	both	_	
170-13	29668-29672	task	_	
170-14	29673-29681	variants	_	
170-15	29682-29685	and	_	
170-16	29686-29695	increased	_	
170-17	29696-29704	response	_	
170-18	29705-29710	times	_	
170-19	29711-29713	on	_	
170-20	29714-29721	average	_	
170-21	29721-29722	.	_	

#Text=We also observed an apparent decrease in task performance with shorter stimulus intervals in both subject groups.
171-1	29723-29725	We	_	
171-2	29726-29730	also	_	
171-3	29731-29739	observed	_	
171-4	29740-29742	an	_	
171-5	29743-29751	apparent	_	
171-6	29752-29760	decrease	_	
171-7	29761-29763	in	_	
171-8	29764-29768	task	_	
171-9	29769-29780	performance	_	
171-10	29781-29785	with	_	
171-11	29786-29793	shorter	_	
171-12	29794-29802	stimulus	_	
171-13	29803-29812	intervals	_	
171-14	29813-29815	in	_	
171-15	29816-29820	both	_	
171-16	29821-29828	subject	_	
171-17	29829-29835	groups	_	
171-18	29835-29836	.	_	

#Text=Both healthy and patient participants demonstrated relative performance decreases in response to increased task demands and results were not dependent on the specific performance metric used, as both classification accuracy and d-Prime metrics revealed similar behaviors as discussed in the Supporting Materials (A1).
172-1	29837-29841	Both	_	
172-2	29842-29849	healthy	_	
172-3	29850-29853	and	_	
172-4	29854-29861	patient	_	
172-5	29862-29874	participants	_	
172-6	29875-29887	demonstrated	_	
172-7	29888-29896	relative	_	
172-8	29897-29908	performance	_	
172-9	29909-29918	decreases	_	
172-10	29919-29921	in	_	
172-11	29922-29930	response	_	
172-12	29931-29933	to	_	
172-13	29934-29943	increased	_	
172-14	29944-29948	task	_	
172-15	29949-29956	demands	_	
172-16	29957-29960	and	_	
172-17	29961-29968	results	_	
172-18	29969-29973	were	_	
172-19	29974-29977	not	_	
172-20	29978-29987	dependent	_	
172-21	29988-29990	on	_	
172-22	29991-29994	the	_	
172-23	29995-30003	specific	_	
172-24	30004-30015	performance	_	
172-25	30016-30022	metric	_	
172-26	30023-30027	used	_	
172-27	30027-30028	,	_	
172-28	30029-30031	as	_	
172-29	30032-30036	both	_	
172-30	30037-30051	classification	_	
172-31	30052-30060	accuracy	_	
172-32	30061-30064	and	_	
172-33	30065-30072	d-Prime	_	
172-34	30073-30080	metrics	_	
172-35	30081-30089	revealed	_	
172-36	30090-30097	similar	_	
172-37	30098-30107	behaviors	_	
172-38	30108-30110	as	_	
172-39	30111-30120	discussed	_	
172-40	30121-30123	in	_	
172-41	30124-30127	the	_	
172-42	30128-30138	Supporting	_	
172-43	30139-30148	Materials	_	
172-44	30149-30150	(	_	
172-45	30150-30152	A1	_	
172-46	30152-30153	)	_	
172-47	30153-30154	.	_	

#Text=Response Times did not appear to be sensitive to task conditions in either group.
173-1	30155-30163	Response	_	
173-2	30164-30169	Times	_	
173-3	30170-30173	did	_	
173-4	30174-30177	not	_	
173-5	30178-30184	appear	_	
173-6	30185-30187	to	_	
173-7	30188-30190	be	_	
173-8	30191-30200	sensitive	_	
173-9	30201-30203	to	_	
173-10	30204-30208	task	_	
173-11	30209-30219	conditions	_	
173-12	30220-30222	in	_	
173-13	30223-30229	either	_	
173-14	30230-30235	group	_	
173-15	30235-30236	.	_	

#Text=Behavior performance results as measured by SAT-Score, largely resembled those observed by Demeter et al. in both Healthy and Clinical Groups.
174-1	30237-30245	Behavior	_	
174-2	30246-30257	performance	_	
174-3	30258-30265	results	_	
174-4	30266-30268	as	_	
174-5	30269-30277	measured	_	
174-6	30278-30280	by	_	
174-7	30281-30290	SAT-Score	_	
174-8	30290-30291	,	_	
174-9	30292-30299	largely	_	
174-10	30300-30309	resembled	_	
174-11	30310-30315	those	_	
174-12	30316-30324	observed	_	
174-13	30325-30327	by	_	
174-14	30328-30335	Demeter	_	
174-15	30336-30338	et	_	
174-16	30339-30341	al	_	
174-17	30341-30342	.	_	
174-18	30343-30345	in	_	
174-19	30346-30350	both	_	
174-20	30351-30358	Healthy	_	
174-21	30359-30362	and	_	
174-22	30363-30371	Clinical	_	
174-23	30372-30378	Groups	_	
174-24	30378-30379	.	_	

#Text=This suggested that the present implementation of the SAT task was largely consistent with previous work, although notably, we did not observe a significant Task Condition x Group interaction in the current study.
175-1	30380-30384	This	_	
175-2	30385-30394	suggested	_	
175-3	30395-30399	that	_	
175-4	30400-30403	the	_	
175-5	30404-30411	present	_	
175-6	30412-30426	implementation	_	
175-7	30427-30429	of	_	
175-8	30430-30433	the	_	
175-9	30434-30437	SAT	_	
175-10	30438-30442	task	_	
175-11	30443-30446	was	_	
175-12	30447-30454	largely	_	
175-13	30455-30465	consistent	_	
175-14	30466-30470	with	_	
175-15	30471-30479	previous	_	
175-16	30480-30484	work	_	
175-17	30484-30485	,	_	
175-18	30486-30494	although	_	
175-19	30495-30502	notably	_	
175-20	30502-30503	,	_	
175-21	30504-30506	we	_	
175-22	30507-30510	did	_	
175-23	30511-30514	not	_	
175-24	30515-30522	observe	_	
175-25	30523-30524	a	_	
175-26	30525-30536	significant	_	
175-27	30537-30541	Task	_	
175-28	30542-30551	Condition	_	
175-29	30552-30553	x	_	
175-30	30554-30559	Group	_	
175-31	30560-30571	interaction	_	
175-32	30572-30574	in	_	
175-33	30575-30578	the	_	
175-34	30579-30586	current	_	
175-35	30587-30592	study	_	
175-36	30592-30593	.	_	

#Text=Comparison with previously published results is explored in detail in the Supporting Materials (A3).
176-1	30594-30604	Comparison	_	
176-2	30605-30609	with	_	
176-3	30610-30620	previously	_	
176-4	30621-30630	published	_	
176-5	30631-30638	results	_	
176-6	30639-30641	is	_	
176-7	30642-30650	explored	_	
176-8	30651-30653	in	_	
176-9	30654-30660	detail	_	
176-10	30661-30663	in	_	
176-11	30664-30667	the	_	
176-12	30668-30678	Supporting	_	
176-13	30679-30688	Materials	_	
176-14	30689-30690	(	_	
176-15	30690-30692	A3	_	
176-16	30692-30693	)	_	
176-17	30693-30694	.	_	

#Text=Task performance and Group appeared to play significant roles in observed hemodynamic activity evoked in right-medial regions of the PFC (medial Superior Frontal Gyrus).
177-1	30695-30699	Task	_	
177-2	30700-30711	performance	_	
177-3	30712-30715	and	_	
177-4	30716-30721	Group	_	
177-5	30722-30730	appeared	_	
177-6	30731-30733	to	_	
177-7	30734-30738	play	_	
177-8	30739-30750	significant	_	
177-9	30751-30756	roles	_	
177-10	30757-30759	in	_	
177-11	30760-30768	observed	_	
177-12	30769-30780	hemodynamic	_	
177-13	30781-30789	activity	_	
177-14	30790-30796	evoked	_	
177-15	30797-30799	in	_	
177-16	30800-30812	right-medial	_	
177-17	30813-30820	regions	_	
177-18	30821-30823	of	_	
177-19	30824-30827	the	_	
177-20	30828-30831	PFC	_	
177-21	30832-30833	(	_	
177-22	30833-30839	medial	_	
177-23	30840-30848	Superior	_	
177-24	30849-30856	Frontal	_	
177-25	30857-30862	Gyrus	_	
177-26	30862-30863	)	_	
177-27	30863-30864	.	_	

#Text=Score and membership in the clinical Group were estimated as a negative modifier to changes in [Oxy], with a stronger estimated negative slope for Score in Healthy Subjects.
178-1	30865-30870	Score	_	
178-2	30871-30874	and	_	
178-3	30875-30885	membership	_	
178-4	30886-30888	in	_	
178-5	30889-30892	the	_	
178-6	30893-30901	clinical	_	
178-7	30902-30907	Group	_	
178-8	30908-30912	were	_	
178-9	30913-30922	estimated	_	
178-10	30923-30925	as	_	
178-11	30926-30927	a	_	
178-12	30928-30936	negative	_	
178-13	30937-30945	modifier	_	
178-14	30946-30948	to	_	
178-15	30949-30956	changes	_	
178-16	30957-30959	in	_	
178-17	30960-30961	[	_	
178-18	30961-30964	Oxy	_	
178-19	30964-30965	]	_	
178-20	30965-30966	,	_	
178-21	30967-30971	with	_	
178-22	30972-30973	a	_	
178-23	30974-30982	stronger	_	
178-24	30983-30992	estimated	_	
178-25	30993-31001	negative	_	
178-26	31002-31007	slope	_	
178-27	31008-31011	for	_	
178-28	31012-31017	Score	_	
178-29	31018-31020	in	_	
178-30	31021-31028	Healthy	_	
178-31	31029-31037	Subjects	_	
178-32	31037-31038	.	_	

#Text=This finding would point to a relative dysregulation in schizophrenia as a failure to efficiently deactivate the right-medial SFG in a manner which increases Task Performance in an area known to be associated with sustained attention.
179-1	31039-31043	This	_	
179-2	31044-31051	finding	_	
179-3	31052-31057	would	_	
179-4	31058-31063	point	_	
179-5	31064-31066	to	_	
179-6	31067-31068	a	_	
179-7	31069-31077	relative	_	
179-8	31078-31091	dysregulation	_	
179-9	31092-31094	in	_	
179-10	31095-31108	schizophrenia	_	
179-11	31109-31111	as	_	
179-12	31112-31113	a	_	
179-13	31114-31121	failure	_	
179-14	31122-31124	to	_	
179-15	31125-31136	efficiently	_	
179-16	31137-31147	deactivate	_	
179-17	31148-31151	the	_	
179-18	31152-31164	right-medial	_	
179-19	31165-31168	SFG	_	
179-20	31169-31171	in	_	
179-21	31172-31173	a	_	
179-22	31174-31180	manner	_	
179-23	31181-31186	which	_	
179-24	31187-31196	increases	_	
179-25	31197-31201	Task	_	
179-26	31202-31213	Performance	_	
179-27	31214-31216	in	_	
179-28	31217-31219	an	_	
179-29	31220-31224	area	_	
179-30	31225-31230	known	_	
179-31	31231-31233	to	_	
179-32	31234-31236	be	_	
179-33	31237-31247	associated	_	
179-34	31248-31252	with	_	
179-35	31253-31262	sustained	_	
179-36	31263-31272	attention	_	
179-37	31272-31273	.	_	

#Text=The anterior PFC, approximating Brodmann’s Area 10, has been frequently associated with both with the control of attention and more broadly with other higher order executive functions including decision making, working memory, problem-solving, and mentalizing responses.
180-1	31274-31277	The	_	
180-2	31278-31286	anterior	_	
180-3	31287-31290	PFC	_	
180-4	31290-31291	,	_	
180-5	31292-31305	approximating	_	
180-6	31306-31314	Brodmann	_	
180-7	31314-31315	’	_	
180-8	31315-31316	s	_	
180-9	31317-31321	Area	_	
180-10	31322-31324	10	_	
180-11	31324-31325	,	_	
180-12	31326-31329	has	_	
180-13	31330-31334	been	_	
180-14	31335-31345	frequently	_	
180-15	31346-31356	associated	_	
180-16	31357-31361	with	_	
180-17	31362-31366	both	_	
180-18	31367-31371	with	_	
180-19	31372-31375	the	_	
180-20	31376-31383	control	_	
180-21	31384-31386	of	_	
180-22	31387-31396	attention	_	
180-23	31397-31400	and	_	
180-24	31401-31405	more	_	
180-25	31406-31413	broadly	_	
180-26	31414-31418	with	_	
180-27	31419-31424	other	_	
180-28	31425-31431	higher	_	
180-29	31432-31437	order	_	
180-30	31438-31447	executive	_	
180-31	31448-31457	functions	_	
180-32	31458-31467	including	_	
180-33	31468-31476	decision	_	
180-34	31477-31483	making	_	
180-35	31483-31484	,	_	
180-36	31485-31492	working	_	
180-37	31493-31499	memory	_	
180-38	31499-31500	,	_	
180-39	31501-31516	problem-solving	_	
180-40	31516-31517	,	_	
180-41	31518-31521	and	_	
180-42	31522-31533	mentalizing	_	
180-43	31534-31543	responses	_	
180-44	31543-31544	.	_	

#Text=We observed a role in the right-medial SFG for performance sensitivity as measured by the relative decrease in SAT-score induced by the vSAT condition (Score Difference).
181-1	31545-31547	We	_	
181-2	31548-31556	observed	_	
181-3	31557-31558	a	_	
181-4	31559-31563	role	_	
181-5	31564-31566	in	_	
181-6	31567-31570	the	_	
181-7	31571-31583	right-medial	_	
181-8	31584-31587	SFG	_	
181-9	31588-31591	for	_	
181-10	31592-31603	performance	_	
181-11	31604-31615	sensitivity	_	
181-12	31616-31618	as	_	
181-13	31619-31627	measured	_	
181-14	31628-31630	by	_	
181-15	31631-31634	the	_	
181-16	31635-31643	relative	_	
181-17	31644-31652	decrease	_	
181-18	31653-31655	in	_	
181-19	31656-31665	SAT-score	_	
181-20	31666-31673	induced	_	
181-21	31674-31676	by	_	
181-22	31677-31680	the	_	
181-23	31681-31685	vSAT	_	
181-24	31686-31695	condition	_	
181-25	31696-31697	(	_	
181-26	31697-31702	Score	_	
181-27	31703-31713	Difference	_	
181-28	31713-31714	)	_	
181-29	31714-31715	.	_	

#Text=We observed that right-PFC activity was differentially modified in response to increased demands with larger relative performance decreases associated with an increase in right-medial SFG activation.
182-1	31716-31718	We	_	
182-2	31719-31727	observed	_	
182-3	31728-31732	that	_	
182-4	31733-31742	right-PFC	_	
182-5	31743-31751	activity	_	
182-6	31752-31755	was	_	
182-7	31756-31770	differentially	_	
182-8	31771-31779	modified	_	
182-9	31780-31782	in	_	
182-10	31783-31791	response	_	
182-11	31792-31794	to	_	
182-12	31795-31804	increased	_	
182-13	31805-31812	demands	_	
182-14	31813-31817	with	_	
182-15	31818-31824	larger	_	
182-16	31825-31833	relative	_	
182-17	31834-31845	performance	_	
182-18	31846-31855	decreases	_	
182-19	31856-31866	associated	_	
182-20	31867-31871	with	_	
182-21	31872-31874	an	_	
182-22	31875-31883	increase	_	
182-23	31884-31886	in	_	
182-24	31887-31899	right-medial	_	
182-25	31900-31903	SFG	_	
182-26	31904-31914	activation	_	
182-27	31914-31915	.	_	

#Text=One possible interpretation for this is this additional activation is related to the increased difficulty of maintaining a broader area of attention or a wider attentional ‘zoom’.
183-1	31916-31919	One	_	
183-2	31920-31928	possible	_	
183-3	31929-31943	interpretation	_	
183-4	31944-31947	for	_	
183-5	31948-31952	this	_	
183-6	31953-31955	is	_	
183-7	31956-31960	this	_	
183-8	31961-31971	additional	_	
183-9	31972-31982	activation	_	
183-10	31983-31985	is	_	
183-11	31986-31993	related	_	
183-12	31994-31996	to	_	
183-13	31997-32000	the	_	
183-14	32001-32010	increased	_	
183-15	32011-32021	difficulty	_	
183-16	32022-32024	of	_	
183-17	32025-32036	maintaining	_	
183-18	32037-32038	a	_	
183-19	32039-32046	broader	_	
183-20	32047-32051	area	_	
183-21	32052-32054	of	_	
183-22	32055-32064	attention	_	
183-23	32065-32067	or	_	
183-24	32068-32069	a	_	
183-25	32070-32075	wider	_	
183-26	32076-32087	attentional	_	
183-27	32088-32089	‘	_	
183-28	32089-32093	zoom	_	
183-29	32093-32094	’	_	
183-30	32094-32095	.	_	

#Text=In a continuous arterial spin labeling (ASL) study conducted by Demeter et.al., the authors observed right-MFG involvement in the sensitivity of performance to a distraction condition using a variation of the SAT in healthy subjects.
184-1	32096-32098	In	_	
184-2	32099-32100	a	_	
184-3	32101-32111	continuous	_	
184-4	32112-32120	arterial	_	
184-5	32121-32125	spin	_	
184-6	32126-32134	labeling	_	
184-7	32135-32136	(	_	
184-8	32136-32139	ASL	_	
184-9	32139-32140	)	_	
184-10	32141-32146	study	_	
184-11	32147-32156	conducted	_	
184-12	32157-32159	by	_	
184-13	32160-32167	Demeter	_	
184-14	32168-32173	et.al	_	
184-15	32173-32174	.	_	
184-16	32174-32175	,	_	
184-17	32176-32179	the	_	
184-18	32180-32187	authors	_	
184-19	32188-32196	observed	_	
184-20	32197-32206	right-MFG	_	
184-21	32207-32218	involvement	_	
184-22	32219-32221	in	_	
184-23	32222-32225	the	_	
184-24	32226-32237	sensitivity	_	
184-25	32238-32240	of	_	
184-26	32241-32252	performance	_	
184-27	32253-32255	to	_	
184-28	32256-32257	a	_	
184-29	32258-32269	distraction	_	
184-30	32270-32279	condition	_	
184-31	32280-32285	using	_	
184-32	32286-32287	a	_	
184-33	32288-32297	variation	_	
184-34	32298-32300	of	_	
184-35	32301-32304	the	_	
184-36	32305-32308	SAT	_	
184-37	32309-32311	in	_	
184-38	32312-32319	healthy	_	
184-39	32320-32328	subjects	_	
184-40	32328-32329	.	_	

#Text=Therefore, this increased activity could point to an increase in required attentional effort in response to task demands, despite an inability to maintain performance relative to initial task conditions.
185-1	32330-32339	Therefore	_	
185-2	32339-32340	,	_	
185-3	32341-32345	this	_	
185-4	32346-32355	increased	_	
185-5	32356-32364	activity	_	
185-6	32365-32370	could	_	
185-7	32371-32376	point	_	
185-8	32377-32379	to	_	
185-9	32380-32382	an	_	
185-10	32383-32391	increase	_	
185-11	32392-32394	in	_	
185-12	32395-32403	required	_	
185-13	32404-32415	attentional	_	
185-14	32416-32422	effort	_	
185-15	32423-32425	in	_	
185-16	32426-32434	response	_	
185-17	32435-32437	to	_	
185-18	32438-32442	task	_	
185-19	32443-32450	demands	_	
185-20	32450-32451	,	_	
185-21	32452-32459	despite	_	
185-22	32460-32462	an	_	
185-23	32463-32472	inability	_	
185-24	32473-32475	to	_	
185-25	32476-32484	maintain	_	
185-26	32485-32496	performance	_	
185-27	32497-32505	relative	_	
185-28	32506-32508	to	_	
185-29	32509-32516	initial	_	
185-30	32517-32521	task	_	
185-31	32522-32532	conditions	_	
185-32	32532-32533	.	_	

#Text=The presence of these similar trends again seems to identify this region as sensitive to attentional demands whether due to the presence of a distractor or spatial variability.
186-1	32534-32537	The	_	
186-2	32538-32546	presence	_	
186-3	32547-32549	of	_	
186-4	32550-32555	these	_	
186-5	32556-32563	similar	_	
186-6	32564-32570	trends	_	
186-7	32571-32576	again	_	
186-8	32577-32582	seems	_	
186-9	32583-32585	to	_	
186-10	32586-32594	identify	_	
186-11	32595-32599	this	_	
186-12	32600-32606	region	_	
186-13	32607-32609	as	_	
186-14	32610-32619	sensitive	_	
186-15	32620-32622	to	_	
186-16	32623-32634	attentional	_	
186-17	32635-32642	demands	_	
186-18	32643-32650	whether	_	
186-19	32651-32654	due	_	
186-20	32655-32657	to	_	
186-21	32658-32661	the	_	
186-22	32662-32670	presence	_	
186-23	32671-32673	of	_	
186-24	32674-32675	a	_	
186-25	32676-32686	distractor	_	
186-26	32687-32689	or	_	
186-27	32690-32697	spatial	_	
186-28	32698-32709	variability	_	
186-29	32709-32710	.	_	

#Text=The absence of an interaction of group for performance sensitivity as well as for brain activity in the presence of significant baseline performance deficits suggests that other factors may contribute to the observed performance deficits in schizophrenia.
187-1	32711-32714	The	_	
187-2	32715-32722	absence	_	
187-3	32723-32725	of	_	
187-4	32726-32728	an	_	
187-5	32729-32740	interaction	_	
187-6	32741-32743	of	_	
187-7	32744-32749	group	_	
187-8	32750-32753	for	_	
187-9	32754-32765	performance	_	
187-10	32766-32777	sensitivity	_	
187-11	32778-32780	as	_	
187-12	32781-32785	well	_	
187-13	32786-32788	as	_	
187-14	32789-32792	for	_	
187-15	32793-32798	brain	_	
187-16	32799-32807	activity	_	
187-17	32808-32810	in	_	
187-18	32811-32814	the	_	
187-19	32815-32823	presence	_	
187-20	32824-32826	of	_	
187-21	32827-32838	significant	_	
187-22	32839-32847	baseline	_	
187-23	32848-32859	performance	_	
187-24	32860-32868	deficits	_	
187-25	32869-32877	suggests	_	
187-26	32878-32882	that	_	
187-27	32883-32888	other	_	
187-28	32889-32896	factors	_	
187-29	32897-32900	may	_	
187-30	32901-32911	contribute	_	
187-31	32912-32914	to	_	
187-32	32915-32918	the	_	
187-33	32919-32927	observed	_	
187-34	32928-32939	performance	_	
187-35	32940-32948	deficits	_	
187-36	32949-32951	in	_	
187-37	32952-32965	schizophrenia	_	
187-38	32965-32966	.	_	

#Text=One possibility is that the right-PFC was unable to recruit connected regions (such as parietal regions and insula) as has been previously proposed or other regions not accessible to the sensor used in this study.
188-1	32967-32970	One	_	
188-2	32971-32982	possibility	_	
188-3	32983-32985	is	_	
188-4	32986-32990	that	_	
188-5	32991-32994	the	_	
188-6	32995-33004	right-PFC	_	
188-7	33005-33008	was	_	
188-8	33009-33015	unable	_	
188-9	33016-33018	to	_	
188-10	33019-33026	recruit	_	
188-11	33027-33036	connected	_	
188-12	33037-33044	regions	_	
188-13	33045-33046	(	_	
188-14	33046-33050	such	_	
188-15	33051-33053	as	_	
188-16	33054-33062	parietal	_	
188-17	33063-33070	regions	_	
188-18	33071-33074	and	_	
188-19	33075-33081	insula	_	
188-20	33081-33082	)	_	
188-21	33083-33085	as	_	
188-22	33086-33089	has	_	
188-23	33090-33094	been	_	
188-24	33095-33105	previously	_	
188-25	33106-33114	proposed	_	
188-26	33115-33117	or	_	
188-27	33118-33123	other	_	
188-28	33124-33131	regions	_	
188-29	33132-33135	not	_	
188-30	33136-33146	accessible	_	
188-31	33147-33149	to	_	
188-32	33150-33153	the	_	
188-33	33154-33160	sensor	_	
188-34	33161-33165	used	_	
188-35	33166-33168	in	_	
188-36	33169-33173	this	_	
188-37	33174-33179	study	_	
188-38	33179-33180	.	_	

#Text=Another possibility is that the vSAT was too easy to elicit a clinically differential response and other modifications may be necessary to capture this aspect.
189-1	33181-33188	Another	_	
189-2	33189-33200	possibility	_	
189-3	33201-33203	is	_	
189-4	33204-33208	that	_	
189-5	33209-33212	the	_	
189-6	33213-33217	vSAT	_	
189-7	33218-33221	was	_	
189-8	33222-33225	too	_	
189-9	33226-33230	easy	_	
189-10	33231-33233	to	_	
189-11	33234-33240	elicit	_	
189-12	33241-33242	a	_	
189-13	33243-33253	clinically	_	
189-14	33254-33266	differential	_	
189-15	33267-33275	response	_	
189-16	33276-33279	and	_	
189-17	33280-33285	other	_	
189-18	33286-33299	modifications	_	
189-19	33300-33303	may	_	
189-20	33304-33306	be	_	
189-21	33307-33316	necessary	_	
189-22	33317-33319	to	_	
189-23	33320-33327	capture	_	
189-24	33328-33332	this	_	
189-25	33333-33339	aspect	_	
189-26	33339-33340	.	_	

#Text=In one recent study investigating the presence of “hyperfocusing” in schizophrenia, Kriether et al. identified that compared to healthy controls, individuals with schizophrenia were unable to properly filter sensory responses to inner vs outer stimuli in a Useful Field of View Task (UFOV).
190-1	33341-33343	In	_	
190-2	33344-33347	one	_	
190-3	33348-33354	recent	_	
190-4	33355-33360	study	_	
190-5	33361-33374	investigating	_	
190-6	33375-33378	the	_	
190-7	33379-33387	presence	_	
190-8	33388-33390	of	_	
190-9	33391-33392	“	_	
190-10	33392-33405	hyperfocusing	_	
190-11	33405-33406	”	_	
190-12	33407-33409	in	_	
190-13	33410-33423	schizophrenia	_	
190-14	33423-33424	,	_	
190-15	33425-33433	Kriether	_	
190-16	33434-33436	et	_	
190-17	33437-33439	al	_	
190-18	33439-33440	.	_	
190-19	33441-33451	identified	_	
190-20	33452-33456	that	_	
190-21	33457-33465	compared	_	
190-22	33466-33468	to	_	
190-23	33469-33476	healthy	_	
190-24	33477-33485	controls	_	
190-25	33485-33486	,	_	
190-26	33487-33498	individuals	_	
190-27	33499-33503	with	_	
190-28	33504-33517	schizophrenia	_	
190-29	33518-33522	were	_	
190-30	33523-33529	unable	_	
190-31	33530-33532	to	_	
190-32	33533-33541	properly	_	
190-33	33542-33548	filter	_	
190-34	33549-33556	sensory	_	
190-35	33557-33566	responses	_	
190-36	33567-33569	to	_	
190-37	33570-33575	inner	_	
190-38	33576-33578	vs	_	
190-39	33579-33584	outer	_	
190-40	33585-33592	stimuli	_	
190-41	33593-33595	in	_	
190-42	33596-33597	a	_	
190-43	33598-33604	Useful	_	
190-44	33605-33610	Field	_	
190-45	33611-33613	of	_	
190-46	33614-33618	View	_	
190-47	33619-33623	Task	_	
190-48	33624-33625	(	_	
190-49	33625-33629	UFOV	_	
190-50	33629-33630	)	_	
190-51	33630-33631	.	_	

#Text=In this work, we observed a tendency towards a performance sensitivity amongst patients between targets which occupied the center position which appeared to support this hypothesis, however, due to the relative rarity of center position targets, the results were inconclusive.
191-1	33632-33634	In	_	
191-2	33635-33639	this	_	
191-3	33640-33644	work	_	
191-4	33644-33645	,	_	
191-5	33646-33648	we	_	
191-6	33649-33657	observed	_	
191-7	33658-33659	a	_	
191-8	33660-33668	tendency	_	
191-9	33669-33676	towards	_	
191-10	33677-33678	a	_	
191-11	33679-33690	performance	_	
191-12	33691-33702	sensitivity	_	
191-13	33703-33710	amongst	_	
191-14	33711-33719	patients	_	
191-15	33720-33727	between	_	
191-16	33728-33735	targets	_	
191-17	33736-33741	which	_	
191-18	33742-33750	occupied	_	
191-19	33751-33754	the	_	
191-20	33755-33761	center	_	
191-21	33762-33770	position	_	
191-22	33771-33776	which	_	
191-23	33777-33785	appeared	_	
191-24	33786-33788	to	_	
191-25	33789-33796	support	_	
191-26	33797-33801	this	_	
191-27	33802-33812	hypothesis	_	
191-28	33812-33813	,	_	
191-29	33814-33821	however	_	
191-30	33821-33822	,	_	
191-31	33823-33826	due	_	
191-32	33827-33829	to	_	
191-33	33830-33833	the	_	
191-34	33834-33842	relative	_	
191-35	33843-33849	rarity	_	
191-36	33850-33852	of	_	
191-37	33853-33859	center	_	
191-38	33860-33868	position	_	
191-39	33869-33876	targets	_	
191-40	33876-33877	,	_	
191-41	33878-33881	the	_	
191-42	33882-33889	results	_	
191-43	33890-33894	were	_	
191-44	33895-33907	inconclusive	_	
191-45	33907-33908	.	_	

#Text=When we examined the interaction of task type and clinical status, we noted significant relations between activity of the left-MFG and clinical status as identified by the Total-PANSS.
192-1	33909-33913	When	_	
192-2	33914-33916	we	_	
192-3	33917-33925	examined	_	
192-4	33926-33929	the	_	
192-5	33930-33941	interaction	_	
192-6	33942-33944	of	_	
192-7	33945-33949	task	_	
192-8	33950-33954	type	_	
192-9	33955-33958	and	_	
192-10	33959-33967	clinical	_	
192-11	33968-33974	status	_	
192-12	33974-33975	,	_	
192-13	33976-33978	we	_	
192-14	33979-33984	noted	_	
192-15	33985-33996	significant	_	
192-16	33997-34006	relations	_	
192-17	34007-34014	between	_	
192-18	34015-34023	activity	_	
192-19	34024-34026	of	_	
192-20	34027-34030	the	_	
192-21	34031-34039	left-MFG	_	
192-22	34040-34043	and	_	
192-23	34044-34052	clinical	_	
192-24	34053-34059	status	_	
192-25	34060-34062	as	_	
192-26	34063-34073	identified	_	
192-27	34074-34076	by	_	
192-28	34077-34080	the	_	
192-29	34081-34092	Total-PANSS	_	
192-30	34092-34093	.	_	

#Text=These relations appeared to be specific to task-related activity associated with the vSAT, with minimal differences observed in the SAT task.
193-1	34094-34099	These	_	
193-2	34100-34109	relations	_	
193-3	34110-34118	appeared	_	
193-4	34119-34121	to	_	
193-5	34122-34124	be	_	
193-6	34125-34133	specific	_	
193-7	34134-34136	to	_	
193-8	34137-34149	task-related	_	
193-9	34150-34158	activity	_	
193-10	34159-34169	associated	_	
193-11	34170-34174	with	_	
193-12	34175-34178	the	_	
193-13	34179-34183	vSAT	_	
193-14	34183-34184	,	_	
193-15	34185-34189	with	_	
193-16	34190-34197	minimal	_	
193-17	34198-34209	differences	_	
193-18	34210-34218	observed	_	
193-19	34219-34221	in	_	
193-20	34222-34225	the	_	
193-21	34226-34229	SAT	_	
193-22	34230-34234	task	_	
193-23	34234-34235	.	_	

#Text=When exploring the clinical subscales that contribute to the Total-PANSS score, we saw that this relationship was driven by the PANSS-General and PANSS-Negative subscales with minimal contribution from the PANSS-Positive scale.
194-1	34236-34240	When	_	
194-2	34241-34250	exploring	_	
194-3	34251-34254	the	_	
194-4	34255-34263	clinical	_	
194-5	34264-34273	subscales	_	
194-6	34274-34278	that	_	
194-7	34279-34289	contribute	_	
194-8	34290-34292	to	_	
194-9	34293-34296	the	_	
194-10	34297-34308	Total-PANSS	_	
194-11	34309-34314	score	_	
194-12	34314-34315	,	_	
194-13	34316-34318	we	_	
194-14	34319-34322	saw	_	
194-15	34323-34327	that	_	
194-16	34328-34332	this	_	
194-17	34333-34345	relationship	_	
194-18	34346-34349	was	_	
194-19	34350-34356	driven	_	
194-20	34357-34359	by	_	
194-21	34360-34363	the	_	
194-22	34364-34377	PANSS-General	_	
194-23	34378-34381	and	_	
194-24	34382-34396	PANSS-Negative	_	
194-25	34397-34406	subscales	_	
194-26	34407-34411	with	_	
194-27	34412-34419	minimal	_	
194-28	34420-34432	contribution	_	
194-29	34433-34437	from	_	
194-30	34438-34441	the	_	
194-31	34442-34456	PANSS-Positive	_	
194-32	34457-34462	scale	_	
194-33	34462-34463	.	_	

#Text=Several optodes in this region expressed rather strong negative correlations with decreased activity being associated with higher Negative symptom scores.
195-1	34464-34471	Several	_	
195-2	34472-34479	optodes	_	
195-3	34480-34482	in	_	
195-4	34483-34487	this	_	
195-5	34488-34494	region	_	
195-6	34495-34504	expressed	_	
195-7	34505-34511	rather	_	
195-8	34512-34518	strong	_	
195-9	34519-34527	negative	_	
195-10	34528-34540	correlations	_	
195-11	34541-34545	with	_	
195-12	34546-34555	decreased	_	
195-13	34556-34564	activity	_	
195-14	34565-34570	being	_	
195-15	34571-34581	associated	_	
195-16	34582-34586	with	_	
195-17	34587-34593	higher	_	
195-18	34594-34602	Negative	_	
195-19	34603-34610	symptom	_	
195-20	34611-34617	scores	_	
195-21	34617-34618	.	_	

#Text=Significant negative correlations in the Left-PFC with PANSS negative symptoms have been previously reported in executive tasks such as the Tower of London and Trail-Making-Test B.
196-1	34619-34630	Significant	_	
196-2	34631-34639	negative	_	
196-3	34640-34652	correlations	_	
196-4	34653-34655	in	_	
196-5	34656-34659	the	_	
196-6	34660-34668	Left-PFC	_	
196-7	34669-34673	with	_	
196-8	34674-34679	PANSS	_	
196-9	34680-34688	negative	_	
196-10	34689-34697	symptoms	_	
196-11	34698-34702	have	_	
196-12	34703-34707	been	_	
196-13	34708-34718	previously	_	
196-14	34719-34727	reported	_	
196-15	34728-34730	in	_	
196-16	34731-34740	executive	_	
196-17	34741-34746	tasks	_	
196-18	34747-34751	such	_	
196-19	34752-34754	as	_	
196-20	34755-34758	the	_	
196-21	34759-34764	Tower	_	
196-22	34765-34767	of	_	
196-23	34768-34774	London	_	
196-24	34775-34778	and	_	
196-25	34779-34796	Trail-Making-Test	_	
196-26	34797-34798	B	_	
196-27	34798-34799	.	_	

#Text=In the vSAT task, this trend was especially strong in Optode 5 for [HbO] (rho = −0.75, p = 0.0001).
197-1	34800-34802	In	_	
197-2	34803-34806	the	_	
197-3	34807-34811	vSAT	_	
197-4	34812-34816	task	_	
197-5	34816-34817	,	_	
197-6	34818-34822	this	_	
197-7	34823-34828	trend	_	
197-8	34829-34832	was	_	
197-9	34833-34843	especially	_	
197-10	34844-34850	strong	_	
197-11	34851-34853	in	_	
197-12	34854-34860	Optode	_	
197-13	34861-34862	5	_	
197-14	34863-34866	for	_	
197-15	34867-34868	[	_	
197-16	34868-34871	HbO	_	
197-17	34871-34872	]	_	
197-18	34873-34874	(	_	
197-19	34874-34877	rho	_	
197-20	34878-34879	=	_	
197-21	34880-34881	−	_	
197-22	34881-34885	0.75	_	
197-23	34885-34886	,	_	
197-24	34887-34888	p	_	
197-25	34889-34890	=	_	
197-26	34891-34897	0.0001	_	
197-27	34897-34898	)	_	
197-28	34898-34899	.	_	

#Text=This region is relatively close to the target of TMS-related therapies for schizophrenia, which currently is among the only treatment methodologies purporting to ameliorate negative symptoms, although studies report varying efficacy in this matter.
198-1	34900-34904	This	_	
198-2	34905-34911	region	_	
198-3	34912-34914	is	_	
198-4	34915-34925	relatively	_	
198-5	34926-34931	close	_	
198-6	34932-34934	to	_	
198-7	34935-34938	the	_	
198-8	34939-34945	target	_	
198-9	34946-34948	of	_	
198-10	34949-34960	TMS-related	_	
198-11	34961-34970	therapies	_	
198-12	34971-34974	for	_	
198-13	34975-34988	schizophrenia	_	
198-14	34988-34989	,	_	
198-15	34990-34995	which	_	
198-16	34996-35005	currently	_	
198-17	35006-35008	is	_	
198-18	35009-35014	among	_	
198-19	35015-35018	the	_	
198-20	35019-35023	only	_	
198-21	35024-35033	treatment	_	
198-22	35034-35047	methodologies	_	
198-23	35048-35058	purporting	_	
198-24	35059-35061	to	_	
198-25	35062-35072	ameliorate	_	
198-26	35073-35081	negative	_	
198-27	35082-35090	symptoms	_	
198-28	35090-35091	,	_	
198-29	35092-35100	although	_	
198-30	35101-35108	studies	_	
198-31	35109-35115	report	_	
198-32	35116-35123	varying	_	
198-33	35124-35132	efficacy	_	
198-34	35133-35135	in	_	
198-35	35136-35140	this	_	
198-36	35141-35147	matter	_	
198-37	35147-35148	.	_	

#Text=Despite this, we observe that mean values in Healthy Controls in this region did not significantly vary from the patient group.
199-1	35149-35156	Despite	_	
199-2	35157-35161	this	_	
199-3	35161-35162	,	_	
199-4	35163-35165	we	_	
199-5	35166-35173	observe	_	
199-6	35174-35178	that	_	
199-7	35179-35183	mean	_	
199-8	35184-35190	values	_	
199-9	35191-35193	in	_	
199-10	35194-35201	Healthy	_	
199-11	35202-35210	Controls	_	
199-12	35211-35213	in	_	
199-13	35214-35218	this	_	
199-14	35219-35225	region	_	
199-15	35226-35229	did	_	
199-16	35230-35233	not	_	
199-17	35234-35247	significantly	_	
199-18	35248-35252	vary	_	
199-19	35253-35257	from	_	
199-20	35258-35261	the	_	
199-21	35262-35269	patient	_	
199-22	35270-35275	group	_	
199-23	35275-35276	.	_	

#Text=These results are more fully explored in the included supporting materials which contains a complete exploration of correlations between behavioral, neurophysiological, and clinical measures (A4).
200-1	35277-35282	These	_	
200-2	35283-35290	results	_	
200-3	35291-35294	are	_	
200-4	35295-35299	more	_	
200-5	35300-35305	fully	_	
200-6	35306-35314	explored	_	
200-7	35315-35317	in	_	
200-8	35318-35321	the	_	
200-9	35322-35330	included	_	
200-10	35331-35341	supporting	_	
200-11	35342-35351	materials	_	
200-12	35352-35357	which	_	
200-13	35358-35366	contains	_	
200-14	35367-35368	a	_	
200-15	35369-35377	complete	_	
200-16	35378-35389	exploration	_	
200-17	35390-35392	of	_	
200-18	35393-35405	correlations	_	
200-19	35406-35413	between	_	
200-20	35414-35424	behavioral	_	
200-21	35424-35425	,	_	
200-22	35426-35444	neurophysiological	_	
200-23	35444-35445	,	_	
200-24	35446-35449	and	_	
200-25	35450-35458	clinical	_	
200-26	35459-35467	measures	_	
200-27	35468-35469	(	_	
200-28	35469-35471	A4	_	
200-29	35471-35472	)	_	
200-30	35472-35473	.	_	

#Text=The clinical symptom correlations of left-PFC region activity and observed differences in right-PFC activity between groups offers supporting evidence of abnormal hemispheric asymmetry in schizophrenia.
201-1	35474-35477	The	_	
201-2	35478-35486	clinical	_	
201-3	35487-35494	symptom	_	
201-4	35495-35507	correlations	_	
201-5	35508-35510	of	_	
201-6	35511-35519	left-PFC	_	
201-7	35520-35526	region	_	
201-8	35527-35535	activity	_	
201-9	35536-35539	and	_	
201-10	35540-35548	observed	_	
201-11	35549-35560	differences	_	
201-12	35561-35563	in	_	
201-13	35564-35573	right-PFC	_	
201-14	35574-35582	activity	_	
201-15	35583-35590	between	_	
201-16	35591-35597	groups	_	
201-17	35598-35604	offers	_	
201-18	35605-35615	supporting	_	
201-19	35616-35624	evidence	_	
201-20	35625-35627	of	_	
201-21	35628-35636	abnormal	_	
201-22	35637-35648	hemispheric	_	
201-23	35649-35658	asymmetry	_	
201-24	35659-35661	in	_	
201-25	35662-35675	schizophrenia	_	
201-26	35675-35676	.	_	

#Text=Early fNIRS studies argued that individuals with schizophrenia had altered asymmetry in executive and attention tasks, and the reduction of hemispheric connectivity has been repeatedly observed in more recent both structural and functional connectivity studies.
202-1	35677-35682	Early	_	
202-2	35683-35688	fNIRS	_	
202-3	35689-35696	studies	_	
202-4	35697-35703	argued	_	
202-5	35704-35708	that	_	
202-6	35709-35720	individuals	_	
202-7	35721-35725	with	_	
202-8	35726-35739	schizophrenia	_	
202-9	35740-35743	had	_	
202-10	35744-35751	altered	_	
202-11	35752-35761	asymmetry	_	
202-12	35762-35764	in	_	
202-13	35765-35774	executive	_	
202-14	35775-35778	and	_	
202-15	35779-35788	attention	_	
202-16	35789-35794	tasks	_	
202-17	35794-35795	,	_	
202-18	35796-35799	and	_	
202-19	35800-35803	the	_	
202-20	35804-35813	reduction	_	
202-21	35814-35816	of	_	
202-22	35817-35828	hemispheric	_	
202-23	35829-35841	connectivity	_	
202-24	35842-35845	has	_	
202-25	35846-35850	been	_	
202-26	35851-35861	repeatedly	_	
202-27	35862-35870	observed	_	
202-28	35871-35873	in	_	
202-29	35874-35878	more	_	
202-30	35879-35885	recent	_	
202-31	35886-35890	both	_	
202-32	35891-35901	structural	_	
202-33	35902-35905	and	_	
202-34	35906-35916	functional	_	
202-35	35917-35929	connectivity	_	
202-36	35930-35937	studies	_	
202-37	35937-35938	.	_	

#Text=This attenuated asymmetry has been related to increased presence of clinical symptoms and proposed to be a trait of schizophrenia.
203-1	35939-35943	This	_	
203-2	35944-35954	attenuated	_	
203-3	35955-35964	asymmetry	_	
203-4	35965-35968	has	_	
203-5	35969-35973	been	_	
203-6	35974-35981	related	_	
203-7	35982-35984	to	_	
203-8	35985-35994	increased	_	
203-9	35995-36003	presence	_	
203-10	36004-36006	of	_	
203-11	36007-36015	clinical	_	
203-12	36016-36024	symptoms	_	
203-13	36025-36028	and	_	
203-14	36029-36037	proposed	_	
203-15	36038-36040	to	_	
203-16	36041-36043	be	_	
203-17	36044-36045	a	_	
203-18	36046-36051	trait	_	
203-19	36052-36054	of	_	
203-20	36055-36068	schizophrenia	_	
203-21	36068-36069	.	_	

#Text=Impairments in the right -MFG may more directly influence cognitive control as observed in this task.
204-1	36070-36081	Impairments	_	
204-2	36082-36084	in	_	
204-3	36085-36088	the	_	
204-4	36089-36094	right	_	
204-5	36095-36096	-	_	
204-6	36096-36099	MFG	_	
204-7	36100-36103	may	_	
204-8	36104-36108	more	_	
204-9	36109-36117	directly	_	
204-10	36118-36127	influence	_	
204-11	36128-36137	cognitive	_	
204-12	36138-36145	control	_	
204-13	36146-36148	as	_	
204-14	36149-36157	observed	_	
204-15	36158-36160	in	_	
204-16	36161-36165	this	_	
204-17	36166-36170	task	_	
204-18	36170-36171	.	_	

#Text=In patients with severe negative symptoms, failure of activation in the left-MFG may occur as a result of reduced connectivity and reduce the ability of patients to compensate as has been observed when the right-MFG is damaged.
205-1	36172-36174	In	_	
205-2	36175-36183	patients	_	
205-3	36184-36188	with	_	
205-4	36189-36195	severe	_	
205-5	36196-36204	negative	_	
205-6	36205-36213	symptoms	_	
205-7	36213-36214	,	_	
205-8	36215-36222	failure	_	
205-9	36223-36225	of	_	
205-10	36226-36236	activation	_	
205-11	36237-36239	in	_	
205-12	36240-36243	the	_	
205-13	36244-36252	left-MFG	_	
205-14	36253-36256	may	_	
205-15	36257-36262	occur	_	
205-16	36263-36265	as	_	
205-17	36266-36267	a	_	
205-18	36268-36274	result	_	
205-19	36275-36277	of	_	
205-20	36278-36285	reduced	_	
205-21	36286-36298	connectivity	_	
205-22	36299-36302	and	_	
205-23	36303-36309	reduce	_	
205-24	36310-36313	the	_	
205-25	36314-36321	ability	_	
205-26	36322-36324	of	_	
205-27	36325-36333	patients	_	
205-28	36334-36336	to	_	
205-29	36337-36347	compensate	_	
205-30	36348-36350	as	_	
205-31	36351-36354	has	_	
205-32	36355-36359	been	_	
205-33	36360-36368	observed	_	
205-34	36369-36373	when	_	
205-35	36374-36377	the	_	
205-36	36378-36387	right-MFG	_	
205-37	36388-36390	is	_	
205-38	36391-36398	damaged	_	
205-39	36398-36399	.	_	

#Text=Future work should investigate how directed connectivity during cognitive control tasks may influence symptom expression in schizophrenia.
206-1	36400-36406	Future	_	
206-2	36407-36411	work	_	
206-3	36412-36418	should	_	
206-4	36419-36430	investigate	_	
206-5	36431-36434	how	_	
206-6	36435-36443	directed	_	
206-7	36444-36456	connectivity	_	
206-8	36457-36463	during	_	
206-9	36464-36473	cognitive	_	
206-10	36474-36481	control	_	
206-11	36482-36487	tasks	_	
206-12	36488-36491	may	_	
206-13	36492-36501	influence	_	
206-14	36502-36509	symptom	_	
206-15	36510-36520	expression	_	
206-16	36521-36523	in	_	
206-17	36524-36537	schizophrenia	_	
206-18	36537-36538	.	_	

#Text=Our study did not show a significant effect for task block number on SAT-Score at any level of stimulus duration in either group (A2).
207-1	36539-36542	Our	_	
207-2	36543-36548	study	_	
207-3	36549-36552	did	_	
207-4	36553-36556	not	_	
207-5	36557-36561	show	_	
207-6	36562-36563	a	_	
207-7	36564-36575	significant	_	
207-8	36576-36582	effect	_	
207-9	36583-36586	for	_	
207-10	36587-36591	task	_	
207-11	36592-36597	block	_	
207-12	36598-36604	number	_	
207-13	36605-36607	on	_	
207-14	36608-36617	SAT-Score	_	
207-15	36618-36620	at	_	
207-16	36621-36624	any	_	
207-17	36625-36630	level	_	
207-18	36631-36633	of	_	
207-19	36634-36642	stimulus	_	
207-20	36643-36651	duration	_	
207-21	36652-36654	in	_	
207-22	36655-36661	either	_	
207-23	36662-36667	group	_	
207-24	36668-36669	(	_	
207-25	36669-36671	A2	_	
207-26	36671-36672	)	_	
207-27	36672-36673	.	_	

#Text=These findings are in support of the work by Demeter et al. which concluded in a separate analysis that patients maintained performance across a 12-minute SAT task, showing no appreciable degradation of task performance, whereas children performing the same task were unable to maintain performance.
208-1	36674-36679	These	_	
208-2	36680-36688	findings	_	
208-3	36689-36692	are	_	
208-4	36693-36695	in	_	
208-5	36696-36703	support	_	
208-6	36704-36706	of	_	
208-7	36707-36710	the	_	
208-8	36711-36715	work	_	
208-9	36716-36718	by	_	
208-10	36719-36726	Demeter	_	
208-11	36727-36729	et	_	
208-12	36730-36732	al	_	
208-13	36732-36733	.	_	
208-14	36734-36739	which	_	
208-15	36740-36749	concluded	_	
208-16	36750-36752	in	_	
208-17	36753-36754	a	_	
208-18	36755-36763	separate	_	
208-19	36764-36772	analysis	_	
208-20	36773-36777	that	_	
208-21	36778-36786	patients	_	
208-22	36787-36797	maintained	_	
208-23	36798-36809	performance	_	
208-24	36810-36816	across	_	
208-25	36817-36818	a	_	
208-26	36819-36821	12	_	
208-27	36821-36822	-	_	
208-28	36822-36828	minute	_	
208-29	36829-36832	SAT	_	
208-30	36833-36837	task	_	
208-31	36837-36838	,	_	
208-32	36839-36846	showing	_	
208-33	36847-36849	no	_	
208-34	36850-36861	appreciable	_	
208-35	36862-36873	degradation	_	
208-36	36874-36876	of	_	
208-37	36877-36881	task	_	
208-38	36882-36893	performance	_	
208-39	36893-36894	,	_	
208-40	36895-36902	whereas	_	
208-41	36903-36911	children	_	
208-42	36912-36922	performing	_	
208-43	36923-36926	the	_	
208-44	36927-36931	same	_	
208-45	36932-36936	task	_	
208-46	36937-36941	were	_	
208-47	36942-36948	unable	_	
208-48	36949-36951	to	_	
208-49	36952-36960	maintain	_	
208-50	36961-36972	performance	_	
208-51	36972-36973	.	_	

#Text=These findings taken together support the existence of general performance deficits in schizophrenia and also provide evidence that attentional differences in schizophrenia are more closely related to difficulties adapting to varying demands in attentional processing rather than issues associated with fatigue.
209-1	36974-36979	These	_	
209-2	36980-36988	findings	_	
209-3	36989-36994	taken	_	
209-4	36995-37003	together	_	
209-5	37004-37011	support	_	
209-6	37012-37015	the	_	
209-7	37016-37025	existence	_	
209-8	37026-37028	of	_	
209-9	37029-37036	general	_	
209-10	37037-37048	performance	_	
209-11	37049-37057	deficits	_	
209-12	37058-37060	in	_	
209-13	37061-37074	schizophrenia	_	
209-14	37075-37078	and	_	
209-15	37079-37083	also	_	
209-16	37084-37091	provide	_	
209-17	37092-37100	evidence	_	
209-18	37101-37105	that	_	
209-19	37106-37117	attentional	_	
209-20	37118-37129	differences	_	
209-21	37130-37132	in	_	
209-22	37133-37146	schizophrenia	_	
209-23	37147-37150	are	_	
209-24	37151-37155	more	_	
209-25	37156-37163	closely	_	
209-26	37164-37171	related	_	
209-27	37172-37174	to	_	
209-28	37175-37187	difficulties	_	
209-29	37188-37196	adapting	_	
209-30	37197-37199	to	_	
209-31	37200-37207	varying	_	
209-32	37208-37215	demands	_	
209-33	37216-37218	in	_	
209-34	37219-37230	attentional	_	
209-35	37231-37241	processing	_	
209-36	37242-37248	rather	_	
209-37	37249-37253	than	_	
209-38	37254-37260	issues	_	
209-39	37261-37271	associated	_	
209-40	37272-37276	with	_	
209-41	37277-37284	fatigue	_	
209-42	37284-37285	.	_	

#Text=Findings in the study while promising are subject to several limitations.
210-1	37286-37294	Findings	_	
210-2	37295-37297	in	_	
210-3	37298-37301	the	_	
210-4	37302-37307	study	_	
210-5	37308-37313	while	_	
210-6	37314-37323	promising	_	
210-7	37324-37327	are	_	
210-8	37328-37335	subject	_	
210-9	37336-37338	to	_	
210-10	37339-37346	several	_	
210-11	37347-37358	limitations	_	
210-12	37358-37359	.	_	

#Text=First, all patients in the study were medicated and it is possible that the effects of varied prescribed antipsychotics may have contributed to the results observed in the study.
211-1	37360-37365	First	_	
211-2	37365-37366	,	_	
211-3	37367-37370	all	_	
211-4	37371-37379	patients	_	
211-5	37380-37382	in	_	
211-6	37383-37386	the	_	
211-7	37387-37392	study	_	
211-8	37393-37397	were	_	
211-9	37398-37407	medicated	_	
211-10	37408-37411	and	_	
211-11	37412-37414	it	_	
211-12	37415-37417	is	_	
211-13	37418-37426	possible	_	
211-14	37427-37431	that	_	
211-15	37432-37435	the	_	
211-16	37436-37443	effects	_	
211-17	37444-37446	of	_	
211-18	37447-37453	varied	_	
211-19	37454-37464	prescribed	_	
211-20	37465-37479	antipsychotics	_	
211-21	37480-37483	may	_	
211-22	37484-37488	have	_	
211-23	37489-37500	contributed	_	
211-24	37501-37503	to	_	
211-25	37504-37507	the	_	
211-26	37508-37515	results	_	
211-27	37516-37524	observed	_	
211-28	37525-37527	in	_	
211-29	37528-37531	the	_	
211-30	37532-37537	study	_	
211-31	37537-37538	.	_	

#Text=Although preliminary analysis indicated that patient performance was not sensitive CPZ equivalent dosage, antipsychotic medication has commonly been reported to have limited effect on cognitive measures including cognitive control and attention.
212-1	37539-37547	Although	_	
212-2	37548-37559	preliminary	_	
212-3	37560-37568	analysis	_	
212-4	37569-37578	indicated	_	
212-5	37579-37583	that	_	
212-6	37584-37591	patient	_	
212-7	37592-37603	performance	_	
212-8	37604-37607	was	_	
212-9	37608-37611	not	_	
212-10	37612-37621	sensitive	_	
212-11	37622-37625	CPZ	_	
212-12	37626-37636	equivalent	_	
212-13	37637-37643	dosage	_	
212-14	37643-37644	,	_	
212-15	37645-37658	antipsychotic	_	
212-16	37659-37669	medication	_	
212-17	37670-37673	has	_	
212-18	37674-37682	commonly	_	
212-19	37683-37687	been	_	
212-20	37688-37696	reported	_	
212-21	37697-37699	to	_	
212-22	37700-37704	have	_	
212-23	37705-37712	limited	_	
212-24	37713-37719	effect	_	
212-25	37720-37722	on	_	
212-26	37723-37732	cognitive	_	
212-27	37733-37741	measures	_	
212-28	37742-37751	including	_	
212-29	37752-37761	cognitive	_	
212-30	37762-37769	control	_	
212-31	37770-37773	and	_	
212-32	37774-37783	attention	_	
212-33	37783-37784	.	_	

#Text=Second, the block -level analysis method used in this study may have overlooked interesting features which could have provided more information regarding visuospatial deficiencies in schizophrenia.
213-1	37785-37791	Second	_	
213-2	37791-37792	,	_	
213-3	37793-37796	the	_	
213-4	37797-37802	block	_	
213-5	37803-37804	-	_	
213-6	37804-37809	level	_	
213-7	37810-37818	analysis	_	
213-8	37819-37825	method	_	
213-9	37826-37830	used	_	
213-10	37831-37833	in	_	
213-11	37834-37838	this	_	
213-12	37839-37844	study	_	
213-13	37845-37848	may	_	
213-14	37849-37853	have	_	
213-15	37854-37864	overlooked	_	
213-16	37865-37876	interesting	_	
213-17	37877-37885	features	_	
213-18	37886-37891	which	_	
213-19	37892-37897	could	_	
213-20	37898-37902	have	_	
213-21	37903-37911	provided	_	
213-22	37912-37916	more	_	
213-23	37917-37928	information	_	
213-24	37929-37938	regarding	_	
213-25	37939-37951	visuospatial	_	
213-26	37952-37964	deficiencies	_	
213-27	37965-37967	in	_	
213-28	37968-37981	schizophrenia	_	
213-29	37981-37982	.	_	

#Text=Future researchers may wish to use systems capable of higher sampling frequencies to investigate event-related responses within trials of the SAT and vSAT.
214-1	37983-37989	Future	_	
214-2	37990-38001	researchers	_	
214-3	38002-38005	may	_	
214-4	38006-38010	wish	_	
214-5	38011-38013	to	_	
214-6	38014-38017	use	_	
214-7	38018-38025	systems	_	
214-8	38026-38033	capable	_	
214-9	38034-38036	of	_	
214-10	38037-38043	higher	_	
214-11	38044-38052	sampling	_	
214-12	38053-38064	frequencies	_	
214-13	38065-38067	to	_	
214-14	38068-38079	investigate	_	
214-15	38080-38093	event-related	_	
214-16	38094-38103	responses	_	
214-17	38104-38110	within	_	
214-18	38111-38117	trials	_	
214-19	38118-38120	of	_	
214-20	38121-38124	the	_	
214-21	38125-38128	SAT	_	
214-22	38129-38132	and	_	
214-23	38133-38137	vSAT	_	
214-24	38137-38138	.	_	

#Text=It has been proposed that higher sampling frequencies may increase the speed of fNIRS response detection and other more rapid imaging techniques such as electroencephalography (EEG) may offer additional insight into the visuospatial dysfunction observed here.
215-1	38139-38141	It	_	
215-2	38142-38145	has	_	
215-3	38146-38150	been	_	
215-4	38151-38159	proposed	_	
215-5	38160-38164	that	_	
215-6	38165-38171	higher	_	
215-7	38172-38180	sampling	_	
215-8	38181-38192	frequencies	_	
215-9	38193-38196	may	_	
215-10	38197-38205	increase	_	
215-11	38206-38209	the	_	
215-12	38210-38215	speed	_	
215-13	38216-38218	of	_	
215-14	38219-38224	fNIRS	_	
215-15	38225-38233	response	_	
215-16	38234-38243	detection	_	
215-17	38244-38247	and	_	
215-18	38248-38253	other	_	
215-19	38254-38258	more	_	
215-20	38259-38264	rapid	_	
215-21	38265-38272	imaging	_	
215-22	38273-38283	techniques	_	
215-23	38284-38288	such	_	
215-24	38289-38291	as	_	
215-25	38292-38314	electroencephalography	_	
215-26	38315-38316	(	_	
215-27	38316-38319	EEG	_	
215-28	38319-38320	)	_	
215-29	38321-38324	may	_	
215-30	38325-38330	offer	_	
215-31	38331-38341	additional	_	
215-32	38342-38349	insight	_	
215-33	38350-38354	into	_	
215-34	38355-38358	the	_	
215-35	38359-38371	visuospatial	_	
215-36	38372-38383	dysfunction	_	
215-37	38384-38392	observed	_	
215-38	38393-38397	here	_	
215-39	38397-38398	.	_	

#Text=Third, the fNIRS system used in the study did not allow regions outside the anterior prefrontal cortex to be monitored.
216-1	38399-38404	Third	_	
216-2	38404-38405	,	_	
216-3	38406-38409	the	_	
216-4	38410-38415	fNIRS	_	
216-5	38416-38422	system	_	
216-6	38423-38427	used	_	
216-7	38428-38430	in	_	
216-8	38431-38434	the	_	
216-9	38435-38440	study	_	
216-10	38441-38444	did	_	
216-11	38445-38448	not	_	
216-12	38449-38454	allow	_	
216-13	38455-38462	regions	_	
216-14	38463-38470	outside	_	
216-15	38471-38474	the	_	
216-16	38475-38483	anterior	_	
216-17	38484-38494	prefrontal	_	
216-18	38495-38501	cortex	_	
216-19	38502-38504	to	_	
216-20	38505-38507	be	_	
216-21	38508-38517	monitored	_	
216-22	38517-38518	.	_	

#Text=It is possible that other brain areas such as parietal cortex might provide additional information.
217-1	38519-38521	It	_	
217-2	38522-38524	is	_	
217-3	38525-38533	possible	_	
217-4	38534-38538	that	_	
217-5	38539-38544	other	_	
217-6	38545-38550	brain	_	
217-7	38551-38556	areas	_	
217-8	38557-38561	such	_	
217-9	38562-38564	as	_	
217-10	38565-38573	parietal	_	
217-11	38574-38580	cortex	_	
217-12	38581-38586	might	_	
217-13	38587-38594	provide	_	
217-14	38595-38605	additional	_	
217-15	38606-38617	information	_	
217-16	38617-38618	.	_	

#Text=Lastly, schizophrenia is also accompanied by visual processing deficits in a variety of modalities which contribute to higher level dysfunctions in a variety of downstream domains.
218-1	38619-38625	Lastly	_	
218-2	38625-38626	,	_	
218-3	38627-38640	schizophrenia	_	
218-4	38641-38643	is	_	
218-5	38644-38648	also	_	
218-6	38649-38660	accompanied	_	
218-7	38661-38663	by	_	
218-8	38664-38670	visual	_	
218-9	38671-38681	processing	_	
218-10	38682-38690	deficits	_	
218-11	38691-38693	in	_	
218-12	38694-38695	a	_	
218-13	38696-38703	variety	_	
218-14	38704-38706	of	_	
218-15	38707-38717	modalities	_	
218-16	38718-38723	which	_	
218-17	38724-38734	contribute	_	
218-18	38735-38737	to	_	
218-19	38738-38744	higher	_	
218-20	38745-38750	level	_	
218-21	38751-38763	dysfunctions	_	
218-22	38764-38766	in	_	
218-23	38767-38768	a	_	
218-24	38769-38776	variety	_	
218-25	38777-38779	of	_	
218-26	38780-38790	downstream	_	
218-27	38791-38798	domains	_	
218-28	38798-38799	.	_	

#Text=Performance differences frequently attributed to failures of attention and other top-down processes may be conflated with dysfunction in the visual processing system.
219-1	38800-38811	Performance	_	
219-2	38812-38823	differences	_	
219-3	38824-38834	frequently	_	
219-4	38835-38845	attributed	_	
219-5	38846-38848	to	_	
219-6	38849-38857	failures	_	
219-7	38858-38860	of	_	
219-8	38861-38870	attention	_	
219-9	38871-38874	and	_	
219-10	38875-38880	other	_	
219-11	38881-38889	top-down	_	
219-12	38890-38899	processes	_	
219-13	38900-38903	may	_	
219-14	38904-38906	be	_	
219-15	38907-38916	conflated	_	
219-16	38917-38921	with	_	
219-17	38922-38933	dysfunction	_	
219-18	38934-38936	in	_	
219-19	38937-38940	the	_	
219-20	38941-38947	visual	_	
219-21	38948-38958	processing	_	
219-22	38959-38965	system	_	
219-23	38965-38966	.	_	

#Text=The magnocellular pathway is critical for the rapid detection of low-contrast and stimuli with low spatial frequency.
220-1	38967-38970	The	_	
220-2	38971-38984	magnocellular	_	
220-3	38985-38992	pathway	_	
220-4	38993-38995	is	_	
220-5	38996-39004	critical	_	
220-6	39005-39008	for	_	
220-7	39009-39012	the	_	
220-8	39013-39018	rapid	_	
220-9	39019-39028	detection	_	
220-10	39029-39031	of	_	
220-11	39032-39044	low-contrast	_	
220-12	39045-39048	and	_	
220-13	39049-39056	stimuli	_	
220-14	39057-39061	with	_	
220-15	39062-39065	low	_	
220-16	39066-39073	spatial	_	
220-17	39074-39083	frequency	_	
220-18	39083-39084	.	_	

#Text=When working together with the slower parvocellular pathway, the two integrate to form a complete visual representation.
221-1	39085-39089	When	_	
221-2	39090-39097	working	_	
221-3	39098-39106	together	_	
221-4	39107-39111	with	_	
221-5	39112-39115	the	_	
221-6	39116-39122	slower	_	
221-7	39123-39136	parvocellular	_	
221-8	39137-39144	pathway	_	
221-9	39144-39145	,	_	
221-10	39146-39149	the	_	
221-11	39150-39153	two	_	
221-12	39154-39163	integrate	_	
221-13	39164-39166	to	_	
221-14	39167-39171	form	_	
221-15	39172-39173	a	_	
221-16	39174-39182	complete	_	
221-17	39183-39189	visual	_	
221-18	39190-39204	representation	_	
221-19	39204-39205	.	_	

#Text=In this “fill and frame model” visual, the magnocellular pathway identifies broad visual descriptions while the parvocellular pathways provide the details.
222-1	39206-39208	In	_	
222-2	39209-39213	this	_	
222-3	39214-39215	“	_	
222-4	39215-39219	fill	_	
222-5	39220-39223	and	_	
222-6	39224-39229	frame	_	
222-7	39230-39235	model	_	
222-8	39235-39236	”	_	
222-9	39237-39243	visual	_	
222-10	39243-39244	,	_	
222-11	39245-39248	the	_	
222-12	39249-39262	magnocellular	_	
222-13	39263-39270	pathway	_	
222-14	39271-39281	identifies	_	
222-15	39282-39287	broad	_	
222-16	39288-39294	visual	_	
222-17	39295-39307	descriptions	_	
222-18	39308-39313	while	_	
222-19	39314-39317	the	_	
222-20	39318-39331	parvocellular	_	
222-21	39332-39340	pathways	_	
222-22	39341-39348	provide	_	
222-23	39349-39352	the	_	
222-24	39353-39360	details	_	
222-25	39360-39361	.	_	

#Text=Patients with schizophrenia possess a demonstrated degradation in the magnocellular pathway that results in reduced visually evoked responses in situations with low contrast (<10% luminance), short stimulus length, and low spatial frequency.
223-1	39362-39370	Patients	_	
223-2	39371-39375	with	_	
223-3	39376-39389	schizophrenia	_	
223-4	39390-39397	possess	_	
223-5	39398-39399	a	_	
223-6	39400-39412	demonstrated	_	
223-7	39413-39424	degradation	_	
223-8	39425-39427	in	_	
223-9	39428-39431	the	_	
223-10	39432-39445	magnocellular	_	
223-11	39446-39453	pathway	_	
223-12	39454-39458	that	_	
223-13	39459-39466	results	_	
223-14	39467-39469	in	_	
223-15	39470-39477	reduced	_	
223-16	39478-39486	visually	_	
223-17	39487-39493	evoked	_	
223-18	39494-39503	responses	_	
223-19	39504-39506	in	_	
223-20	39507-39517	situations	_	
223-21	39518-39522	with	_	
223-22	39523-39526	low	_	
223-23	39527-39535	contrast	_	
223-24	39536-39537	(	_	
223-25	39537-39538	<	_	
223-26	39538-39541	10%	_	
223-27	39542-39551	luminance	_	
223-28	39551-39552	)	_	
223-29	39552-39553	,	_	
223-30	39554-39559	short	_	
223-31	39560-39568	stimulus	_	
223-32	39569-39575	length	_	
223-33	39575-39576	,	_	
223-34	39577-39580	and	_	
223-35	39581-39584	low	_	
223-36	39585-39592	spatial	_	
223-37	39593-39602	frequency	_	
223-38	39602-39603	.	_	

#Text=In the presently reported experiment, the varied stimuli locations in the vSAT task when paired with reduced contrast stimuli may have contributed to performance differences between patients and healthy controls.
224-1	39604-39606	In	_	
224-2	39607-39610	the	_	
224-3	39611-39620	presently	_	
224-4	39621-39629	reported	_	
224-5	39630-39640	experiment	_	
224-6	39640-39641	,	_	
224-7	39642-39645	the	_	
224-8	39646-39652	varied	_	
224-9	39653-39660	stimuli	_	
224-10	39661-39670	locations	_	
224-11	39671-39673	in	_	
224-12	39674-39677	the	_	
224-13	39678-39682	vSAT	_	
224-14	39683-39687	task	_	
224-15	39688-39692	when	_	
224-16	39693-39699	paired	_	
224-17	39700-39704	with	_	
224-18	39705-39712	reduced	_	
224-19	39713-39721	contrast	_	
224-20	39722-39729	stimuli	_	
224-21	39730-39733	may	_	
224-22	39734-39738	have	_	
224-23	39739-39750	contributed	_	
224-24	39751-39753	to	_	
224-25	39754-39765	performance	_	
224-26	39766-39777	differences	_	
224-27	39778-39785	between	_	
224-28	39786-39794	patients	_	
224-29	39795-39798	and	_	
224-30	39799-39806	healthy	_	
224-31	39807-39815	controls	_	
224-32	39815-39816	.	_	

#Text=However, we suggest that differences due to magnocellular deficits may only be apparent at the shortest interstimulus intervals.
225-1	39817-39824	However	_	
225-2	39824-39825	,	_	
225-3	39826-39828	we	_	
225-4	39829-39836	suggest	_	
225-5	39837-39841	that	_	
225-6	39842-39853	differences	_	
225-7	39854-39857	due	_	
225-8	39858-39860	to	_	
225-9	39861-39874	magnocellular	_	
225-10	39875-39883	deficits	_	
225-11	39884-39887	may	_	
225-12	39888-39892	only	_	
225-13	39893-39895	be	_	
225-14	39896-39904	apparent	_	
225-15	39905-39907	at	_	
225-16	39908-39911	the	_	
225-17	39912-39920	shortest	_	
225-18	39921-39934	interstimulus	_	
225-19	39935-39944	intervals	_	
225-20	39944-39945	.	_	

#Text=The experimental setup used (single monitor at a comfortable distance from subject) in this study was not designed in a manner which would have field of view to be sensitive to the difference between magnocellular and parvocellular processes.
226-1	39946-39949	The	_	
226-2	39950-39962	experimental	_	
226-3	39963-39968	setup	_	
226-4	39969-39973	used	_	
226-5	39974-39975	(	_	
226-6	39975-39981	single	_	
226-7	39982-39989	monitor	_	
226-8	39990-39992	at	_	
226-9	39993-39994	a	_	
226-10	39995-40006	comfortable	_	
226-11	40007-40015	distance	_	
226-12	40016-40020	from	_	
226-13	40021-40028	subject	_	
226-14	40028-40029	)	_	
226-15	40030-40032	in	_	
226-16	40033-40037	this	_	
226-17	40038-40043	study	_	
226-18	40044-40047	was	_	
226-19	40048-40051	not	_	
226-20	40052-40060	designed	_	
226-21	40061-40063	in	_	
226-22	40064-40065	a	_	
226-23	40066-40072	manner	_	
226-24	40073-40078	which	_	
226-25	40079-40084	would	_	
226-26	40085-40089	have	_	
226-27	40090-40095	field	_	
226-28	40096-40098	of	_	
226-29	40099-40103	view	_	
226-30	40104-40106	to	_	
226-31	40107-40109	be	_	
226-32	40110-40119	sensitive	_	
226-33	40120-40122	to	_	
226-34	40123-40126	the	_	
226-35	40127-40137	difference	_	
226-36	40138-40145	between	_	
226-37	40146-40159	magnocellular	_	
226-38	40160-40163	and	_	
226-39	40164-40177	parvocellular	_	
226-40	40178-40187	processes	_	
226-41	40187-40188	.	_	

#Text=Although we note that performing this experiment using a display arrangement that is capable of targeting peripheral vision (>30 deg) may be an interesting avenue of research.
227-1	40189-40197	Although	_	
227-2	40198-40200	we	_	
227-3	40201-40205	note	_	
227-4	40206-40210	that	_	
227-5	40211-40221	performing	_	
227-6	40222-40226	this	_	
227-7	40227-40237	experiment	_	
227-8	40238-40243	using	_	
227-9	40244-40245	a	_	
227-10	40246-40253	display	_	
227-11	40254-40265	arrangement	_	
227-12	40266-40270	that	_	
227-13	40271-40273	is	_	
227-14	40274-40281	capable	_	
227-15	40282-40284	of	_	
227-16	40285-40294	targeting	_	
227-17	40295-40305	peripheral	_	
227-18	40306-40312	vision	_	
227-19	40313-40314	(	_	
227-20	40314-40315	>	_	
227-21	40315-40317	30	_	
227-22	40318-40321	deg	_	
227-23	40321-40322	)	_	
227-24	40323-40326	may	_	
227-25	40327-40329	be	_	
227-26	40330-40332	an	_	
227-27	40333-40344	interesting	_	
227-28	40345-40351	avenue	_	
227-29	40352-40354	of	_	
227-30	40355-40363	research	_	
227-31	40363-40364	.	_	

#Text=A combination of attentional tasks and manipulation of low-level visual-detection could provide a novel evaluative technique pairing low and high-level brain function.
228-1	40365-40366	A	_	
228-2	40367-40378	combination	_	
228-3	40379-40381	of	_	
228-4	40382-40393	attentional	_	
228-5	40394-40399	tasks	_	
228-6	40400-40403	and	_	
228-7	40404-40416	manipulation	_	
228-8	40417-40419	of	_	
228-9	40420-40429	low-level	_	
228-10	40430-40446	visual-detection	_	
228-11	40447-40452	could	_	
228-12	40453-40460	provide	_	
228-13	40461-40462	a	_	
228-14	40463-40468	novel	_	
228-15	40469-40479	evaluative	_	
228-16	40480-40489	technique	_	
228-17	40490-40497	pairing	_	
228-18	40498-40501	low	_	
228-19	40502-40505	and	_	
228-20	40506-40516	high-level	_	
228-21	40517-40522	brain	_	
228-22	40523-40531	function	_	
228-23	40531-40532	.	_	

#Text=Conclusion
#Text=In summary, we confirmed a general attentional deficit in patients with schizophrenia as demonstrated by decreased task performance and increased response time compared with the healthy controls.
229-1	40533-40543	Conclusion	_	
229-2	40544-40546	In	_	
229-3	40547-40554	summary	_	
229-4	40554-40555	,	_	
229-5	40556-40558	we	_	
229-6	40559-40568	confirmed	_	
229-7	40569-40570	a	_	
229-8	40571-40578	general	_	
229-9	40579-40590	attentional	_	
229-10	40591-40598	deficit	_	
229-11	40599-40601	in	_	
229-12	40602-40610	patients	_	
229-13	40611-40615	with	_	
229-14	40616-40629	schizophrenia	_	
229-15	40630-40632	as	_	
229-16	40633-40645	demonstrated	_	
229-17	40646-40648	by	_	
229-18	40649-40658	decreased	_	
229-19	40659-40663	task	_	
229-20	40664-40675	performance	_	
229-21	40676-40679	and	_	
229-22	40680-40689	increased	_	
229-23	40690-40698	response	_	
229-24	40699-40703	time	_	
229-25	40704-40712	compared	_	
229-26	40713-40717	with	_	
229-27	40718-40721	the	_	
229-28	40722-40729	healthy	_	
229-29	40730-40738	controls	_	
229-30	40738-40739	.	_	

#Text=In both healthy and patient populations, we found a decrease in performance associated with task-type manipulation and a change in the target stimulus duration, but task parameters did not interact with subject group.
230-1	40740-40742	In	_	
230-2	40743-40747	both	_	
230-3	40748-40755	healthy	_	
230-4	40756-40759	and	_	
230-5	40760-40767	patient	_	
230-6	40768-40779	populations	_	
230-7	40779-40780	,	_	
230-8	40781-40783	we	_	
230-9	40784-40789	found	_	
230-10	40790-40791	a	_	
230-11	40792-40800	decrease	_	
230-12	40801-40803	in	_	
230-13	40804-40815	performance	_	
230-14	40816-40826	associated	_	
230-15	40827-40831	with	_	
230-16	40832-40841	task-type	_	
230-17	40842-40854	manipulation	_	
230-18	40855-40858	and	_	
230-19	40859-40860	a	_	
230-20	40861-40867	change	_	
230-21	40868-40870	in	_	
230-22	40871-40874	the	_	
230-23	40875-40881	target	_	
230-24	40882-40890	stimulus	_	
230-25	40891-40899	duration	_	
230-26	40899-40900	,	_	
230-27	40901-40904	but	_	
230-28	40905-40909	task	_	
230-29	40910-40920	parameters	_	
230-30	40921-40924	did	_	
230-31	40925-40928	not	_	
230-32	40929-40937	interact	_	
230-33	40938-40942	with	_	
230-34	40943-40950	subject	_	
230-35	40951-40956	group	_	
230-36	40956-40957	.	_	

#Text=The results confirm that the right frontopolar region plays a role in control of attention for both patients and healthy controls.
231-1	40958-40961	The	_	
231-2	40962-40969	results	_	
231-3	40970-40977	confirm	_	
231-4	40978-40982	that	_	
231-5	40983-40986	the	_	
231-6	40987-40992	right	_	
231-7	40993-41004	frontopolar	_	
231-8	41005-41011	region	_	
231-9	41012-41017	plays	_	
231-10	41018-41019	a	_	
231-11	41020-41024	role	_	
231-12	41025-41027	in	_	
231-13	41028-41035	control	_	
231-14	41036-41038	of	_	
231-15	41039-41048	attention	_	
231-16	41049-41052	for	_	
231-17	41053-41057	both	_	
231-18	41058-41066	patients	_	
231-19	41067-41070	and	_	
231-20	41071-41078	healthy	_	
231-21	41079-41087	controls	_	
231-22	41087-41088	.	_	

#Text=However, patients with schizophrenia exhibited a general attentional deficit and inefficient right-medial PFC activation.
232-1	41089-41096	However	_	
232-2	41096-41097	,	_	
232-3	41098-41106	patients	_	
232-4	41107-41111	with	_	
232-5	41112-41125	schizophrenia	_	
232-6	41126-41135	exhibited	_	
232-7	41136-41137	a	_	
232-8	41138-41145	general	_	
232-9	41146-41157	attentional	_	
232-10	41158-41165	deficit	_	
232-11	41166-41169	and	_	
232-12	41170-41181	inefficient	_	
232-13	41182-41194	right-medial	_	
232-14	41195-41198	PFC	_	
232-15	41199-41209	activation	_	
232-16	41209-41210	.	_	

#Text=Finally, we observed a strong regional association between the left-MFG activity during the vSAT task and the PANSS score driven by the negative symptom subscale.
233-1	41211-41218	Finally	_	
233-2	41218-41219	,	_	
233-3	41220-41222	we	_	
233-4	41223-41231	observed	_	
233-5	41232-41233	a	_	
233-6	41234-41240	strong	_	
233-7	41241-41249	regional	_	
233-8	41250-41261	association	_	
233-9	41262-41269	between	_	
233-10	41270-41273	the	_	
233-11	41274-41282	left-MFG	_	
233-12	41283-41291	activity	_	
233-13	41292-41298	during	_	
233-14	41299-41302	the	_	
233-15	41303-41307	vSAT	_	
233-16	41308-41312	task	_	
233-17	41313-41316	and	_	
233-18	41317-41320	the	_	
233-19	41321-41326	PANSS	_	
233-20	41327-41332	score	_	
233-21	41333-41339	driven	_	
233-22	41340-41342	by	_	
233-23	41343-41346	the	_	
233-24	41347-41355	negative	_	
233-25	41356-41363	symptom	_	
233-26	41364-41372	subscale	_	
233-27	41372-41373	.	_	

#Text=We suggest that the presence of aberrant activation differences within the left-MFG region may be related to dysregulation of attentional networks which plays a role in the clinical expression of negative and general symptoms.
234-1	41374-41376	We	_	
234-2	41377-41384	suggest	_	
234-3	41385-41389	that	_	
234-4	41390-41393	the	_	
234-5	41394-41402	presence	_	
234-6	41403-41405	of	_	
234-7	41406-41414	aberrant	_	
234-8	41415-41425	activation	_	
234-9	41426-41437	differences	_	
234-10	41438-41444	within	_	
234-11	41445-41448	the	_	
234-12	41449-41457	left-MFG	_	
234-13	41458-41464	region	_	
234-14	41465-41468	may	_	
234-15	41469-41471	be	_	
234-16	41472-41479	related	_	
234-17	41480-41482	to	_	
234-18	41483-41496	dysregulation	_	
234-19	41497-41499	of	_	
234-20	41500-41511	attentional	_	
234-21	41512-41520	networks	_	
234-22	41521-41526	which	_	
234-23	41527-41532	plays	_	
234-24	41533-41534	a	_	
234-25	41535-41539	role	_	
234-26	41540-41542	in	_	
234-27	41543-41546	the	_	
234-28	41547-41555	clinical	_	
234-29	41556-41566	expression	_	
234-30	41567-41569	of	_	
234-31	41570-41578	negative	_	
234-32	41579-41582	and	_	
234-33	41583-41590	general	_	
234-34	41591-41599	symptoms	_	
234-35	41599-41600	.	_	

#Text=Supplementary information
#Text=Publisher’s note: Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
235-1	41601-41614	Supplementary	_	
235-2	41615-41626	information	_	
235-3	41627-41636	Publisher	_	
235-4	41636-41637	’	_	
235-5	41637-41638	s	_	
235-6	41639-41643	note	_	
235-7	41643-41644	:	_	
235-8	41645-41653	Springer	_	
235-9	41654-41660	Nature	_	
235-10	41661-41668	remains	_	
235-11	41669-41676	neutral	_	
235-12	41677-41681	with	_	
235-13	41682-41688	regard	_	
235-14	41689-41691	to	_	
235-15	41692-41706	jurisdictional	_	
235-16	41707-41713	claims	_	
235-17	41714-41716	in	_	
235-18	41717-41726	published	_	
235-19	41727-41731	maps	_	
235-20	41732-41735	and	_	
235-21	41736-41749	institutional	_	
235-22	41750-41762	affiliations	_	
235-23	41762-41763	.	_	

#Text=Supplementary information
#Text=Supplementary information accompanies this paper at 10.1038/s41598-019-45893-7.
236-1	41764-41777	Supplementary	_	
236-2	41778-41789	information	_	
236-3	41790-41803	Supplementary	_	
236-4	41804-41815	information	_	
236-5	41816-41827	accompanies	_	
236-6	41828-41832	this	_	
236-7	41833-41838	paper	_	
236-8	41839-41841	at	_	
236-9	41842-41849	10.1038	_	
236-10	41849-41850	/	_	
236-11	41850-41856	s41598	_	
236-12	41856-41857	-	_	
236-13	41857-41860	019	_	
236-14	41860-41861	-	_	
236-15	41861-41866	45893	_	
236-16	41866-41867	-	_	
236-17	41867-41868	7	_	
236-18	41868-41869	.	_	

#Text=Author Contributions
#Text=A.C. drafted the manuscript and analyzed the data.
237-1	41870-41876	Author	_	
237-2	41877-41890	Contributions	_	
237-3	41891-41894	A.C	_	
237-4	41894-41895	.	_	
237-5	41896-41903	drafted	_	
237-6	41904-41907	the	_	
237-7	41908-41918	manuscript	_	
237-8	41919-41922	and	_	
237-9	41923-41931	analyzed	_	
237-10	41932-41935	the	_	
237-11	41936-41940	data	_	
237-12	41940-41941	.	_	

#Text=Q.Z. and J.W. collected the data.
238-1	41942-41945	Q.Z	_	
238-2	41945-41946	.	_	
238-3	41947-41950	and	_	
238-4	41951-41954	J.W	_	
238-5	41954-41955	.	_	
238-6	41956-41965	collected	_	
238-7	41966-41969	the	_	
238-8	41970-41974	data	_	
238-9	41974-41975	.	_	

#Text=H.A., S.T. and A.C. designed the experiment and prepared the figures.
239-1	41976-41979	H.A	_	
239-2	41979-41980	.	_	
239-3	41980-41981	,	_	
239-4	41982-41985	S.T	_	
239-5	41985-41986	.	_	
239-6	41987-41990	and	_	
239-7	41991-41994	A.C	_	
239-8	41994-41995	.	_	
239-9	41996-42004	designed	_	
239-10	42005-42008	the	_	
239-11	42009-42019	experiment	_	
239-12	42020-42023	and	_	
239-13	42024-42032	prepared	_	
239-14	42033-42036	the	_	
239-15	42037-42044	figures	_	
239-16	42044-42045	.	_	

#Text=J.S., J.W., S.T., B.O. and H.A. discussed the results and revised the manuscript.
240-1	42046-42049	J.S	_	
240-2	42049-42050	.	_	
240-3	42050-42051	,	_	
240-4	42052-42055	J.W	_	
240-5	42055-42056	.	_	
240-6	42056-42057	,	_	
240-7	42058-42061	S.T	_	
240-8	42061-42062	.	_	
240-9	42062-42063	,	_	
240-10	42064-42067	B.O	_	
240-11	42067-42068	.	_	
240-12	42069-42072	and	_	
240-13	42073-42076	H.A	_	
240-14	42076-42077	.	_	
240-15	42078-42087	discussed	_	
240-16	42088-42091	the	_	
240-17	42092-42099	results	_	
240-18	42100-42103	and	_	
240-19	42104-42111	revised	_	
240-20	42112-42115	the	_	
240-21	42116-42126	manuscript	_	
240-22	42126-42127	.	_	

#Text=Data Availability
#Text=The datasets generated during and/or analyzed during the current study are available from the corresponding author on reasonable request.
241-1	42128-42132	Data	_	
241-2	42133-42145	Availability	_	
241-3	42146-42149	The	_	
241-4	42150-42158	datasets	_	
241-5	42159-42168	generated	_	
241-6	42169-42175	during	_	
241-7	42176-42179	and	_	
241-8	42179-42180	/	_	
241-9	42180-42182	or	_	
241-10	42183-42191	analyzed	_	
241-11	42192-42198	during	_	
241-12	42199-42202	the	_	
241-13	42203-42210	current	_	
241-14	42211-42216	study	_	
241-15	42217-42220	are	_	
241-16	42221-42230	available	_	
241-17	42231-42235	from	_	
241-18	42236-42239	the	_	
241-19	42240-42253	corresponding	_	
241-20	42254-42260	author	_	
241-21	42261-42263	on	_	
241-22	42264-42274	reasonable	_	
241-23	42275-42282	request	_	
241-24	42282-42283	.	_	

#Text=Competing Interests
#Text=fNIR Devices, LLC manufactures the optical brain imaging instrument and licensed IP and know-how from Drexel University.
242-1	42284-42293	Competing	_	
242-2	42294-42303	Interests	_	
242-3	42304-42308	fNIR	_	
242-4	42309-42316	Devices	_	
242-5	42316-42317	,	_	
242-6	42318-42321	LLC	_	
242-7	42322-42334	manufactures	_	
242-8	42335-42338	the	_	
242-9	42339-42346	optical	_	
242-10	42347-42352	brain	_	
242-11	42353-42360	imaging	_	
242-12	42361-42371	instrument	_	
242-13	42372-42375	and	_	
242-14	42376-42384	licensed	_	
242-15	42385-42387	IP	_	
242-16	42388-42391	and	_	
242-17	42392-42400	know-how	_	
242-18	42401-42405	from	_	
242-19	42406-42412	Drexel	_	
242-20	42413-42423	University	_	
242-21	42423-42424	.	_	

#Text=H.A. and B.O. were involved in the technology development and thus offered a minor share in the startup firm fNIR Devices, LLC.
243-1	42425-42428	H.A	_	
243-2	42428-42429	.	_	
243-3	42430-42433	and	_	
243-4	42434-42437	B.O	_	
243-5	42437-42438	.	_	
243-6	42439-42443	were	_	
243-7	42444-42452	involved	_	
243-8	42453-42455	in	_	
243-9	42456-42459	the	_	
243-10	42460-42470	technology	_	
243-11	42471-42482	development	_	
243-12	42483-42486	and	_	
243-13	42487-42491	thus	_	
243-14	42492-42499	offered	_	
243-15	42500-42501	a	_	
243-16	42502-42507	minor	_	
243-17	42508-42513	share	_	
243-18	42514-42516	in	_	
243-19	42517-42520	the	_	
243-20	42521-42528	startup	_	
243-21	42529-42533	firm	_	
243-22	42534-42538	fNIR	_	
243-23	42539-42546	Devices	_	
243-24	42546-42547	,	_	
243-25	42548-42551	LLC	_	
243-26	42551-42552	.	_	

#Text=A.C., J.S., Q.Z., J.W. and S.T. declare no potential conflict of interest.
244-1	42553-42556	A.C	_	
244-2	42556-42557	.	_	
244-3	42557-42558	,	_	
244-4	42559-42562	J.S	_	
244-5	42562-42563	.	_	
244-6	42563-42564	,	_	
244-7	42565-42568	Q.Z	_	
244-8	42568-42569	.	_	
244-9	42569-42570	,	_	
244-10	42571-42574	J.W	_	
244-11	42574-42575	.	_	
244-12	42576-42579	and	_	
244-13	42580-42583	S.T	_	
244-14	42583-42584	.	_	
244-15	42585-42592	declare	_	
244-16	42593-42595	no	_	
244-17	42596-42605	potential	_	
244-18	42606-42614	conflict	_	
244-19	42615-42617	of	_	
244-20	42618-42626	interest	_	
244-21	42626-42627	.	_	

#Text=References
#Text=Prevalence studies in schizophrenia
#Text=What are the functional consequences of neurocognitive deficits in schizophrenia?
245-1	42628-42638	References	_	
245-2	42639-42649	Prevalence	_	
245-3	42650-42657	studies	_	
245-4	42658-42660	in	_	
245-5	42661-42674	schizophrenia	_	
245-6	42675-42679	What	_	
245-7	42680-42683	are	_	
245-8	42684-42687	the	_	
245-9	42688-42698	functional	_	
245-10	42699-42711	consequences	_	
245-11	42712-42714	of	_	
245-12	42715-42729	neurocognitive	_	
245-13	42730-42738	deficits	_	
245-14	42739-42741	in	_	
245-15	42742-42755	schizophrenia	_	
245-16	42755-42756	?	_	

#Text=Effects of atypical neuroleptics on sustained attention deficits in schizophrenia: A trial of risperidone versus haloperidol
#Text=Stability of attention deficits in schizophrenia
#Text=A meta-analysis of cognitive deficits in adults with a diagnosis of schizophrenia
#Text=Schizophrenia, neuroimaging and connectomics
#Text=Association of fronto-temporal function with cognitive ability in schizophrenia
#Text=Beyond hypofrontality: a quantitative meta-analysis of functional neuroimaging studies of working memory in schizophrenia
#Text=Prefrontal cortex dysfunction during working memory performance in schizophrenia: reconciling discrepant findings
#Text=Attention deficits in schizophrenia - Preliminary evidence of dissociable transient and sustained deficits
#Text=Turning it upside down: Areas of preserved cognitive function in schizophrenia
#Text=CNTRICS final biomarker selection: Control of attention
#Text=Top-down and bottom-up mechanisms in biasing competition in the human brain
#Text=Cognitive neuroscience-based approaches to measuring and improving treatment effects on cognition in schizophrenia: The CNTRICS initiative
#Text=The attention system of the human brain: 20 years after
#Text=Visual attention within and around the field of focal attention: a zoom lens model
#Text=Hyperfocusing in schizophrenia: Evidence from interactions between working memory and eye movements
#Text=Visual search performance among persons with schizophrenia as a function of target eccentricity
#Text=[A deficit in preattentive processing of visual information in schizophrenic patients]
#Text=Spatial working memory as an endophenotype for schizophrenia
#Text=Challenges to attention: a continuous arterial spin labeling (ASL) study of the effects of distraction on sustained attention
#Text=Increased distractor vulnerability but preserved vigilance in patients with schizophrenia: Evidence from a translational Sustained Attention Task
#Text=The continuous performance test: a window on the neural substrates for attention?
246-1	42757-42764	Effects	_	
246-2	42765-42767	of	_	
246-3	42768-42776	atypical	_	
246-4	42777-42789	neuroleptics	_	
246-5	42790-42792	on	_	
246-6	42793-42802	sustained	_	
246-7	42803-42812	attention	_	
246-8	42813-42821	deficits	_	
246-9	42822-42824	in	_	
246-10	42825-42838	schizophrenia	_	
246-11	42838-42839	:	_	
246-12	42840-42841	A	_	
246-13	42842-42847	trial	_	
246-14	42848-42850	of	_	
246-15	42851-42862	risperidone	_	
246-16	42863-42869	versus	_	
246-17	42870-42881	haloperidol	_	
246-18	42882-42891	Stability	_	
246-19	42892-42894	of	_	
246-20	42895-42904	attention	_	
246-21	42905-42913	deficits	_	
246-22	42914-42916	in	_	
246-23	42917-42930	schizophrenia	_	
246-24	42931-42932	A	_	
246-25	42933-42946	meta-analysis	_	
246-26	42947-42949	of	_	
246-27	42950-42959	cognitive	_	
246-28	42960-42968	deficits	_	
246-29	42969-42971	in	_	
246-30	42972-42978	adults	_	
246-31	42979-42983	with	_	
246-32	42984-42985	a	_	
246-33	42986-42995	diagnosis	_	
246-34	42996-42998	of	_	
246-35	42999-43012	schizophrenia	_	
246-36	43013-43026	Schizophrenia	_	
246-37	43026-43027	,	_	
246-38	43028-43040	neuroimaging	_	
246-39	43041-43044	and	_	
246-40	43045-43057	connectomics	_	
246-41	43058-43069	Association	_	
246-42	43070-43072	of	_	
246-43	43073-43088	fronto-temporal	_	
246-44	43089-43097	function	_	
246-45	43098-43102	with	_	
246-46	43103-43112	cognitive	_	
246-47	43113-43120	ability	_	
246-48	43121-43123	in	_	
246-49	43124-43137	schizophrenia	_	
246-50	43138-43144	Beyond	_	
246-51	43145-43159	hypofrontality	_	
246-52	43159-43160	:	_	
246-53	43161-43162	a	_	
246-54	43163-43175	quantitative	_	
246-55	43176-43189	meta-analysis	_	
246-56	43190-43192	of	_	
246-57	43193-43203	functional	_	
246-58	43204-43216	neuroimaging	_	
246-59	43217-43224	studies	_	
246-60	43225-43227	of	_	
246-61	43228-43235	working	_	
246-62	43236-43242	memory	_	
246-63	43243-43245	in	_	
246-64	43246-43259	schizophrenia	_	
246-65	43260-43270	Prefrontal	_	
246-66	43271-43277	cortex	_	
246-67	43278-43289	dysfunction	_	
246-68	43290-43296	during	_	
246-69	43297-43304	working	_	
246-70	43305-43311	memory	_	
246-71	43312-43323	performance	_	
246-72	43324-43326	in	_	
246-73	43327-43340	schizophrenia	_	
246-74	43340-43341	:	_	
246-75	43342-43353	reconciling	_	
246-76	43354-43364	discrepant	_	
246-77	43365-43373	findings	_	
246-78	43374-43383	Attention	_	
246-79	43384-43392	deficits	_	
246-80	43393-43395	in	_	
246-81	43396-43409	schizophrenia	_	
246-82	43410-43411	-	_	
246-83	43412-43423	Preliminary	_	
246-84	43424-43432	evidence	_	
246-85	43433-43435	of	_	
246-86	43436-43447	dissociable	_	
246-87	43448-43457	transient	_	
246-88	43458-43461	and	_	
246-89	43462-43471	sustained	_	
246-90	43472-43480	deficits	_	
246-91	43481-43488	Turning	_	
246-92	43489-43491	it	_	
246-93	43492-43498	upside	_	
246-94	43499-43503	down	_	
246-95	43503-43504	:	_	
246-96	43505-43510	Areas	_	
246-97	43511-43513	of	_	
246-98	43514-43523	preserved	_	
246-99	43524-43533	cognitive	_	
246-100	43534-43542	function	_	
246-101	43543-43545	in	_	
246-102	43546-43559	schizophrenia	_	
246-103	43560-43567	CNTRICS	_	
246-104	43568-43573	final	_	
246-105	43574-43583	biomarker	_	
246-106	43584-43593	selection	_	
246-107	43593-43594	:	_	
246-108	43595-43602	Control	_	
246-109	43603-43605	of	_	
246-110	43606-43615	attention	_	
246-111	43616-43624	Top-down	_	
246-112	43625-43628	and	_	
246-113	43629-43638	bottom-up	_	
246-114	43639-43649	mechanisms	_	
246-115	43650-43652	in	_	
246-116	43653-43660	biasing	_	
246-117	43661-43672	competition	_	
246-118	43673-43675	in	_	
246-119	43676-43679	the	_	
246-120	43680-43685	human	_	
246-121	43686-43691	brain	_	
246-122	43692-43701	Cognitive	_	
246-123	43702-43720	neuroscience-based	_	
246-124	43721-43731	approaches	_	
246-125	43732-43734	to	_	
246-126	43735-43744	measuring	_	
246-127	43745-43748	and	_	
246-128	43749-43758	improving	_	
246-129	43759-43768	treatment	_	
246-130	43769-43776	effects	_	
246-131	43777-43779	on	_	
246-132	43780-43789	cognition	_	
246-133	43790-43792	in	_	
246-134	43793-43806	schizophrenia	_	
246-135	43806-43807	:	_	
246-136	43808-43811	The	_	
246-137	43812-43819	CNTRICS	_	
246-138	43820-43830	initiative	_	
246-139	43831-43834	The	_	
246-140	43835-43844	attention	_	
246-141	43845-43851	system	_	
246-142	43852-43854	of	_	
246-143	43855-43858	the	_	
246-144	43859-43864	human	_	
246-145	43865-43870	brain	_	
246-146	43870-43871	:	_	
246-147	43872-43874	20	_	
246-148	43875-43880	years	_	
246-149	43881-43886	after	_	
246-150	43887-43893	Visual	_	
246-151	43894-43903	attention	_	
246-152	43904-43910	within	_	
246-153	43911-43914	and	_	
246-154	43915-43921	around	_	
246-155	43922-43925	the	_	
246-156	43926-43931	field	_	
246-157	43932-43934	of	_	
246-158	43935-43940	focal	_	
246-159	43941-43950	attention	_	
246-160	43950-43951	:	_	
246-161	43952-43953	a	_	
246-162	43954-43958	zoom	_	
246-163	43959-43963	lens	_	
246-164	43964-43969	model	_	
246-165	43970-43983	Hyperfocusing	_	
246-166	43984-43986	in	_	
246-167	43987-44000	schizophrenia	_	
246-168	44000-44001	:	_	
246-169	44002-44010	Evidence	_	
246-170	44011-44015	from	_	
246-171	44016-44028	interactions	_	
246-172	44029-44036	between	_	
246-173	44037-44044	working	_	
246-174	44045-44051	memory	_	
246-175	44052-44055	and	_	
246-176	44056-44059	eye	_	
246-177	44060-44069	movements	_	
246-178	44070-44076	Visual	_	
246-179	44077-44083	search	_	
246-180	44084-44095	performance	_	
246-181	44096-44101	among	_	
246-182	44102-44109	persons	_	
246-183	44110-44114	with	_	
246-184	44115-44128	schizophrenia	_	
246-185	44129-44131	as	_	
246-186	44132-44133	a	_	
246-187	44134-44142	function	_	
246-188	44143-44145	of	_	
246-189	44146-44152	target	_	
246-190	44153-44165	eccentricity	_	
246-191	44166-44167	[	_	
246-192	44167-44168	A	_	
246-193	44169-44176	deficit	_	
246-194	44177-44179	in	_	
246-195	44180-44192	preattentive	_	
246-196	44193-44203	processing	_	
246-197	44204-44206	of	_	
246-198	44207-44213	visual	_	
246-199	44214-44225	information	_	
246-200	44226-44228	in	_	
246-201	44229-44242	schizophrenic	_	
246-202	44243-44251	patients	_	
246-203	44251-44252	]	_	
246-204	44253-44260	Spatial	_	
246-205	44261-44268	working	_	
246-206	44269-44275	memory	_	
246-207	44276-44278	as	_	
246-208	44279-44281	an	_	
246-209	44282-44295	endophenotype	_	
246-210	44296-44299	for	_	
246-211	44300-44313	schizophrenia	_	
246-212	44314-44324	Challenges	_	
246-213	44325-44327	to	_	
246-214	44328-44337	attention	_	
246-215	44337-44338	:	_	
246-216	44339-44340	a	_	
246-217	44341-44351	continuous	_	
246-218	44352-44360	arterial	_	
246-219	44361-44365	spin	_	
246-220	44366-44374	labeling	_	
246-221	44375-44376	(	_	
246-222	44376-44379	ASL	_	
246-223	44379-44380	)	_	
246-224	44381-44386	study	_	
246-225	44387-44389	of	_	
246-226	44390-44393	the	_	
246-227	44394-44401	effects	_	
246-228	44402-44404	of	_	
246-229	44405-44416	distraction	_	
246-230	44417-44419	on	_	
246-231	44420-44429	sustained	_	
246-232	44430-44439	attention	_	
246-233	44440-44449	Increased	_	
246-234	44450-44460	distractor	_	
246-235	44461-44474	vulnerability	_	
246-236	44475-44478	but	_	
246-237	44479-44488	preserved	_	
246-238	44489-44498	vigilance	_	
246-239	44499-44501	in	_	
246-240	44502-44510	patients	_	
246-241	44511-44515	with	_	
246-242	44516-44529	schizophrenia	_	
246-243	44529-44530	:	_	
246-244	44531-44539	Evidence	_	
246-245	44540-44544	from	_	
246-246	44545-44546	a	_	
246-247	44547-44560	translational	_	
246-248	44561-44570	Sustained	_	
246-249	44571-44580	Attention	_	
246-250	44581-44585	Task	_	
246-251	44586-44589	The	_	
246-252	44590-44600	continuous	_	
246-253	44601-44612	performance	_	
246-254	44613-44617	test	_	
246-255	44617-44618	:	_	
246-256	44619-44620	a	_	
246-257	44621-44627	window	_	
246-258	44628-44630	on	_	
246-259	44631-44634	the	_	
246-260	44635-44641	neural	_	
246-261	44642-44652	substrates	_	
246-262	44653-44656	for	_	
246-263	44657-44666	attention	_	
246-264	44666-44667	?	_	

#Text=Imaging brain fatigue from sustained mental workload: An ASL perfusion study of the time-on-task effect
#Text=Decreased cerebral activation during CPT performance: structural and functional deficits in schizophrenic patients
#Text=Neural primacy of the salience processing system in schizophrenia
#Text=Reduced frontal functional asymmetry in schizophrenia during a cued continuous performance test assessed with near-infrared spectroscopy
#Text=Impaired modulation of attention and emotion in schizophrenia
#Text=A pilot study on the effects of cognitive remediation on hemodynamic responses in the prefrontal cortices of patients with schizophrenia: A multi-channel near-infrared spectroscopy study
#Text=The evolution of field deployable fNIR spectroscopy from bench to clinical settings
#Text=Continuous monitoring of brain dynamics with functional near infrared spectroscopy as a tool for neuroergonomic research: empirical examples and a technological development
#Text=Demeter, E.
247-1	44668-44675	Imaging	_	
247-2	44676-44681	brain	_	
247-3	44682-44689	fatigue	_	
247-4	44690-44694	from	_	
247-5	44695-44704	sustained	_	
247-6	44705-44711	mental	_	
247-7	44712-44720	workload	_	
247-8	44720-44721	:	_	
247-9	44722-44724	An	_	
247-10	44725-44728	ASL	_	
247-11	44729-44738	perfusion	_	
247-12	44739-44744	study	_	
247-13	44745-44747	of	_	
247-14	44748-44751	the	_	
247-15	44752-44764	time-on-task	_	
247-16	44765-44771	effect	_	
247-17	44772-44781	Decreased	_	
247-18	44782-44790	cerebral	_	
247-19	44791-44801	activation	_	
247-20	44802-44808	during	_	
247-21	44809-44812	CPT	_	
247-22	44813-44824	performance	_	
247-23	44824-44825	:	_	
247-24	44826-44836	structural	_	
247-25	44837-44840	and	_	
247-26	44841-44851	functional	_	
247-27	44852-44860	deficits	_	
247-28	44861-44863	in	_	
247-29	44864-44877	schizophrenic	_	
247-30	44878-44886	patients	_	
247-31	44887-44893	Neural	_	
247-32	44894-44901	primacy	_	
247-33	44902-44904	of	_	
247-34	44905-44908	the	_	
247-35	44909-44917	salience	_	
247-36	44918-44928	processing	_	
247-37	44929-44935	system	_	
247-38	44936-44938	in	_	
247-39	44939-44952	schizophrenia	_	
247-40	44953-44960	Reduced	_	
247-41	44961-44968	frontal	_	
247-42	44969-44979	functional	_	
247-43	44980-44989	asymmetry	_	
247-44	44990-44992	in	_	
247-45	44993-45006	schizophrenia	_	
247-46	45007-45013	during	_	
247-47	45014-45015	a	_	
247-48	45016-45020	cued	_	
247-49	45021-45031	continuous	_	
247-50	45032-45043	performance	_	
247-51	45044-45048	test	_	
247-52	45049-45057	assessed	_	
247-53	45058-45062	with	_	
247-54	45063-45076	near-infrared	_	
247-55	45077-45089	spectroscopy	_	
247-56	45090-45098	Impaired	_	
247-57	45099-45109	modulation	_	
247-58	45110-45112	of	_	
247-59	45113-45122	attention	_	
247-60	45123-45126	and	_	
247-61	45127-45134	emotion	_	
247-62	45135-45137	in	_	
247-63	45138-45151	schizophrenia	_	
247-64	45152-45153	A	_	
247-65	45154-45159	pilot	_	
247-66	45160-45165	study	_	
247-67	45166-45168	on	_	
247-68	45169-45172	the	_	
247-69	45173-45180	effects	_	
247-70	45181-45183	of	_	
247-71	45184-45193	cognitive	_	
247-72	45194-45205	remediation	_	
247-73	45206-45208	on	_	
247-74	45209-45220	hemodynamic	_	
247-75	45221-45230	responses	_	
247-76	45231-45233	in	_	
247-77	45234-45237	the	_	
247-78	45238-45248	prefrontal	_	
247-79	45249-45257	cortices	_	
247-80	45258-45260	of	_	
247-81	45261-45269	patients	_	
247-82	45270-45274	with	_	
247-83	45275-45288	schizophrenia	_	
247-84	45288-45289	:	_	
247-85	45290-45291	A	_	
247-86	45292-45305	multi-channel	_	
247-87	45306-45319	near-infrared	_	
247-88	45320-45332	spectroscopy	_	
247-89	45333-45338	study	_	
247-90	45339-45342	The	_	
247-91	45343-45352	evolution	_	
247-92	45353-45355	of	_	
247-93	45356-45361	field	_	
247-94	45362-45372	deployable	_	
247-95	45373-45377	fNIR	_	
247-96	45378-45390	spectroscopy	_	
247-97	45391-45395	from	_	
247-98	45396-45401	bench	_	
247-99	45402-45404	to	_	
247-100	45405-45413	clinical	_	
247-101	45414-45422	settings	_	
247-102	45423-45433	Continuous	_	
247-103	45434-45444	monitoring	_	
247-104	45445-45447	of	_	
247-105	45448-45453	brain	_	
247-106	45454-45462	dynamics	_	
247-107	45463-45467	with	_	
247-108	45468-45478	functional	_	
247-109	45479-45483	near	_	
247-110	45484-45492	infrared	_	
247-111	45493-45505	spectroscopy	_	
247-112	45506-45508	as	_	
247-113	45509-45510	a	_	
247-114	45511-45515	tool	_	
247-115	45516-45519	for	_	
247-116	45520-45534	neuroergonomic	_	
247-117	45535-45543	research	_	
247-118	45543-45544	:	_	
247-119	45545-45554	empirical	_	
247-120	45555-45563	examples	_	
247-121	45564-45567	and	_	
247-122	45568-45569	a	_	
247-123	45570-45583	technological	_	
247-124	45584-45595	development	_	
247-125	45596-45603	Demeter	_	
247-126	45603-45604	,	_	
247-127	45605-45606	E	_	
247-128	45606-45607	.	_	

#Text=Translational research on sustained attention and attentional control in rats, healthy humans and patients with Schizophrenia.
248-1	45608-45621	Translational	_	
248-2	45622-45630	research	_	
248-3	45631-45633	on	_	
248-4	45634-45643	sustained	_	
248-5	45644-45653	attention	_	
248-6	45654-45657	and	_	
248-7	45658-45669	attentional	_	
248-8	45670-45677	control	_	
248-9	45678-45680	in	_	
248-10	45681-45685	rats	_	
248-11	45685-45686	,	_	
248-12	45687-45694	healthy	_	
248-13	45695-45701	humans	_	
248-14	45702-45705	and	_	
248-15	45706-45714	patients	_	
248-16	45715-45719	with	_	
248-17	45720-45733	Schizophrenia	_	
248-18	45733-45734	.	_	

#Text=(University of Michigan, 2011).
249-1	45735-45736	(	_	
249-2	45736-45746	University	_	
249-3	45747-45749	of	_	
249-4	45750-45758	Michigan	_	
249-5	45758-45759	,	_	
249-6	45760-45764	2011	_	
249-7	45764-45765	)	_	
249-8	45765-45766	.	_	

#Text=Behavioral vigilance in rats: task validation and effects of age, amphetamine, and benzodiazepine receptor ligands
#Text=Ayaz, H. et al.
250-1	45767-45777	Behavioral	_	
250-2	45778-45787	vigilance	_	
250-3	45788-45790	in	_	
250-4	45791-45795	rats	_	
250-5	45795-45796	:	_	
250-6	45797-45801	task	_	
250-7	45802-45812	validation	_	
250-8	45813-45816	and	_	
250-9	45817-45824	effects	_	
250-10	45825-45827	of	_	
250-11	45828-45831	age	_	
250-12	45831-45832	,	_	
250-13	45833-45844	amphetamine	_	
250-14	45844-45845	,	_	
250-15	45846-45849	and	_	
250-16	45850-45864	benzodiazepine	_	
250-17	45865-45873	receptor	_	
250-18	45874-45881	ligands	_	
250-19	45882-45886	Ayaz	_	
250-20	45886-45887	,	_	
250-21	45888-45889	H	_	
250-22	45889-45890	.	_	
250-23	45891-45893	et	_	
250-24	45894-45896	al	_	
250-25	45896-45897	.	_	

#Text=Using MazeSuite and functional near infrared spectroscopy to study learning in spatial navigation.
251-1	45898-45903	Using	_	
251-2	45904-45913	MazeSuite	_	
251-3	45914-45917	and	_	
251-4	45918-45928	functional	_	
251-5	45929-45933	near	_	
251-6	45934-45942	infrared	_	
251-7	45943-45955	spectroscopy	_	
251-8	45956-45958	to	_	
251-9	45959-45964	study	_	
251-10	45965-45973	learning	_	
251-11	45974-45976	in	_	
251-12	45977-45984	spatial	_	
251-13	45985-45995	navigation	_	
251-14	45995-45996	.	_	

#Text=J.
252-1	45997-45998	J	_	
252-2	45998-45999	.	_	

#Text=Vis.
253-1	46000-46003	Vis	_	
253-2	46003-46004	.	_	

#Text=Exp, 10.3791/3443 (2011).
254-1	46005-46008	Exp	_	
254-2	46008-46009	,	_	
254-3	46010-46017	10.3791	_	
254-4	46017-46018	/	_	
254-5	46018-46022	3443	_	
254-6	46023-46024	(	_	
254-7	46024-46028	2011	_	
254-8	46028-46029	)	_	
254-9	46029-46030	.	_	

#Text=Reduced frontopolar activation during verbal fluency task in schizophrenia: A multi-channel near-infrared spectroscopy study
#Text=Sliding-window motion artifact rejection for Functional Near-Infrared Spectroscopy
#Text=Spontaneous fluctuations in brain activity observed with functional magnetic resonance imaging
#Text=Cope, M.
255-1	46031-46038	Reduced	_	
255-2	46039-46050	frontopolar	_	
255-3	46051-46061	activation	_	
255-4	46062-46068	during	_	
255-5	46069-46075	verbal	_	
255-6	46076-46083	fluency	_	
255-7	46084-46088	task	_	
255-8	46089-46091	in	_	
255-9	46092-46105	schizophrenia	_	
255-10	46105-46106	:	_	
255-11	46107-46108	A	_	
255-12	46109-46122	multi-channel	_	
255-13	46123-46136	near-infrared	_	
255-14	46137-46149	spectroscopy	_	
255-15	46150-46155	study	_	
255-16	46156-46170	Sliding-window	_	
255-17	46171-46177	motion	_	
255-18	46178-46186	artifact	_	
255-19	46187-46196	rejection	_	
255-20	46197-46200	for	_	
255-21	46201-46211	Functional	_	
255-22	46212-46225	Near-Infrared	_	
255-23	46226-46238	Spectroscopy	_	
255-24	46239-46250	Spontaneous	_	
255-25	46251-46263	fluctuations	_	
255-26	46264-46266	in	_	
255-27	46267-46272	brain	_	
255-28	46273-46281	activity	_	
255-29	46282-46290	observed	_	
255-30	46291-46295	with	_	
255-31	46296-46306	functional	_	
255-32	46307-46315	magnetic	_	
255-33	46316-46325	resonance	_	
255-34	46326-46333	imaging	_	
255-35	46334-46338	Cope	_	
255-36	46338-46339	,	_	
255-37	46340-46341	M	_	
255-38	46341-46342	.	_	

#Text=The Application Of Near Infrared Spectroscopy To Non Invasive Monitoring Of Cerebral Oxygenation In The Newborn Infant.
256-1	46343-46346	The	_	
256-2	46347-46358	Application	_	
256-3	46359-46361	Of	_	
256-4	46362-46366	Near	_	
256-5	46367-46375	Infrared	_	
256-6	46376-46388	Spectroscopy	_	
256-7	46389-46391	To	_	
256-8	46392-46395	Non	_	
256-9	46396-46404	Invasive	_	
256-10	46405-46415	Monitoring	_	
256-11	46416-46418	Of	_	
256-12	46419-46427	Cerebral	_	
256-13	46428-46439	Oxygenation	_	
256-14	46440-46442	In	_	
256-15	46443-46446	The	_	
256-16	46447-46454	Newborn	_	
256-17	46455-46461	Infant	_	
256-18	46461-46462	.	_	

#Text=(University College, London, 1991).
257-1	46463-46464	(	_	
257-2	46464-46474	University	_	
257-3	46475-46482	College	_	
257-4	46482-46483	,	_	
257-5	46484-46490	London	_	
257-6	46490-46491	,	_	
257-7	46492-46496	1991	_	
257-8	46496-46497	)	_	
257-9	46497-46498	.	_	

#Text=Optical brain monitoring for operator training and mental workload assessment
#Text=Registering fNIR data to brain surface image using MRI templates
#Text=Measuring speaker–listener neural coupling with functional near infrared spectroscopy
#Text=Controlling the false discovery rate in behavior genetics research
#Text=A comparison of the general linear mixed model and repeated measures ANOVA using a dataset with multiple missing data points
#Text=Enhancing dual-task performance with verbal and spatial working memory training: Continuous monitoring of cerebral hemodynamics with NIRS
#Text=Statistical analysis of fNIRS data: A comprehensive review
#Text=Memory and Language Mixed-effects modeling with crossed random effects for subjects and items
#Text=Fitting Linear Mixed-Effects Models Using lme4
#Text=Thresholding of statistical maps in functional neuroimaging using the false discovery rate
#Text=Akaike, H.
258-1	46499-46506	Optical	_	
258-2	46507-46512	brain	_	
258-3	46513-46523	monitoring	_	
258-4	46524-46527	for	_	
258-5	46528-46536	operator	_	
258-6	46537-46545	training	_	
258-7	46546-46549	and	_	
258-8	46550-46556	mental	_	
258-9	46557-46565	workload	_	
258-10	46566-46576	assessment	_	
258-11	46577-46588	Registering	_	
258-12	46589-46593	fNIR	_	
258-13	46594-46598	data	_	
258-14	46599-46601	to	_	
258-15	46602-46607	brain	_	
258-16	46608-46615	surface	_	
258-17	46616-46621	image	_	
258-18	46622-46627	using	_	
258-19	46628-46631	MRI	_	
258-20	46632-46641	templates	_	
258-21	46642-46651	Measuring	_	
258-22	46652-46668	speaker–listener	_	
258-23	46669-46675	neural	_	
258-24	46676-46684	coupling	_	
258-25	46685-46689	with	_	
258-26	46690-46700	functional	_	
258-27	46701-46705	near	_	
258-28	46706-46714	infrared	_	
258-29	46715-46727	spectroscopy	_	
258-30	46728-46739	Controlling	_	
258-31	46740-46743	the	_	
258-32	46744-46749	false	_	
258-33	46750-46759	discovery	_	
258-34	46760-46764	rate	_	
258-35	46765-46767	in	_	
258-36	46768-46776	behavior	_	
258-37	46777-46785	genetics	_	
258-38	46786-46794	research	_	
258-39	46795-46796	A	_	
258-40	46797-46807	comparison	_	
258-41	46808-46810	of	_	
258-42	46811-46814	the	_	
258-43	46815-46822	general	_	
258-44	46823-46829	linear	_	
258-45	46830-46835	mixed	_	
258-46	46836-46841	model	_	
258-47	46842-46845	and	_	
258-48	46846-46854	repeated	_	
258-49	46855-46863	measures	_	
258-50	46864-46869	ANOVA	_	
258-51	46870-46875	using	_	
258-52	46876-46877	a	_	
258-53	46878-46885	dataset	_	
258-54	46886-46890	with	_	
258-55	46891-46899	multiple	_	
258-56	46900-46907	missing	_	
258-57	46908-46912	data	_	
258-58	46913-46919	points	_	
258-59	46920-46929	Enhancing	_	
258-60	46930-46939	dual-task	_	
258-61	46940-46951	performance	_	
258-62	46952-46956	with	_	
258-63	46957-46963	verbal	_	
258-64	46964-46967	and	_	
258-65	46968-46975	spatial	_	
258-66	46976-46983	working	_	
258-67	46984-46990	memory	_	
258-68	46991-46999	training	_	
258-69	46999-47000	:	_	
258-70	47001-47011	Continuous	_	
258-71	47012-47022	monitoring	_	
258-72	47023-47025	of	_	
258-73	47026-47034	cerebral	_	
258-74	47035-47047	hemodynamics	_	
258-75	47048-47052	with	_	
258-76	47053-47057	NIRS	_	
258-77	47058-47069	Statistical	_	
258-78	47070-47078	analysis	_	
258-79	47079-47081	of	_	
258-80	47082-47087	fNIRS	_	
258-81	47088-47092	data	_	
258-82	47092-47093	:	_	
258-83	47094-47095	A	_	
258-84	47096-47109	comprehensive	_	
258-85	47110-47116	review	_	
258-86	47117-47123	Memory	_	
258-87	47124-47127	and	_	
258-88	47128-47136	Language	_	
258-89	47137-47150	Mixed-effects	_	
258-90	47151-47159	modeling	_	
258-91	47160-47164	with	_	
258-92	47165-47172	crossed	_	
258-93	47173-47179	random	_	
258-94	47180-47187	effects	_	
258-95	47188-47191	for	_	
258-96	47192-47200	subjects	_	
258-97	47201-47204	and	_	
258-98	47205-47210	items	_	
258-99	47211-47218	Fitting	_	
258-100	47219-47225	Linear	_	
258-101	47226-47239	Mixed-Effects	_	
258-102	47240-47246	Models	_	
258-103	47247-47252	Using	_	
258-104	47253-47257	lme4	_	
258-105	47258-47270	Thresholding	_	
258-106	47271-47273	of	_	
258-107	47274-47285	statistical	_	
258-108	47286-47290	maps	_	
258-109	47291-47293	in	_	
258-110	47294-47304	functional	_	
258-111	47305-47317	neuroimaging	_	
258-112	47318-47323	using	_	
258-113	47324-47327	the	_	
258-114	47328-47333	false	_	
258-115	47334-47343	discovery	_	
258-116	47344-47348	rate	_	
258-117	47349-47355	Akaike	_	
258-118	47355-47356	,	_	
258-119	47357-47358	H	_	
258-120	47358-47359	.	_	

#Text=Information theory and an extension of the maximum likelihood principle.
259-1	47360-47371	Information	_	
259-2	47372-47378	theory	_	
259-3	47379-47382	and	_	
259-4	47383-47385	an	_	
259-5	47386-47395	extension	_	
259-6	47396-47398	of	_	
259-7	47399-47402	the	_	
259-8	47403-47410	maximum	_	
259-9	47411-47421	likelihood	_	
259-10	47422-47431	principle	_	
259-11	47431-47432	.	_	

#Text=In 2nd International Symposium on Information Theory (ed.
260-1	47433-47435	In	_	
260-2	47436-47439	2nd	_	
260-3	47440-47453	International	_	
260-4	47454-47463	Symposium	_	
260-5	47464-47466	on	_	
260-6	47467-47478	Information	_	
260-7	47479-47485	Theory	_	
260-8	47486-47487	(	_	
260-9	47487-47489	ed	_	
260-10	47489-47490	.	_	

#Text=Csaki, B.
261-1	47491-47496	Csaki	_	
261-2	47496-47497	,	_	
261-3	47498-47499	B	_	
261-4	47499-47500	.	_	

#Text=P.
262-1	47501-47502	P	_	
262-2	47502-47503	.	_	

#Text=F.) 267–281 (Akadémiai Kiadó, 1973).
263-1	47504-47505	F	_	
263-2	47505-47506	.	_	
263-3	47506-47507	)	_	
263-4	47508-47511	267	_	
263-5	47511-47512	–	_	
263-6	47512-47515	281	_	
263-7	47516-47517	(	_	
263-8	47517-47526	Akadémiai	_	
263-9	47527-47532	Kiadó	_	
263-10	47532-47533	,	_	
263-11	47534-47538	1973	_	
263-12	47538-47539	)	_	
263-13	47539-47540	.	_	

#Text=Burnham, K.
264-1	47541-47548	Burnham	_	
264-2	47548-47549	,	_	
264-3	47550-47551	K	_	
264-4	47551-47552	.	_	

#Text=P. & Anderson, D.
265-1	47553-47554	P	_	
265-2	47554-47555	.	_	
265-3	47556-47557	&	_	
265-4	47558-47566	Anderson	_	
265-5	47566-47567	,	_	
265-6	47568-47569	D	_	
265-7	47569-47570	.	_	

#Text=R.
266-1	47571-47572	R	_	
266-2	47572-47573	.	_	

#Text=Model Selection and Multimodel Inference: A Practical Information-Theoretic Approach.
267-1	47574-47579	Model	_	
267-2	47580-47589	Selection	_	
267-3	47590-47593	and	_	
267-4	47594-47604	Multimodel	_	
267-5	47605-47614	Inference	_	
267-6	47614-47615	:	_	
267-7	47616-47617	A	_	
267-8	47618-47627	Practical	_	
267-9	47628-47649	Information-Theoretic	_	
267-10	47650-47658	Approach	_	
267-11	47658-47659	.	_	

#Text=(Springer Science & Business Media, 2003).
268-1	47660-47661	(	_	
268-2	47661-47669	Springer	_	
268-3	47670-47677	Science	_	
268-4	47678-47679	&	_	
268-5	47680-47688	Business	_	
268-6	47689-47694	Media	_	
268-7	47694-47695	,	_	
268-8	47696-47700	2003	_	
268-9	47700-47701	)	_	
268-10	47701-47702	.	_	

#Text=Behavioral vigilance following infusions of 192 IgG-saporin into the basal forebrain: selectivity of the behavioral impairment and relation to cortical AChE-positive fiber density
#Text=Rats and humans paying attention: cross-species task development for translational research
#Text=Anterior prefrontal contributions to implicit attention control
#Text=Functional specialization within rostral prefrontal cortex (area 10): a meta-analysis
#Text=Electrophysiological Evidence for Hyperfocusing of Spatial Attention in Schizophrenia
#Text=Impaired regional hemodynamic response in schizophrenia during multiple prefrontal activation tasks: a two-channel near-infrared spectroscopy study
#Text=Reduced prefrontal cortex activation using the Trail Making Test in schizophrenia
#Text=Evidence-based guidelines on the therapeutic use of repetitive transcranial magnetic stimulation (rTMS)
#Text=Impaired interhemispheric integration in brain oxygenation and hemodynamics in schizophrenia
#Text=Fallgatter, A. & Strik, W.
269-1	47703-47713	Behavioral	_	
269-2	47714-47723	vigilance	_	
269-3	47724-47733	following	_	
269-4	47734-47743	infusions	_	
269-5	47744-47746	of	_	
269-6	47747-47750	192	_	
269-7	47751-47762	IgG-saporin	_	
269-8	47763-47767	into	_	
269-9	47768-47771	the	_	
269-10	47772-47777	basal	_	
269-11	47778-47787	forebrain	_	
269-12	47787-47788	:	_	
269-13	47789-47800	selectivity	_	
269-14	47801-47803	of	_	
269-15	47804-47807	the	_	
269-16	47808-47818	behavioral	_	
269-17	47819-47829	impairment	_	
269-18	47830-47833	and	_	
269-19	47834-47842	relation	_	
269-20	47843-47845	to	_	
269-21	47846-47854	cortical	_	
269-22	47855-47868	AChE-positive	_	
269-23	47869-47874	fiber	_	
269-24	47875-47882	density	_	
269-25	47883-47887	Rats	_	
269-26	47888-47891	and	_	
269-27	47892-47898	humans	_	
269-28	47899-47905	paying	_	
269-29	47906-47915	attention	_	
269-30	47915-47916	:	_	
269-31	47917-47930	cross-species	_	
269-32	47931-47935	task	_	
269-33	47936-47947	development	_	
269-34	47948-47951	for	_	
269-35	47952-47965	translational	_	
269-36	47966-47974	research	_	
269-37	47975-47983	Anterior	_	
269-38	47984-47994	prefrontal	_	
269-39	47995-48008	contributions	_	
269-40	48009-48011	to	_	
269-41	48012-48020	implicit	_	
269-42	48021-48030	attention	_	
269-43	48031-48038	control	_	
269-44	48039-48049	Functional	_	
269-45	48050-48064	specialization	_	
269-46	48065-48071	within	_	
269-47	48072-48079	rostral	_	
269-48	48080-48090	prefrontal	_	
269-49	48091-48097	cortex	_	
269-50	48098-48099	(	_	
269-51	48099-48103	area	_	
269-52	48104-48106	10	_	
269-53	48106-48107	)	_	
269-54	48107-48108	:	_	
269-55	48109-48110	a	_	
269-56	48111-48124	meta-analysis	_	
269-57	48125-48145	Electrophysiological	_	
269-58	48146-48154	Evidence	_	
269-59	48155-48158	for	_	
269-60	48159-48172	Hyperfocusing	_	
269-61	48173-48175	of	_	
269-62	48176-48183	Spatial	_	
269-63	48184-48193	Attention	_	
269-64	48194-48196	in	_	
269-65	48197-48210	Schizophrenia	_	
269-66	48211-48219	Impaired	_	
269-67	48220-48228	regional	_	
269-68	48229-48240	hemodynamic	_	
269-69	48241-48249	response	_	
269-70	48250-48252	in	_	
269-71	48253-48266	schizophrenia	_	
269-72	48267-48273	during	_	
269-73	48274-48282	multiple	_	
269-74	48283-48293	prefrontal	_	
269-75	48294-48304	activation	_	
269-76	48305-48310	tasks	_	
269-77	48310-48311	:	_	
269-78	48312-48313	a	_	
269-79	48314-48325	two-channel	_	
269-80	48326-48339	near-infrared	_	
269-81	48340-48352	spectroscopy	_	
269-82	48353-48358	study	_	
269-83	48359-48366	Reduced	_	
269-84	48367-48377	prefrontal	_	
269-85	48378-48384	cortex	_	
269-86	48385-48395	activation	_	
269-87	48396-48401	using	_	
269-88	48402-48405	the	_	
269-89	48406-48411	Trail	_	
269-90	48412-48418	Making	_	
269-91	48419-48423	Test	_	
269-92	48424-48426	in	_	
269-93	48427-48440	schizophrenia	_	
269-94	48441-48455	Evidence-based	_	
269-95	48456-48466	guidelines	_	
269-96	48467-48469	on	_	
269-97	48470-48473	the	_	
269-98	48474-48485	therapeutic	_	
269-99	48486-48489	use	_	
269-100	48490-48492	of	_	
269-101	48493-48503	repetitive	_	
269-102	48504-48516	transcranial	_	
269-103	48517-48525	magnetic	_	
269-104	48526-48537	stimulation	_	
269-105	48538-48539	(	_	
269-106	48539-48543	rTMS	_	
269-107	48543-48544	)	_	
269-108	48545-48553	Impaired	_	
269-109	48554-48570	interhemispheric	_	
269-110	48571-48582	integration	_	
269-111	48583-48585	in	_	
269-112	48586-48591	brain	_	
269-113	48592-48603	oxygenation	_	
269-114	48604-48607	and	_	
269-115	48608-48620	hemodynamics	_	
269-116	48621-48623	in	_	
269-117	48624-48637	schizophrenia	_	
269-118	48638-48648	Fallgatter	_	
269-119	48648-48649	,	_	
269-120	48650-48651	A	_	
269-121	48651-48652	.	_	
269-122	48653-48654	&	_	
269-123	48655-48660	Strik	_	
269-124	48660-48661	,	_	
269-125	48662-48663	W	_	
269-126	48663-48664	.	_	

#Text=Reduced frontal functional asymmetry in schizophrenia during a cued continuous ….
270-1	48665-48672	Reduced	_	
270-2	48673-48680	frontal	_	
270-3	48681-48691	functional	_	
270-4	48692-48701	asymmetry	_	
270-5	48702-48704	in	_	
270-6	48705-48718	schizophrenia	_	
270-7	48719-48725	during	_	
270-8	48726-48727	a	_	
270-9	48728-48732	cued	_	
270-10	48733-48743	continuous	_	
270-11	48744-48745	…	_	
270-12	48745-48746	.	_	

#Text=Schizophr.
271-1	48747-48756	Schizophr	_	
271-2	48756-48757	.	_	

#Text=Bull. 913–919 (2000).
272-1	48758-48762	Bull	_	
272-2	48762-48763	.	_	
272-3	48764-48767	913	_	
272-4	48767-48768	–	_	
272-5	48768-48771	919	_	
272-6	48772-48773	(	_	
272-7	48773-48777	2000	_	
272-8	48777-48778	)	_	
272-9	48778-48779	.	_	

#Text=Reduced laterality as a trait marker of schizophrenia–evidence from structural and functional neuroimaging
#Text=Global brain asymmetry is increased in schizophrenia and related to avolition
#Text=Decreased hemispheric connectivity and decreased intra- and inter- hemisphere asymmetry of resting state functional network connectivity in schizophrenia
#Text=Abnormal asymmetry of brain connectivity in schizophrenia
#Text=Strengthening of Top-Down Frontal Cognitive Control Networks Underlying the Development of Inhibitory Control: An fMRI Effective Connectivity Study
#Text=A role of right middle frontal gyrus in reorienting of attention: a case study
#Text=Reaction time and sustained attention in schizophrenia and its genetic predisposition
#Text=Neurocognitive effects of antipsychotic medications in patients with chronic schizophrenia in the CATIE Trial
#Text=Cognitive dysfunction in psychiatric disorders: characteristics, causes and the quest for improved therapy
#Text=Cui, X., Bray, S. & Reiss, A.
273-1	48780-48787	Reduced	_	
273-2	48788-48798	laterality	_	
273-3	48799-48801	as	_	
273-4	48802-48803	a	_	
273-5	48804-48809	trait	_	
273-6	48810-48816	marker	_	
273-7	48817-48819	of	_	
273-8	48820-48842	schizophrenia–evidence	_	
273-9	48843-48847	from	_	
273-10	48848-48858	structural	_	
273-11	48859-48862	and	_	
273-12	48863-48873	functional	_	
273-13	48874-48886	neuroimaging	_	
273-14	48887-48893	Global	_	
273-15	48894-48899	brain	_	
273-16	48900-48909	asymmetry	_	
273-17	48910-48912	is	_	
273-18	48913-48922	increased	_	
273-19	48923-48925	in	_	
273-20	48926-48939	schizophrenia	_	
273-21	48940-48943	and	_	
273-22	48944-48951	related	_	
273-23	48952-48954	to	_	
273-24	48955-48964	avolition	_	
273-25	48965-48974	Decreased	_	
273-26	48975-48986	hemispheric	_	
273-27	48987-48999	connectivity	_	
273-28	49000-49003	and	_	
273-29	49004-49013	decreased	_	
273-30	49014-49019	intra	_	
273-31	49019-49020	-	_	
273-32	49021-49024	and	_	
273-33	49025-49030	inter	_	
273-34	49030-49031	-	_	
273-35	49032-49042	hemisphere	_	
273-36	49043-49052	asymmetry	_	
273-37	49053-49055	of	_	
273-38	49056-49063	resting	_	
273-39	49064-49069	state	_	
273-40	49070-49080	functional	_	
273-41	49081-49088	network	_	
273-42	49089-49101	connectivity	_	
273-43	49102-49104	in	_	
273-44	49105-49118	schizophrenia	_	
273-45	49119-49127	Abnormal	_	
273-46	49128-49137	asymmetry	_	
273-47	49138-49140	of	_	
273-48	49141-49146	brain	_	
273-49	49147-49159	connectivity	_	
273-50	49160-49162	in	_	
273-51	49163-49176	schizophrenia	_	
273-52	49177-49190	Strengthening	_	
273-53	49191-49193	of	_	
273-54	49194-49202	Top-Down	_	
273-55	49203-49210	Frontal	_	
273-56	49211-49220	Cognitive	_	
273-57	49221-49228	Control	_	
273-58	49229-49237	Networks	_	
273-59	49238-49248	Underlying	_	
273-60	49249-49252	the	_	
273-61	49253-49264	Development	_	
273-62	49265-49267	of	_	
273-63	49268-49278	Inhibitory	_	
273-64	49279-49286	Control	_	
273-65	49286-49287	:	_	
273-66	49288-49290	An	_	
273-67	49291-49295	fMRI	_	
273-68	49296-49305	Effective	_	
273-69	49306-49318	Connectivity	_	
273-70	49319-49324	Study	_	
273-71	49325-49326	A	_	
273-72	49327-49331	role	_	
273-73	49332-49334	of	_	
273-74	49335-49340	right	_	
273-75	49341-49347	middle	_	
273-76	49348-49355	frontal	_	
273-77	49356-49361	gyrus	_	
273-78	49362-49364	in	_	
273-79	49365-49376	reorienting	_	
273-80	49377-49379	of	_	
273-81	49380-49389	attention	_	
273-82	49389-49390	:	_	
273-83	49391-49392	a	_	
273-84	49393-49397	case	_	
273-85	49398-49403	study	_	
273-86	49404-49412	Reaction	_	
273-87	49413-49417	time	_	
273-88	49418-49421	and	_	
273-89	49422-49431	sustained	_	
273-90	49432-49441	attention	_	
273-91	49442-49444	in	_	
273-92	49445-49458	schizophrenia	_	
273-93	49459-49462	and	_	
273-94	49463-49466	its	_	
273-95	49467-49474	genetic	_	
273-96	49475-49489	predisposition	_	
273-97	49490-49504	Neurocognitive	_	
273-98	49505-49512	effects	_	
273-99	49513-49515	of	_	
273-100	49516-49529	antipsychotic	_	
273-101	49530-49541	medications	_	
273-102	49542-49544	in	_	
273-103	49545-49553	patients	_	
273-104	49554-49558	with	_	
273-105	49559-49566	chronic	_	
273-106	49567-49580	schizophrenia	_	
273-107	49581-49583	in	_	
273-108	49584-49587	the	_	
273-109	49588-49593	CATIE	_	
273-110	49594-49599	Trial	_	
273-111	49600-49609	Cognitive	_	
273-112	49610-49621	dysfunction	_	
273-113	49622-49624	in	_	
273-114	49625-49636	psychiatric	_	
273-115	49637-49646	disorders	_	
273-116	49646-49647	:	_	
273-117	49648-49663	characteristics	_	
273-118	49663-49664	,	_	
273-119	49665-49671	causes	_	
273-120	49672-49675	and	_	
273-121	49676-49679	the	_	
273-122	49680-49685	quest	_	
273-123	49686-49689	for	_	
273-124	49690-49698	improved	_	
273-125	49699-49706	therapy	_	
273-126	49707-49710	Cui	_	
273-127	49710-49711	,	_	
273-128	49712-49713	X	_	
273-129	49713-49714	.	_	
273-130	49714-49715	,	_	
273-131	49716-49720	Bray	_	
273-132	49720-49721	,	_	
273-133	49722-49723	S	_	
273-134	49723-49724	.	_	
273-135	49725-49726	&	_	
273-136	49727-49732	Reiss	_	
273-137	49732-49733	,	_	
273-138	49734-49735	A	_	
273-139	49735-49736	.	_	

#Text=L.
274-1	49737-49738	L	_	
274-2	49738-49739	.	_	

#Text=Speeded near infrared spectroscopy (NIRS) response detection.
275-1	49740-49747	Speeded	_	
275-2	49748-49752	near	_	
275-3	49753-49761	infrared	_	
275-4	49762-49774	spectroscopy	_	
275-5	49775-49776	(	_	
275-6	49776-49780	NIRS	_	
275-7	49780-49781	)	_	
275-8	49782-49790	response	_	
275-9	49791-49800	detection	_	
275-10	49800-49801	.	_	

#Text=PLoS One5 (2010).
276-1	49802-49806	PLoS	_	
276-2	49807-49811	One5	_	
276-3	49812-49813	(	_	
276-4	49813-49817	2010	_	
276-5	49817-49818	)	_	
276-6	49818-49819	.	_	

#Text=Visual Perception and Its Impairment in Schizophrenia
#Text=When Doors of Perception Close: Bottom-up Models of Disrupted Cognition in Schizophrenia
#Text=Subcortical visual dysfunction in schizophrenia drives secondary cortical impairments
#Text=Butler, P.
277-1	49820-49826	Visual	_	
277-2	49827-49837	Perception	_	
277-3	49838-49841	and	_	
277-4	49842-49845	Its	_	
277-5	49846-49856	Impairment	_	
277-6	49857-49859	in	_	
277-7	49860-49873	Schizophrenia	_	
277-8	49874-49878	When	_	
277-9	49879-49884	Doors	_	
277-10	49885-49887	of	_	
277-11	49888-49898	Perception	_	
277-12	49899-49904	Close	_	
277-13	49904-49905	:	_	
277-14	49906-49915	Bottom-up	_	
277-15	49916-49922	Models	_	
277-16	49923-49925	of	_	
277-17	49926-49935	Disrupted	_	
277-18	49936-49945	Cognition	_	
277-19	49946-49948	in	_	
277-20	49949-49962	Schizophrenia	_	
277-21	49963-49974	Subcortical	_	
277-22	49975-49981	visual	_	
277-23	49982-49993	dysfunction	_	
277-24	49994-49996	in	_	
277-25	49997-50010	schizophrenia	_	
277-26	50011-50017	drives	_	
277-27	50018-50027	secondary	_	
277-28	50028-50036	cortical	_	
277-29	50037-50048	impairments	_	
277-30	50049-50055	Butler	_	
277-31	50055-50056	,	_	
277-32	50057-50058	P	_	
277-33	50058-50059	.	_	

#Text=D. & Javitt, D.
278-1	50060-50061	D	_	
278-2	50061-50062	.	_	
278-3	50063-50064	&	_	
278-4	50065-50071	Javitt	_	
278-5	50071-50072	,	_	
278-6	50073-50074	D	_	
278-7	50074-50075	.	_	

#Text=C.
279-1	50076-50077	C	_	
279-2	50077-50078	.	_	

#Text=Early-stage visual processing deficits in schizophrenia.
280-1	50079-50090	Early-stage	_	
280-2	50091-50097	visual	_	
280-3	50098-50108	processing	_	
280-4	50109-50117	deficits	_	
280-5	50118-50120	in	_	
280-6	50121-50134	schizophrenia	_	
280-7	50134-50135	.	_	

#Text=Curr.
281-1	50136-50140	Curr	_	
281-2	50140-50141	.	_	

#Text=Opin.
282-1	50142-50146	Opin	_	
282-2	50146-50147	.	_	

#Text=Psychiatry18, 151–157 10/29/2018;06/14/2019 (2005).
283-1	50148-50160	Psychiatry18	_	
283-2	50160-50161	,	_	
283-3	50162-50165	151	_	
283-4	50165-50166	–	_	
283-5	50166-50169	157	_	
283-6	50170-50172	10	_	
283-7	50172-50173	/	_	
283-8	50173-50175	29	_	
283-9	50175-50176	/	_	
283-10	50176-50180	2018	_	
283-11	50180-50181	;	_	
283-12	50181-50183	06	_	
283-13	50183-50184	/	_	
283-14	50184-50186	14	_	
283-15	50186-50187	/	_	
283-16	50187-50191	2019	_	
283-17	50192-50193	(	_	
283-18	50193-50197	2005	_	
283-19	50197-50198	)	_	
283-20	50198-50199	.	_	
